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Prostate Cancer and MRI
Magnetic resonance imaging (MRI) is a technique that allows visualization of 
internal body structures and their function. The basis of MRI is the nuclear magnetic 
resonance (NMR) phenomenon, which was discovered in the 1930s. NMR evolved 
from a purely physical tool to a technique with extensive applications in chemistry 
and medicine. Since the introduction of the first clinical MRI scanners in the early 
1980s, MRI has revolutionized the diagnosis and treatment of a wide variety of 
medical conditions. 
An example of such a medical condition is prostate cancer. The prostate is part of the 
male reproductive system, and is located just below the bladder in the human body 
(Fig. 1.1). The lifetime risk of a man to develop prostate cancer is 16%, which makes 
prostate cancer the most common non-skin cancer in men in the western world (1). 
Although most types of prostate cancer grow slowly and may need minimal or no 
treatment, some types are aggressive and have a high risk to metastasize quickly 
(2,3). Accurate diagnosis of the type of prostate cancer is therefore required when a 
man is suspected of having the disease. 
The traditional diagnostic tools of urologists provide only limited information about 
the possible cancer. The urologist can feel the structure of the prostate with a finger 
during a rectal examination; the prostate-specific antigen (PSA) level in the blood 
can be tested; and transrectal ultrasound (TRUS)–guided biopsies of the prostate 
can be taken. Abnormal findings in the rectal examination and a high PSA level 
might be an indication for prostate cancer, but only histopathological examination 
of the biopsies can confirm the presence of cancer as well as the aggressiveness of 
the cancer (4). Unfortunately, the risk of sampling errors with TRUS guided biopsy 
is very high, since prostate cancer is often multifocal and heterogeneous and hard 
to recognize on ultrasound images (5,6). Thus, a considerable risk of under- or over-
estimating prostate cancer aggressiveness exists when using only these conventional 
diagnostic tools. An inaccurate diagnosis may lead to inappropriate treatment and 
corresponding consequences (e.g. adverse quality-of-life effects such as incontinence 
and impotence in case of overtreatment). 
MRI techniques have shown great potential for improving the diagnostic accuracy 
of prostate cancer assessment (7). Anatomical MRI can provide excellent contrast 
of the different anatomical zones within the prostate, the outer peripheral zone, 
and the inner central and transition zone, as well as of the neurovascular bundles, 
the anterior fibrous stroma, and the seminal vesicles (Fig. 1.2). Some tumors in 
the peripheral zone can be readily detected using anatomical MRI only, but many 
show similar characteristics with normal prostatic structures or other prostatic 
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diseases. To improve prostate cancer diagnosis, more advanced functional magnetic 
resonance (MR) techniques are used in combination with anatomical MR imaging. 
These techniques provide information about tissue physiology, e.g. the diffusion of 
water molecules, blood flow and metabolism in the prostate. 
An MR exam in which both anatomical and functional MR images of the prostate 
are obtained is called a multiparametric MR exam. Multiparametric MR images 
allow detection, localization, and clinical staging (i.e. assessment of the extent of the 
primary tumor) of prostate cancer and the images even contain information about 
prostate cancer aggressiveness (8–10). This information can be used to improve the 
biopsy accuracy and success rate, and thus lower the number of unnecessary biopsies 
(11). Biopsies can be performed under MR guidance, but recent developments in 
MR-ultrasound fusion software will probably soon allow urologists to perform MR-
guided biopsies also in their regular workflow (12–14). The non-invasive aspect 
of MR is particularly relevant for monitoring men diagnosed with low-aggressive 
prostate cancer over time. These men can follow so-called ‘watchful waiting’ 
approaches to prevent them for overtreatment. 
Figure 1.1 - Location of the prostate in the male human body (top) and a zoom of the prostate region 
showing detailed anatomy (bottom). Source: (20) and (21).
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Although prostate MR has not been implemented broadly in daily clinical practice 
yet, it is increasingly mentioned in prostate cancer guidelines (4,15). The latest 
diagnostic consensus statement by the European Society of Urogenital Radiology 
(ESUR) recommends the use of anatomical MRI and at least two functional MR 
techniques (16). Moreover, a structured reporting system for prostate multiparametric 
MRI (PI-RADS) was introduced by this society to standardize classification. 
Prospective studies lead by both urologists and radiologists are being undertaken to 
identify in which situations prostate MR is useful and cost-effective (17–19). 
The current state of prostate MRI is the result of many years of unite engineering 
efforts and clinical research. MR scanner hardware has been continuously improved, 
and new techniques to retrieve different kinds of anatomical and functional 
information from the prostate have been introduced by making smart use of MR 
physics. Nowadays, existing MR techniques still undergo technical improvements, 
Figure 1.2 - Zonal anatomy of the prostate in a 50-year old man, visualized by MRI. Transversal images 
at the level of the mid gland (A) and the apex of the gland (B), sagittal image (C) and coronal image (D). 
PZ: peripheral zone; CG; central gland (central zone and transition zone); NV: neurovascular bundle; FS: 
anterior fibromuscular stroma; V: verumontanum; BL: urinary bladder; SV: seminal vesicles; U: urethra. 
Source: (21).
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and once in a while even new MR techniques are introduced. One important technical 
development involves increased speed of prostate MR exams to reduce costs. Next 
to this, the technical developments serve to find new biomarkers for prostate cancer 
or to reveal relevant details in anatomical or functional prostate imaging. New MR 
techniques have to be evaluated in a research setting, first on their feasibility, i.e. if 
the technique works in humans and if it provides reliable data, and later in a clinical 
study to investigate if the technique can be used to detect differences between 
normal prostate tissue and prostate cancer or improves this with respect to already 
existing techniques. 
The aim of the work presented in this thesis was to develop and evaluate MR techniques 
which potentially provide new or more detailed information about the prostate, 
allowing better assessment of prostate cancer. All experiments were performed on a 
7 Tesla (7 T) human MR system. This ultra-high magnetic field strength system is not 
yet released for clinical use, but it provides several opportunities that can be studied 
in a research setting. 
As an introduction to the MR work presented in this thesis, the basics of NMR, MRI, 
and MR spectroscopy are described in the following paragraphs. Since the strength 
of the magnetic field played an important role in this thesis work, the physical 
aspects and specific challenges of a higher magnetic field strength for prostate MR 
are described in Chapter 2. 
Nuclear Magnetic Resonance
The NMR phenomenon relies on the interaction of the nuclei of certain atoms with 
a static magnetic field. Most atomic nuclei possess spin, a quantum mechanical 
property determined by the composition of the nucleus. Spin is a form of angular 
momentum, although it is not produced by a rotation of a particle. The absence of 
a visible macroscopic example of this property makes it hard to grasp. The exact 
behavior of nuclei with spin that are placed in a magnetic field can only be described 
completely by quantum mechanics, but it is also possible to approach it by a classical 
description. Here, a semi-quantum mechanical description is used to explain the 
physical principles of NMR. 
Quantum mechanics describe that the spin angular momentum is limited to discrete 
values, i.e. it is quantized. The spin quantum number of a particle determines the 
number of sublevels in the total angular momentum. In absence of a magnetic field, 
these sublevels have the same energy. However, the application of a magnetic field 
causes the sublevels to have slightly different energy. Nuclei which possess a spin 
quantum number of 1/2, so-called spin-1/2 nuclei, are very important in NMR. In 
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a magnetic field, they show two energy sublevels, the low-energy state α and the 
high-energy state β. (Fig. 1.3A).
The energy difference between the two spin states is related to the magnetic 
properties of nuclei and the effect of a magnetic field on nuclear spin. Particles 
with spin also have a spin magnetic moment, which determines the interaction of 
the particle with a magnetic field. The spin angular moment and spin magnetic 
moment of a particle are parallel oriented and proportional to each other. When no 
magnetic field is applied, the spin orientation (i.e. polarization direction) is random. 
The effect of the two spin moments in a magnetic field prevents direct alignment of 
the magnetic moment with the field. Instead, the spin polarization starts to move 
around the magnetic field, a process called spin precession (Fig. 1.3B). The frequency 
of the precession is determined by the nucleus-specific gyromagnetic ratio γ and the 
strength of the magnetic field (B0):
  ω0 = γ ∙ B0      [1.1]
ω0 is called the nuclear Larmor frequency. The magnetic field also induces slight 
anisotropy in spin polarization (Fig. 1.4A). Spin orientations with magnetic moments 
(partially) aligned with the magnetic field appear slightly more often because this 
state has the lowest magnetic energy. At thermal equilibrium, this leads to a net total 
magnetization (M0) of a macroscopic sample of:
  M0 = (  )∙(    )     [1.2]
where h is Planck’s constant, n is total number of nuclei in the sample, k is Boltzmann 
constant and T is absolute temperature. Nuclei with high gyromagnetic ratios are 
thus beneficial for the sensitivity of NMR, as are high magnetic field strengths. 
Hydrogen (1H) has spin-1/2, the highest γ of the commonly encountered nuclei, and 
Figure 1.3 - A: Nuclear spin energy for a spin-1/2 nucleus as a function of the magnetic field strength 
(B0). The splitting of the nuclear spin energy levels in a low energy α spin state and a high energy β spin 
state is called the Zeeman splitting. Adapted from (22). B: Spin precession around B0. Adapted from (23).
γh       nB0
2π      4kT
2
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it is abundant in the human body, constituting water and many other molecules. 
This makes it the most commonly studied nucleus with in vivo NMR, i.e. MRI or MR 
spectroscopy. Also other spin-1/2 nuclei such as 31P, 19F and 13C are often considered 
for investigation despite their lower gyromagnetic ratios. Common isotopes in the 
human body such as 12C and 16O are spinless and can not be studied by NMR.
It is difficult to detect the total spin magnetization along the direction of the 
magnetic field, i.e. the longitudinal magnetization. The magnetism originating from 
the electrons in the sample is about four orders of magnitude higher than that of the 
nuclei. In order to observe nuclear magnetization, the precessional motion of the 
nuclear spins needs to be detected. This is possible in the plane perpendicular to the 
magnetic field. 
To bring the magnetization towards the transversal plane, a second magnetic 
field (B1) needs to applied perpendicular to the main magnetic field. If this field 
oscillates at the Larmor frequency of the nuclei of interest, it matches the energy 
difference between the two spin states and can thereby induce transitions in spin 
states. The Larmor frequency is in the range of radiofrequencies (MHz), so the 
B1 field is generally applied as a radiofrequency (RF) pulse generated by RF coil. 
Transversal magnetization can be generated by an RF pulse with a specific duration 
and strength that effectively equalizes the populations of the two spin states. The 
Figure 1.4 - A: Spin polarization in B0 leading to a net total magnetization (M0) in thermal 
equilibrium. For positive γ, the low-energy α state is populated slightly more than the high-energy 
β state. B: An RF pulse induces transitions in spin states. By applying a 90° RF pulse, the spin 
states get equally populated, creating magnetization perpendicular to the main magnetic field. 
Adapted from (23).
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population difference between the spin states is converted into coherences, which 
indicates transverse spin magnetization (Fig 1.4B). This pulse is therefore called a 
90° RF pulse. It is also possible to inverse the direction of the magnetization by a 
180° RF pulse. 
After the RF pulse is turned off, the spins resume their precessional motion 
simultaneously, creating a temporary state of phase coherence. This coherent 
precessing of transversal magnetization is very small, but it can be detected by a 
receiver RF coil (Fig. 1.5). 
The NMR signal created in this way decays over time and is therefore known as the 
free induction decay (FID). The decay is caused by loss of the phase coherence in 
the transversal plane because of small changes in the local magnetic field induced 
by surrounding spins. This is called T2 relaxation. The transversal magnetization is 
lost even more rapidly in the presence of macroscopic field inhomogeneities. The 
combined effect of spin interactions (microscopic) and macroscopic inhomogeneities 
is called T2* relaxation. The return of the magnetization towards the longitudinal 
direction to thermal equilibrium is called T1 relaxation. T1 relaxation is by definition 
slower than T2 and T2* relaxation. 
Magnetic Resonance Imaging
The introduction of magnetic field gradients for spatial encoding of the NMR 
signal in 1973 represents a milestone in the development of NMR in medicine. It 
allowed imaging of objects in the magnet. Water protons obtain different frequencies 
depending on their location in the object when a gradient, i.e. a position dependent 
magnetic field, is applied in addition to the static magnetic field. The recorded 
Figure 1.5 - Detection of the precessing transverse magnetization using a RF coil. The induced oscillating 
electric current in the coil is called the NMR signal or free induction decay (FID). Adapted from (23).
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NMR signal will contain location dependent information by playing out RF pulses 
and switching of gradients in a specific pattern, the so-called pulse sequence. The 
spatial information mapped using basic sequences are differences in T1, T2 and 
T2* relaxation between various tissues. These differences provide contrast between 
tissues and thus result in anatomical information in an NMR image. The N of nuclear 
was dropped in the in vivo MR field to prevent confusion about possible harmful 
nuclear radiation, which is why we are generally talking about MR imaging or MRI.
Basic MRI sequences localize signals in a 3D object in three steps: slice selection, 
frequency encoding and phase encoding. A slice can be selected by simultaneously 
applying a frequency-selective RF pulse and a gradient. The RF pulse excites a 
selective frequency range which corresponds to a selective range of positions because 
of the gradient (Fig. 1.6). Next, the spatial information inside the selected slice can 
be obtained using the orthogonal frequency and phase encoding gradients. The 
frequency encoding gradient is turned on during the acquisition of the MR signal. 
The acquired signal therefore consists of a range of frequencies that can be related to 
their spatial positions. For phase encoding, a short gradient is switched on between 
excitation and acquisition of the signal. The spins acquire a phase-shift depending 
on the amplitude and duration of this gradient. To be able to retrieve all spatial 
information, the sequence with slice selection and frequency encoding during signal 
readout needs to be repeated with different phase encoding gradient amplitudes 
Figure 1.6 - Principle of slice selection with magnetic field gradients. A magnetic field gradient 
in the z direction generates a distribution of magnetic field strengths (superimposed on the main 
magnetic field B0). The resonance frequencies therefore become linearly dependent on the spatial 
position z. A selective range of frequencies Δω can be excited by a frequency-selective RF pulse. 
This range of frequencies corresponds directly to a selective range of spatial positions Δz, i.e. a slice. 
Adapted from: (22).
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Figure 1.7 - Standard gradient-echo (A) and spin-echo (B) MRI sequences. In gradient-echo, opposite 
signed gradients in the frequency encoding direction dephase and rephase the signal to generate an echo. 
The excitation pulse is usually smaller than 90° to reduce T1 saturation at short repetition times. In spin-
echo, the 180° RF refocusing pulse reverses the direction of the spins processing in the transversal plane, 
thereby also refocusing signal decay caused by field inhomogeneities (T2* decay). The negative gradient 
following the excitation pulse is necessary to refocus signal that was dephased during excitation. The 
echo is frequency and phase encoded to obtain spatial localization in the plane selected by the excitation 
pulse. Adapted from: (22).
(phase steps). The time signals recorded during the different phase encoding steps 
are stored in a 2D complex data space called k-space. The MR image is obtained 
after Fourier transformation of k-space. The number of phase steps and the strength 
of the frequency encoding gradient determine the in-plane resolution of the image. 
The majority of MRI sequences usually record a signal echo (gradient echo or spin-
echo, Fig. 1.7) instead of the FID, which allows better definition of the frequency 
and phase encoding gradients. Using opposite signed gradients in the frequency 
encoding direction in gradient-echo sequences, spins in the transversal plane are 
first dephased and during the signal acquisition rephased again, generating an 
echo. The 180° RF refocusing pulse in a spin-echo sequence reverses the direction of 
the spins processing in the transversal plane, thereby also refocusing signal decay 
caused by field inhomogeneities (T2* decay).
The contrast in an MR image is determined by the type of sequence, the echo timing 
(TE) in the sequence and the repetition time (TR) of the sequence. Multiple sequences 
with different timings are therefore used to optimally display different anatomical 
structures or pathologies. 
In prostate MR imaging, T2-weighted spin-echo based images provide optimal tissue 
contrast and are therefore of major importance to obtain anatomical information in a 
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prostate MR exam. Peripheral zone cancer can be recognized on T2-weighted images 
as round or ill-defined hypointensive foci (Fig. 1.8A). However, there are several 
confounders which show the same characteristics as a tumor lesion, e.g. prostatitis 
and hemorrhage. T1-weighted images are of less direct value as one cannot delineate 
the zonal anatomy or tumor lesions. Despite this they are useful for detecting post-
biopsy hemorrhage, which appears hyperintensive in these images (24).
Starting from the basic gradient-echo and spin-echo principle, many MR techniques 
have been developed which provide insight in tissue physiology. The most important 
sequences for prostate examinations are diffusion weighted imaging (DWI), dynamic 
contrast enhanced MR imaging (DCE-MRI) and MR spectroscopic imaging (MRSI). 
Using DWI, the mobility of water can be probed. This mobility has a complex relation 
with tissue structure, but generally densely cellular tissues or those with cellular 
swelling exhibit lower diffusion coefficients. Gradients and delays are added to a 
basic imaging sequence which create differences in phase coherence between static 
and diffusing spins. By varying the diffusion gradient strength (b-value) between 
acquisitions, the apparent diffusion coefficient (ADC) can be determined. Tumors in 
the peripheral zone of the prostate often show restricted diffusion, i.e. lower ADC 
values, than normal prostate tissue (Fig. 1.8B). 
In DCE-MRI, a gadolinium chelate contrast agent is administered intravenously to 
the patient to study tissue permeability and pharmacokinetic parameters. Using a 
series of fast T1-weighted acquisitions before and after rapid injection of a bolus of 
the contrast agent, the uptake of the contrast agent in the prostate can be followed. 
Prostate tumors usually enhance fast, similar to prostatitis in the peripheral zone 
and highly vascularized benign prostatic hyperplasia (BPH) in the transition zone 
Fig. 1.8 - Multiparametric MRI of a prostate with  a cancer lesion in the left peripheral zone. A: Anatomical 
imaging. Transversal T2-weighted turbo spin-echo MR image shows a low-signal-intensity lesion in left 
peripheral zone (outline) next to a region of high signal intensity in peripheral zone, with minimal signs 
of extracapsular extension (arrow). B: Diffusion weighted imaging. Transversal ADC map at the same 
level as A shows restricted diffusion in laterodorsal peripheral zone (T). C: Dynamic contrast enhanced 
MRI. Transversal MR image with a superimposed tissue permeability map at the same level as A shows 
multiple enhancing areas in both peripheral and transition zones, not exclusively in the tumor area (T). 
Adapted from: (7).
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(Fig 1.8C). DCE-MRI is therefore a very sensitive technique, but not very specific for 
prostate cancer only. 
MRSI allows spatial mapping of tissue metabolism. It is an imaging technique based 
on NMR spectroscopy principles. Where water protons provide the signal for MRI 
based techniques, the signals of other molecules are of interest in NMR spectroscopy. 
Often studied molecules in the prostate are citrate, choline and creatine. Since 
development of prostate MRSI techniques was subject of this thesis, the technique of 
NMR spectroscopy is introduced in more detail in the following section. 
(Nuclear) Magnetic Resonance 
Spectroscopy
Years before radiologists started to use MRI as a diagnostic tool, the principle of 
NMR was already used by chemists and physicist to characterize material. Instead 
of recording images, they produced NMR spectra. An NMR spectrum contains 
information about the molecular composition of a sample under investigation.  
Although the resonance frequency of a specific atomic nucleus is mainly determined 
by the magnetic field strength (Eq. 1.2), it is also slightly affected by the chemical 
environment of the nuclei. The nuclei are shielded from the external magnetic field 
by the electrons surrounding them, thereby reducing their resonance frequency with 
a shielding constant σ that depends on the chemical environment of the nucleus:
  ω = γ ∙ B0 (1-σ)      [1.3]
Nuclei at different positions in a molecule and in different molecules thus show 
different resonance frequencies. This effect explains why NMR has become such 
a powerful technique in chemistry; it allows the study of the chemical structure of 
molecules. 
A recorded FID contains combined signals of different frequencies, which can be 
unraveled by applying a Fourier transform. This results in a frequency-domain 
NMR spectrum, in which nuclei of different resonance frequencies are recognized as 
separate vertical lines, also called resonances or peaks (Fig. 1.9). The intensity of the 
resonances reflects the amount of the nuclei present in a sample (NMR spectroscopy) 
or at a certain location in the human body (in vivo MR spectroscopy). 
Because the exact resonance frequencies are dependent on the magnetic field strength, 
a field independent measure is used for the x-axis of NMR spectra: chemical shift 
(Fig. 1.9). Chemical shift (δ) is calculated by:
    δ = (       ) ∙ 106     [1.4]ω - ωrefωref
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and is therefore expressed in parts per million (ppm). ωref is the resonance frequency 
of a reference compound. In in vivo MR spectroscopy, conventions regarding 
chemical shift referencing are adapted, assigning for example water to 4.7 ppm in 1H 
spectroscopy and phosphocreatine to 0.0 ppm in 31P spectroscopy. 
The spectral resolution of (N)MR spectra is determined by the combination 
of the magnetic field strength (number of Hz per ppm) and the magnetic field 
homogeneity. The line width of spectral resonances is proportional to 1/(πT2*), 
and inhomogeneities in the field decrease T2* relaxation times. A living subject in 
the magnet reduces the field homogeneity more than a small non-moving sample. 
Although field homogeneity can be optimized in the body part of interest by 
applying so-called shimming gradients, in vivo MR spectra show much broader 
lines than spectra obtained from samples with a high resolution NMR spectrometer. 
RF coils are capable of transmitting and/or receiving signals of a limited range of 
frequencies. They are therefore tuned to capture a window of Larmor frequencies of 
a specific nucleus, e.g. hydrogen (1H). Most MR equipment is dedicated to a single 
frequency window only (often 1H in clinical MR scanners), but so-called multi-
nuclear (N)MR systems are also available. These systems extend the possibilities to 
characterize complex molecular structures, since couplings between nuclear spins 
have a strong effect on the appearance of the spectra and can be used to perform 
spectral editing. 
There are two different mechanisms of interactions between spins, through-bond 
scalar coupling and through-space dipolar coupling. The first mechanism, scalar 
Figure 1.9 - Proton NMR spectrum of ethanol at 4.7 T. The protons of the CH2 group give rise to the left 
group of peaks with chemical shift 3.65 ppm and the protons of the CH3 group to the right group of peaks 
with chemical shift 1.17 ppm. The protons within each group are magnetically equivalent, the splitting of 
the peaks is caused by j-coupling between the groups. Adapted from (23).
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coupling or j-coupling, leads to splitting of resonances into several smaller lines. The 
splitting results from J-coupling induced changes in the spin energy levels (22). The 
splitting pattern of resonance provides information about molecular structure, e.g. 
a doublet indicates scalar coupling with a one other spin, a triplet with two other 
spins etc (Fig. 1.10). The splitting distance is defined by the J-coupling value in Hertz. 
J-coupling between similar nuclei as well as between different nuclei can be present, 
respectively called homonuclear and heteronuclear couplings. The combination of 
chemical shift with J-coupling patterns can thus be used to identify molecules in a 
sample. A prerequisite here is however a high spectral resolution of the spectra. 
In some case the splitting behavior is undesirable. Because of the splitting, signal 
intensity is distributed over many small peaks. This complicates the detection of low-
concentration compounds. Some resonances from different molecules show very 
similar chemical shift, and therefore overlap at lower spectral resolutions. Splitting 
because of J-coupling often aggravates the overlap. Fortunately, heteronuclear 
couplings can be eliminated by decoupling techniques. When for example a 31P 
spectrum is acquired, high-power RF irradiation on the 1H channel during signal 
acquisition results in a spectrum with mostly singlet 31P resonances. (Fig. 1.11).
Homonuclear J-coupling between two nuclei in the order of their mutual chemical 
shift causes overlap in their individual resonances. This creates variation in their 
Figure 1.10 - J-splitting phenomenon of coupled spins. A: a 13C doublet, caused by coupling to one proton. 
B: A 13C triplet, caused by coupling to 2 protons. C: A 13C quartet, caused by coupling to 3 protons. In all 
cases the heteronuclear J-coupling between the carbon and proton(s) was JCH = 100 Hz. Adapted from (23).
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resulting joint spectral shape, so-called strong coupling effects. Because the individual 
resonances have different frequencies, the phase of their signals is modulated as a 
function of the echo time. The joint spectral shape of strongly coupled resonances 
therefore depends on the timings in the spectroscopy sequence used to obtain 
the spectrum and the magnetic field strength. An example of a strongly coupled 
molecule is citrate. This molecule is present in high concentrations in the human 
prostate. Figure 1.12 shows the modulation of the shape of citrate at 3 T.  
The other type of coupling, through-space dipolar coupling, involves the influence 
of each spin on its neighbor through its own magnetic field. It is the main mechanism 
for relaxation in liquids and often for tissues as well. In MR spectroscopy it is further 
used to generate the Nuclear Overhauser Effect (NOE), in which nuclear spin 
polarization is transferred from one spin population to another via dipolar relaxation 
processes. NOE experiments can be employed to establish distances between atoms 
or to enhance signals of nuclei with lower sensitivity than 1H, the latter being of 
special interest in in vivo MR spectroscopy. To establish a NOE, low-power RF 
irradiation has to be applied to saturate the 1H spins before signal acquisition. 
In vivo MR spectroscopy probes metabolic processes by measuring the presence of 
small molecules in living tissue. These small molecules involved in tissue metabolism 
Figure 1.11 - Effect of 1H decoupling on in vivo 31P brain spectra acquired at 1.5 T. A: No decoupling. 
B: Proton decoupled. Spectra are scaled to the phosphocreatine (PCr) amplitude in spectrum A. In 
the decoupled spectrum the metabolite peaks of phosphoethanolamine (PE), phosphocholine (PC), 
glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC) are well resolved in the regions 
which can only be defined as phosphomonoesters (PME) and phosphodiesters (PDE) in the non-
decoupled spectrum. The ATP peaks are splitted in both spectra because of their homonuclear 31P 
J-couplings. Adapted from (34).
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are called metabolites. Commonly, the strength of the signals of these metabolites in 
MR spectroscopy is low compared with the water signal employed in standard MRI, 
since the concentration of metabolites in the body is orders of magnitude lower than 
that of water. 
In the early days of in vivo MR spectroscopy, spectra were acquired using surface 
RF coils placed against the tissue of interest, without any further type of localization. 
Using pulse sequences with only one or two RF pulses (one for signal excitation, 
one for water suppression in case of 1H MR spectroscopy), a spectrum dominated 
by signal from superficial tissue was acquired by signal averaging. An exception to 
the superficial tissues studied was the prostate, which can be easily reached by an 
endorectal RF coil. In the early 1990s, several reports were published about human 
1H and 31P MR spectroscopy of the prostate at 1.5 and 2 T, showing indication of 
differences in metabolite levels between prostates of healthy volunteers and prostates 
of patients with prostate cancer (25–28). 
The advent of more advanced RF coils generating uniform fields through the body 
and localization techniques using gradients enabled more precise detection of 
metabolites at a certain location, also of tissues deeper in the body. Using single voxel 
localization techniques, spectra can be obtained from a well-defined volume in the 
body, thereby minimizing contamination from adjacent tissues such as superficial 
lipids. 
Figure 1.12 - Modulation of the spectral shape of citrate at 3 T. Resulting spectral shape at different timings 
of PRESS sequence (see Fig. 1.13) are shown. Source: (35).
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An often employed localization technique for prostate 1H MR spectroscopy is 
point resolved spectroscopy (PRESS). The PRESS sequence is a double spin-echo 
localization method (Fig. 1.13). The recorded echo only contains signal of the 
intersection volume of three slices, the so-called volume of interest (VOI). A 1H 
MR spectrum of the prostate generally shows signals from the metabolites choline, 
spermine, creatine and citrate. By recording spectra from VOIs located in healthy 
prostate tissue and in prostate cancer tissue, it was observed that citrate levels 
decrease in prostate cancer, while choline levels increase (29,30). 
Using multi-voxel spectroscopy techniques, spectra from different spatial locations 
can be measured within one spectroscopic exam (Fig. 1.14). These techniques combine 
MR spectroscopy and MR imaging, and are therefore called MR spectroscopic 
imaging (MRSI). To record an MRSI dataset, 2D or 3D phase encoding is used. The 
amplitudes of the phase encoding gradients are changed every TR to fill a k-space 
matrix like in MRI. This results in long data acquisition times, even though the 
matrices are several times smaller than used for MRI. Faster read-out schemes are 
possible (31,32), but the low intrinsic sensitivity of MRSI at clinical field strengths 
prevents taking full advantage of these techniques.  
MRSI can be performed with and without additional VOI selection. The selection of 
a VOI allows a smaller field of view and thereby higher spatial MRSI resolutions. 
In prostate 1H MRSI, it is common to select a VOI that covers the full prostate, but 
also some of the surrounding lipid tissue, since the VOI is cubical. The lipid signals 
are much stronger than the metabolite signals and this will lead to contamination of 
Figure 1.13 - PRESS pulse sequence for spatial localization of an MR spectrum. The first spin-echo 
is formed at time 2τ1, the second 180° pulse refocuses this spin-echo during delay 2τ2, such that the 
final spin-echo is formed at TE = 2τ1 + 2τ2. Two pairs of crusher gradients (different in direction and/or 
amplitude) surrounding the 180◦ refocusing pulses ensure the selection of the desired coherences, while 
simultaneously destroying all others. Source: (22).
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the prostate spectra if no precautions are taken. A combination of spatial saturation 
bands and frequency selective lipid suppression pulses can be used to minimize 
lipid contamination (33). 
Currently, MR spectroscopy is not often part of clinical MR routine in radiology. 
The main reasons for this are the relatively long acquisition times needed, and 
the lack of adequate automatic processing and easy digestible data display tools. 
Nevertheless, in a (clinical) research setting MR spectroscopy is a valuable tool to 
gain more fundamental insights into metabolism of many tissues in normal and 
diseased state. Frequently studied tissues include the brain, muscle, liver, heart, 
breast and prostate. 
Fig. 1.14 - 1H MR spectroscopic imaging of the prostate at 3 T using a PRESS sequence. A: The spectroscopic 
matrix is displayed on top of the T2-weighted prostate image. The outer yellow square indicates the field 
of view, the smaller white square is the volume of interest. Saturation bands are not indicated in this 
image, but were used to suppress lipids. B: Spectrum from a voxel in normal peripheral zone tissue (left 
sphere in A) with choline (Cho), creatine (Cr), spermine (Spm) and citrate (Cit) resonances. C: Spectrum 
of tumor tissue (right sphere in A) showing increased Cho and decreased Cit levels compared with B. 
Adapted from (9).
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Outline of this thesis
The work presented in this thesis focused on developing, implementing and 
evaluating new MR techniques for prostate research at a magnetic field strength 
of 7 T. This ultra-high field strength is not yet available for clinical examinations, 
but is of interest because signal-to-noise ratios in MR increase approximately linear 
with field strength. A higher signal-to-noise ratio is especially beneficial for MR 
techniques with a low intrinsic sensitivity, such as MR spectroscopy. The techniques 
of main interest in this thesis work were therefore 1H and 31P MR spectroscopic 
imaging. 
Performing in vivo prostate MR at a higher field strength is not a straightforward 
process of copying MR pulse sequences from the lower field strength, and taking 
advantage of the higher signal-to-noise by increasing spatial resolution or decreasing 
scan time. In Chapter 2, the effect of field strength on prostate MR exams including 
T2-weighted imaging, diffusion weighted imaging, MR spectroscopic imaging 
and dynamic-contrast enhanced imaging is described. The step from 1.5 T to 3 T is 
evaluated from a technical perspective. Moreover, the particular challenges related 
to even higher field strengths such as 7 T are introduced. 
In Chapter 3, the concept to perform 1H MR spectroscopic imaging of the prostate at 
7 T is revisited. A MR pulse sequence using spectral-spatial RF pulses was developed, 
which was used in combination with a hardware setup consisting of an external 
multi-channel transmit coil and an endorectal receive coil. The increased spectral 
resolution at 7 T was exploited in the spectral selectivity of the pulses to obviate the 
need for additional water and lipid suppression RF pulses. Moreover, the hardware 
allowed the use of conventional low-power RF pulses, keeping power absorption 
by the body during the sequence low. The effect of this new pulse sequence on the 
appearance of the prostate metabolites was investigated using simulations, phantom 
measurements and in vivo measurements. 
The strength of prostate MR lies in the combination of anatomical T2-weighted 
imaging with one or more functional MR techniques. Any added value of 7 T for a 
single MR technique could only be exploited if the other techniques are available at 
7 T as well. Chapter 4 shows the feasibility to perform a multiparametric MR exam 
of the prostate at 7 T including T2-weighted imaging, diffusion weighted imaging 
and 1H MR spectroscopic imaging in 14 patients with prostate cancer. Image quality 
was evaluated by radiologists and artifacts were identified to optimize the protocol 
for future use. 
Next to proton-based MR spectroscopic imaging, it is of interest to study the 
prostate using phosphorus (31P) MR spectroscopy. A phosphorus spectrum contains 
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information about the energy metabolism of the tissue as well as about the metabolism 
involved in cell membrane turnover. Cancer distorts metabolic processes and the 
increase of the choline peak observable in proton MR spectra of prostate cancer is 
related to this. This peak however represents several metabolites of which most can 
be studied individually using 31P spectroscopy. 31P spectra therefore complement the 
information of 1H spectra, presumably improving tumor characterization. The aim 
of the work presented in Chapter 5 was to develop and optimize a measurement 
protocol for 31P MR spectroscopic imaging at 7 T. This protocol was used to study 
15 patients with prostate cancer. The results of this patient study are presented in 
Chapter 6. 
Part of the optimization strategy employed for 31P MR spectroscopic imaging was the 
use of the Nuclear Overhauser Effect (NOE). This effect is utilized to enhance signals 
of nuclei with lower sensitivity than 1H. The optimization study however showed 
quite variable NOE enhancement factors. The cause of this variability was subject of 
the in Chapter 7 presented repeatability study of native and NOE-enhanced 31P MR 
spectroscopic imaging. 
Finally, the work described in this thesis is discussed in Chapter 8 and summarized 
in Chapter 9. 
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Abstract
Magnetic resonance imaging is attracting increasing attention from the uroradiological 
community as a modality to guide the management of prostate cancer. With the 
high incidence of prostate cancer it might come as a surprise that for a very long time 
(and in many places even at present) treatment decisions were being made without 
the use of detailed anatomical and functional imaging of the prostate gland at hand. 
Although T2-weighted MRI can provide great anatomical detail, by itself it is not 
specific enough to discriminate cancer from benign disease, so other functional MRI 
techniques have been explored to aid in detection, localization, staging and risk 
assessment of prostate cancer. With the current evolution of clinical MR systems 
from 1.5 to 3 T it is important to understand the advantages and the challenges of 
the higher magnetic field strength for the different functional MR techniques most 
used in the prostate: T2-weighted MRI, diffusion-weighted MRI, MR spectroscopic 
imaging and dynamic contrast-enhanced imaging. In addition to this, the use of the 
endorectal coil at different field strengths is discussed in this review, together with 
an outlook of the possibilities of ultra-high field MR for the prostate.
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Introduction
The use of MRI and functional MR techniques in the management of prostate cancer 
has gradually gained importance during the last decades. In the late 1980s it was 
recognized that the excellent soft tissue contrast provided by MR could be beneficial 
in assessing prostate abnormalities (1). Initial studies showed the opportunities to 
detect prostate cancer on T2-weighted (T2W) MR images (2). Moreover, MR was 
found to be moderately sensitive as a staging modality to differentiate patients 
with organ-confined prostate cancer from those with extracapsular tumor extension 
(2,3). An accurate assessment of this local stage is of the highest importance in the 
treatment decision tree: confined disease can be treated with curative intent (radical 
prostatectomy or external beam radiotherapy), whereas extended disease has 
traditionally been treated without curative intent (different kinds of radiotherapy, 
hormone therapy), and traditional diagnostic methods such as digital rectal 
examination (DRE) and transrectal ultrasound provide little information about it. 
The increasing use of prostate-specific antigen (PSA) tests has extended the patient 
population, with more men initially presenting at low clinical stage (T1 and T2) of 
prostate cancer. This earlier detection of prostate cancer has led to concerns about 
possible overdiagnosis and overtreatment (4,5). Regular PSA testing has also led to 
a large number of patients suspected of having prostate cancer, because of a high 
or rising PSA level, but with negative DRE and ultrasound-guided biopsies. These 
changes in patient population asked for both a change in treatment options and 
better diagnostic methods. 
New focal therapies such as intensity modulated radiation therapy, cryotherapy and 
laser therapy to treat intra-prostatic low-stage prostate cancer are currently under 
investigation (6). They may become an alternative to radical prostatectomy and 
high-dose conformal radiotherapy, the current methods of treatment for patients 
with organ-confined prostate cancer and a life expectancy of at least 10-15 years, but 
associated with several co-morbidities. As a reaction to the trend of overtreatment 
of prostate cancer, and as a recognition of the often slow progression of the disease, 
active surveillance of low-risk cancer instead of direct therapy is considered more 
often these days (7). The success of many, if not all, of these treatments depends, 
or should depend more, on accurate information about the presence, location, size, 
local stage and aggressiveness of the tumor(s) at hand. MR is therefore gaining 
importance since it will help urologists to determine the best treatment strategy for 
each patient. 
As MR technology has continuously been making progress, with a growing number 
of imaging techniques, but also with a gradual increase in magnetic field strength, 
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it can currently provide much more information about prostate cancer than in 
the early days of prostate MR. In addition to conventional anatomic T2W-MRI, 
functional MR techniques such as diffusion-weighted imaging (DWI), dynamic 
contrast-enhanced MR imaging (DCE-MRI) and proton MR spectroscopic imaging 
(1H MRSI), nowadays combined in a multiparametric MR examination, have shown 
their benefit in detecting, localizing and assessing prostate cancer (8). 
The step from 1.5 to 3 T can greatly improve the quality of prostate MR exams, 
because of the clinically established approximately linear increase of signal-to-
noise ratio (SNR) with static magnetic field strength (9). This SNR increase can 
be exploited to increase the spatial resolution of the different functional imaging 
techniques (T2W-MRI, DWI, 1H MRSI) and/or to reduce scanning times, increasing 
temporal resolution (DCE-MRI). 1H MRSI also benefits from the increased spectral 
resolution, which improves separation of closely adjacent metabolite peaks. Other 
than advantages in SNR, a higher field strength also entails several technical 
challenges to overcome, such as increased RF energy deposition, changes in 
relaxation times, stronger susceptibility effects and undesired dielectric resonance 
effects. Adjustments to pulse sequences and coils are therefore required to obtain 
prostate MR images with good quality.
This review will describe the step from 1.5 to 3 T for the most widely used MR 
techniques to image prostate cancer (T2W-MRI, DCE-MRI, DWI and 1H MRSI). For 
each technique, the specific advantages of the higher field strength are presented, 
together with the technical challenges that have to be overcome for proper imaging. 
In the light of the increased SNR at 3 T, the use of an endorectal coil for prostate MR 
exams is discussed separately. In addition, an outlook for the possibilities of MR of 
prostate cancer at even higher field strengths is provided. 
T2-weighted MRI of the Prostate
T2W-imaging provides anatomical contrast because of the variety in transverse 
relaxation times (T2) of the different structures and tissues in the prostate. To depict 
prostate anatomy, high resolution T2W turbo spin-echo (TSE) MR images are 
generally obtained in 2 or 3 orthogonal planes. 
As T2W-MRI is the clinical workhorse for depicting prostate anatomy, the most 
significant benefit of moving to 3 T is the possible increase in spatial resolution to 
improve visualization of the anatomical details (Fig. 2.1). From 1.5 to 3 T, the pixel 
volume can roughly be halved, if the performances of the coil setups at both fields 
were similar (see Prostate imaging – use of different coils). 
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A state-of-the-art T2W-MRI of the prostate at 3 T in 3 directions with an in-plane 
resolution of 0.4 x 0.4 mm and a slice thickness of 3 mm can be performed within 
13 min with a combination of a pelvic phased array and endorectal coil. The same 
spatial resolution with a similar coil setup at 1.5 T would require an unacceptable 
acquisition time of approximately 50 min. In clinical practice at 1.5 T, an in-plane 
resolution of 0.6 x 0.6 mm is employed at similar slice thickness and total acquisition 
time. 
Staging accuracy of biopsy-proven local prostate cancer by T2W-MRI with 
an endorectal coil at 3 T has been reported up to 94% when performed by an 
experienced radiologist (10) compared with 83% at 1.5 T in the same institution (11). 
Other work from different institutions at either 1.5 or 3 T reports conflicting staging 
performances for the two field strengths, nicely summarized in (8). Difficulties 
remain in comparing these studies with only field strength in mind, as coil types, 
patient cohorts and staging endpoints were not the same. In the absence of large 
studies that directly compare staging performance in the same patient cohort with 
similar setups at the two field strengths, we can only assume a staging performance 
gain with the increase in spatial resolution at 3 T. With the spatial resolution available 
at 3 T, minimal capsular invasion could also be detected (10), which imposes a new 
challenge to the urologist: traditionally, based on DRE, the difference between 
organ-confined (stage T2) and locally advanced (stage T3) prostate cancer led the 
choice of treatment (curative intent for stage T2 or delaying and palliative intent for 
Figure 2.1 - Prostate carcinoma in a 64-year-old male. A, B: T2W axial TSE image at 1.5 T (TE: 120 ms) 
(A) and at 3 T (TE: 119 ms) (B), both with an in-plane resolution of 0.35 x 0.35 mm. A low-signal-intensity 
lesion in the right peripheral zone and central gland (arrows) is visible, corresponding to positive biopsy 
findings. The capsule at the right side of the prostate demonstrates bulging (arrowhead) and irregular 
capsule suggesting invasion. C: T2W high-resolution axial image at the same slice position as A and B 
using TSE (TE: 162 ms) with an in-plane resolution of 0.18 x 0.18 mm at 3 T. The capsule demonstrates 
bulging (arrowhead) and is disrupted (open arrow) indicating extracapsular extension. D,E and F: detail 
(3x zoom) of A, B and C, respectively, with increased anatomical detail of F compared with A and B. 
Source: (15).
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stage T3). It is unknown whether for minimal capsular invasion, perhaps capturing 
very early onset of T3 disease, the same treatment decision is the best choice. 
In addition to a gain in spatial resolution, image contrast is an aspect that needs to 
be optimized for a specific field strength. The T2 relaxation times of tissues generally 
decrease slightly with increase in field strength (9). The knowledge of T2 relaxation 
times in the different prostate tissues should be utilized to maximize contrast 
between normal peripheral zone prostate tissue, normal transition zone prostate 
tissue and, most importantly, prostate cancer tissue. At 1.5 T, the peripheral zone T2 
is longer than the transition zone and tumor tissue T2-values (122±34 ms, 88±13 ms 
and 82±18 ms, respectively) (12). The small difference in T2 between transition zone 
tissue, which often expresses BPH (T2=91±13 ms), and tumor tissue makes tumor 
recognition in this zone based on T2-value only more difficult than in the peripheral 
zone. When moving to 3 T, de Bazelaire et al. found a slight decrease in T2 of the 
overall gland compared with 1.5 T (88±0 and 74±9ms for 1.5 and 3 T, respectively) 
(13), while Gibbs et al. reported an increase in T2 in both peripheral zone (142±24 
ms) and tumor tissue (109±20ms) with respect to their values measured at 1.5 T (14). 
The differences in T2 relaxation times in prostate between 1.5 and 3 T are thus not 
very pronounced, making changes in echo time (TE) for optimal contrast in T2W-
MRI when moving from 1.5 to 3 T not very crucial (15–17). 
Using TEs beyond the T2 of normal prostate tissue is common practice at both 1.5 
and 3 T (e.g., TE of 96–132 ms versus T2 of 88 ms at 1.5 T and TE of 109-124 ms versus 
T2 of 74 ms at 3 T) (10,11,18–20). The difference between cancer and healthy prostate 
tissue becomes more profound at longer TEs, provided the tissue with the shortest 
T2 still has adequate SNR (20). 
The amount of energy that is absorbed by tissue when it is exposed to an 
electromagnetic field (the specific absorption rate or SAR) is determined by the 
electrical component of the radiofrequency (RF) pulse. When moving from 1.5 to 
3 T, the frequency of the RF oscillations doubles, which leads to an approximate 
quadratic increase in SAR (for an equal RF pulse). To stay within European Union 
imposed SAR safety limits the RF-intensive sequences, such as the TSE sequence 
for T2W-imaging of the prostate, need some alterations to their conventional (1.5 T) 
parameters. For prostate examinations at 3 T, partial refocusing pulses (120-150 
degrees instead of 180 degrees) or the use of variable flip angles in the multiple 
echo train (21,22) are usually enough to adhere to SAR safety limits (assuming 
homogeneous distribution of the electrical component of the RF pulse over the 
whole exposed body).
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Diffusion-Weighted Imaging 
of the Prostate
Although the exact origin of contrast in DWI has not been fully established yet, the 
degree of apparent water diffusion in biological tissue is related to many aspects 
of the tissue, such as structural organization, cellularity and the integrity of cell 
membranes. The tubular structure of healthy prostate tissue in the peripheral zone 
allows extensive unrestricted diffusion of water molecules. This normal glandular 
structure is destroyed or displaced by prostate cancer tissue with a higher cellular 
density. The loss of glandular tissue and increase in cell density lead to more 
restrictions for diffusion of water molecules in cancer tissue, decreasing the mean 
distance the average molecule can travel within a certain time, which can be 
effectively probed by DWI (23). DWI was shown to have incremental value relative 
to T2W-MRI in detecting prostate cancer, and it may play a role in determining the 
aggressiveness of the prostate tumor (24–26). 
Many studies have demonstrated the feasibility of DWI at 1.5 T in the human 
prostate as well as its ability to visualize tumor lesions in both the peripheral and 
transition zone (12,27–31). Prostate DWI is typically obtained using spin-echo echo-
planar imaging (EPI) techniques (usually single-shot) with two diffusion-encoding 
gradients (or gradient pairs) in three directions. The product of the squared duration, 
squared amplitude and diffusion time (temporal separation) of these two gradients 
are used to calculate the so-called b-value. The apparent diffusion coefficient (ADC) 
can be deduced from the exponential attenuation of DWI signal intensity with 
b-value: the limited SNR of a single shot EPI image without diffusion gradients (b = 
0) is even further reduced by attenuation with these gradients (b = several hundred 
to thousands). Due to these SNR limitations DWI started to attract more attention in 
the prostate MR field after the introduction of magnetic field strengths of 3 T. 
The increase in SNR at 3 T enables either an increased spatial resolution or an 
increase in SNR of the ADC maps (Fig. 2.2). An increased spatial resolution puts 
strain on the performance of the EPI imaging module of DWI, as a larger matrix 
requires a longer EPI echo train, which is prone to artifacts. With the increase in 
field strength, susceptibility differences within tissue or at tissue-air interfaces also 
increase. These degrade image quality with single-shot EPI since this method has 
only a very small bandwidth per pixel along the phase encoding direction (9,32). To 
reduce these artifacts at 3 T, diffusion-weighted single-shot EPI is combined with 
parallel imaging strategies, shortening echo train lengths and thus reducing the 
accumulation of phase errors. 
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A large variety exists of imaging parameters for DWI at 1.5 and 3 T, both in spatial 
resolution and in the number and size of b-values needed (24,33–35). In recently 
published recommendations from a European consensus meeting on prostate MR 
an in-plane resolution of 1.5 x 1.5 mm, a slice thickness of 4 mm and acquisition of 
3 b-values in three orthogonal directions (0, 100 and 900-1000 s/mm2) are posed as 
minimum requirements for DWI at 3 T (36). At our institution, prostate DWI at 3 T 
with a multi-element phased-array coil for signal reception is performed in the axial 
plane with a single shot EPI sequence with diffusion-encoding gradients in three 
directions (b-values of 0, 50, 500, and 800 s/mm2). Further parameters are as follows: 
TR range/TE range, 2300-4100 ms/81-96 ms; slice thickness 3 mm, interslice gap 0.6 
mm, in-plane resolution of 1.5 x 1.5 mm, GRAPPA factor 2, averages 6 to 8. ADC maps 
are automatically calculated from the 4 b-value images by fitting signal attenuation 
as a function of the b-value to mono-exponential decay. Excluding b = 0 from the fit 
limits the effect of macroscopic motion due to flow (microcapillary perfusion) on the 
calculation of the ADC (37), as unidirectionally moving spins cause fast attenuation 
of the signal. In a DWI image with b = 50 or 100 the signal contribution of flowing 
spins is already negligible. Very recently, it has been shown that this phenomenon 
can be used to calculate the perfusion fraction with a combination of b = 0 and two 
other b-value images (<750 s/mm2). This fraction correlated well with DCE-MRI 
parameters, with elevated values in tumor compared with normal prostate tissue 
(38). The acquisition of a b = 0 image can also be of importance in image registration 
of multiparametric MRI. 
DWI at higher diffusion gradients (b>800 s/mm2) can identify areas with smaller 
ADC due to severe restrictions in motion and has less T2W shine-through (30), but 
leads to more signal attenuation. At 1.5 T, or at too high spatial resolution, a low 
SNR at these high b-values may confound interpretation of different ADC values, as 
it could be impossible to determine whether the decrease in ADC is due to reduced 
SNR or true restriction of diffusion (39). The information obtained from high b-value 
images and corresponding ADC maps at 3 T may however increase the accuracy 
of prostate cancer detection (35). Moreover, high b-values may help to improve 
differentiation of BPH from prostate cancer (40). Instead of being measured with 
low SNR, these high b-value DWI images can also be synthesized by extrapolating 
the mono-exponential decay curve from lower b-value images.
Figure 2.2 - T2W, DWI, and calculated ADC images of three patients with suspected prostate cancer 
with (A-F) and without (G-I) an endorectal coil at 1.5 T (A-C) and 3 T (D-I). The reception profile of the 
endorectal coil is visible in the T2W images (A, D) and the b = 0 DWI images (B, E), but is not present 
in the calculated ADC maps (C, F). The spatial resolution of DWI is considerably lower than for T2W-
MRI. Hypointense lesions on ADC maps, corresponding to anatomic abnormalities on T2W-MRI are 
suspicious for prostate cancer.
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Although DWI provides quantitative numbers for ADC, the calculated diffusion 
coefficient is indeed apparent, as what the actual diffusion time is (spacing between 
diffusion gradients) depends on the performance of the gradient system and chosen 
b-value. With linear dependence on diffusion time, but squared dependence on 
gradient duration and amplitude, it is a major shortcoming of MR system vendors 
not to show what these exact values are. At the same or similar b-values but with 
different diffusion times, ADC-values of tissue will be different, which makes a 
clean comparison of ADC-values from one study to another impossible. Therefore, 
although encouraging performance for the detection and characterization of 
prostate cancer has been reported, a general definition of cut-off values for the 
ADC to distinguish between cancer and non-cancer tissue in the prostate should be 
interpreted with caution.  
1H MR Spectroscopic Imaging 
of the Prostate
MR spectroscopic imaging of the prostate provides 3D spatially localized information 
about the presence of specific metabolites in a selected part of the proton spectrum 
in prostate tissue, such as citrate (2.60 ppm), choline (3.20 ppm), creatine (3.04 ppm) 
and polyamines (multiplet around 3.10 ppm) (Fig. 2.3). A high level of citrate is an 
important marker for healthy or benign prostate tissue, whereas prostate cancer is 
characterized by a combination of a reduced amount of citrate and increased choline 
levels (41,42). The ratio of signal integrals of choline + creatine to citrate combines 
these effects and is used as a marker for prostate cancer. This quantitative marker 
can be analyzed separately or in combination with the choline-to-creatine ratio in 
the standardized threshold approach (43,44), providing a reproducible measure (45) 
to be used to predict tumor presence and absence in both the peripheral as well as 
the transition zone, and it can help in determining prostate cancer aggressiveness 
(46–49).  
Since the signal in MR spectroscopy results from low abundant metabolites instead 
of from highly abundant water, an increase in intrinsic SNR by moving to a higher 
field strength is directly advantageous for this technique. Long acquisition times 
are required at 1.5 T to obtain 3D datasets with voxel volumes of about 0.5 cm3, 
which corresponds to the size of clinically significant tumors (50,51). At 3 T, 1H MRSI 
can be performed at a resolution of 0.6 cm3 effective voxel volume (nominal voxel 
resolution 6 x 6 x 6 mm) within 9 min (52) using an endorectal coil, or even without 
an endorectal coil in the same time at 1.0 cm3 effective voxel volume (nominal voxel 
resolution 6 x 6 x 6 mm) (53). At 1.5 T a similar resolution is obtained in 12 to 16 min, 
Chapter 2
2
40 41
Figure 2.3 - Typical spectra of voxels in the healthy peripheral zone (A-C) and in prostate cancer (D, E) at 
three different field strengths: 1.5 T (A, D), 3 T (B, E) and 7 T (C). Note the difference in spectral shape of 
citrate across the different field strengths, and the relative difference in metabolite levels between healthy 
peripheral zone and cancer. All spectra were acquired as part of a 3D MRSI measurement with the 
following effective voxel volumes (incorporating weighted k-space acquisition and filtering): 0.64 cm3 at 
1.5 T, 0.37 cm3 at 3 T and 0.19 cm3 at 7 T. PZ: peripheral zone; PCa: prostate cancer; Cho: choline containing 
compounds; Cr: creatine and phosphocreatine; Cit: citrate; and PA: polyamines, mainly spermine and 
spermidine. Collection of modified spectra from (46,49,97).
depending on whether k-space weighted acquisition and filtering has been applied 
(54) or not (42). At this resolution at 3 T with an endorectal coil, the SNR is not the 
limiting factor of the pulse sequence anymore. It is the acquisition of all steps in 
the weighted k-space sampling scheme that accounts for the total acquisition time, 
rather than multiple averaging for adequate SNR. New acquisition strategies are 
developed to overcome these limitations of 3 T and keep scan time short (55). 
For MRSI an increase in field strength is beneficial not only in terms of SNR, but also 
in terms of spectral resolution. The frequency dispersion between the different peaks 
in an MR spectrum increases linearly with field strength, whereas the line width 
of each peak depends on the T2* of the metabolites, reflecting the B0 homogeneity 
(compare Fig. 2.3A-C). Due to stronger susceptibility differences between tissues 
and between tissue and air or rectal gas, B0 homogeneity in and around the prostate 
deteriorates at higher fields. In order to make full use of the increased spectral 
resolution, the linewidths of the metabolites of interest in the spectra need to increase 
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less than linearly with field. Currently, supervised automated shimming procedures 
need to be employed to optimize the local B0 homogeneity in the prostate just before 
the MRSI data acquisition (56). The use of an endorectal coil is often combined with 
an inert fluid inside the inner balloon of this coil to locally reduce susceptibility 
differences, resulting in reduced mean line widths of voxels in the prostate of 7.3±2.0 
Hz (perfluorocarbon in endorectal coil) versus 13.3±3.0 Hz (air in endorectal coil) at 
1.5 T (57).
Another aspect of moving to a higher field strength is the inter-RF-pulse timing 
in the 3D point-resolved spectroscopy (PRESS) sequence for prostate MRSI. This 
pulse timing should be optimized with regard to the shape of citrate, of which 
four protons form a strongly coupled spin system around 2.60 ppm, and its shape 
depends on the pulse timings as well as on the magnetic field strength (58,59). The 
resulting TE of the PRESS sequence should also be smaller than or at least of the 
order of the T2 relaxation time of citrate and choline to have sufficient signal left 
at TE. The T2 values of 0.22±0.09 s for choline, and 0.17±0.05 s for citrate at 3 T (59) 
do not significantly differ from the values at 1.5 T (0.23±0.06 s for choline (60), and 
an averaged apparent T2 value of 0.13±0.03 s for citrate in the whole prostate (61)), 
but they emphasize the need to choose a short TE at both field strengths. At 1.5 T 
the optimal TE of the PRESS was therefore determined to be ~120 ms, where the 
central peaks of the citrate multiplet have the highest intensity and both citrate and 
choline still have sufficient signal left (62). For 3 T there are several possibilities for 
an in-phase spectral shape of citrate; a TE of 145 ms is often chosen as it provides 
a maximum positive citrate shape, which without spectral line fitting is easier to 
interpret than the negative citrate shapes at a TE of 75 and 100 ms (56,59). 
One would expect a better separation of the creatine and choline resonances at 
3 T compared with 1.5 T, because of the increase in spectral resolution. However, 
resonances from polyamines are often present between 3.0 and 3.3 ppm (63,64), 
which prevents the spectrum from reaching the spectral baseline between the 
creatine and choline signals (53). Signal intensities of the strongly coupled molecule 
spermine, the most abundant polyamine (63), also vary largely with magnetic field 
strength and pulse timing, just like citrate (65). The exact spectral shape of spermine 
around 3.10 ppm with regard to pulse sequence timing and field strength needs 
more investigation to improve the manual or automatic analysis of the spectra. 
As short repetition times are often used in 3D MRSI at both 1.5 and 3 T, knowledge 
of T1 relaxation times of the different metabolites can be of importance for correct 
interpretation and absolute quantification of the spectra. The T1 of citrate increases 
from 0.34±0.04 s at 1.5 T to 0.47±0.14 s at 3 T, where choline was measured to have a 
T1 of 0.84±0.09 s at 1.5 T and 1.1±0.4 s at 3 T (59,60). In 3D PRESS MRSI of the prostate 
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using weighted acquisition, the repetition time (TR) of choice to enable as many 
weighted acquisitions as possible in a clinically acceptable measurement time was 
640 ms and 750 ms for 1.5 and 3 T, respectively (54,59). Absolute quantification of the 
different metabolites would be desirable, but suffers from too many uncertainties 
at short TR, long TE, and changing spectral shapes with the currently employed 
sequences. Utilizing tissue water as an internal reference and correcting for the 
above-mentioned factors has been attempted to obtain absolute metabolite levels 
of the prostate at 1.5 T (60,66), but the accuracy of the results is questionable due to 
the number of corrections applied and assumptions made, e.g. equal tissue water 
content and metabolite relaxation times throughout the whole prostate. The current 
quantitative marker for prostate cancer – the choline + creatine to citrate ratio – 
should therefore be validated for the used pulse sequence timing and field strength 
(46). 
Dynamic Contrast Enhanced 
MRI of the Prostate
Contrast agents affect T1 relaxation times of water in tissue and this can be used 
to assess prostate vascularization. A bolus of low-molecular-weight paramagnetic 
contrast agent (gadolinium chelates, e.g. Gd-DTPA) is administered intravenously, 
distributes through the body and extravasates out of leaky vessels to extracellular 
compartments. There, the gadolinium chelate shortens the T1 relaxation times 
of the tissue, which can be probed with T1-weighted MR measurements. DCE 
techniques typically use fast spoiled 3D T1-weighted gradient-echo MRI sequences 
to repeatedly image a volume of interest during and after the administration of a 
bolus of intravenous contrast agent to monitor the contrast uptake and drainage in 
the organ of interest. If the vessel integrity of the capillary bed is degraded in tumors 
because of neoangiogenesis, the perfusion and microvessel permeability properties 
of these tumors deviate from normal tissue. Dynamic contrast enhancement in 
T1W-imaging can be assessed qualitatively or quantitatively by applying complex 
compartmental pharmacokinetic modeling techniques (67). Prostate cancer tends 
to enhance earlier, faster and to a greater extent, and shows earlier contrast agent 
washout, as compared with healthy prostate tissue. This makes DCE-MRI a sensitive 
technique for prostate cancer localization (68). DCE-MRI may also increase staging 
accuracy when performed at a high spatial resolution (69). 
Longitudinal relaxation times (T1) of prostate tissue are prolonged at higher field 
strength, while the relaxivity properties of Gd-DTPA stay almost constant at different 
field strengths (70,71). This results in larger signal differences between enhancing 
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and non-enhancing tissue at higher field, and together with the field-related increase 
in SNR, this could be exploited to increase the spatial or temporal resolution (15). 
Traditional fast gradient echo DCE-MRI is however usually not used in the SNR 
limited regime, either at 3 or at 1.5 T. The limiting factor at both field strengths is 
the time needed for full spatial encoding of the signal in 2 phase encode dimensions 
of the 3D sequence, resulting in a compromise between temporal resolution, spatial 
coverage and spatial resolution. 
An advantage of this high SNR of DCE-MRI is the possibility to reduce image 
acquisition time by intelligent k-space sampling and reconstruction techniques 
known as keyhole or time-resolved imaging (72,73). More recent examples of 
these techniques are time-resolved imaging of contrast kinetics (TRICKS; GE 
Healthcare), time-resolved angiography with interleaved stochastic trajectories 
(TWIST; Siemens Healthcare), and contrast-enhanced timing robust angiography 
keyhole (CENTRA-keyhole; Philips Healthcare). Combined with parallel imaging 
strategies, these techniques enable a temporal resolution as short as 2 s or less at 
3 T in brain (74). With more SNR to burn, spiral acquisition techniques and higher 
parallel imaging acceleration factors could further improve this. In our institute, the 
temporal resolution of prostate DCE-MRI at 3 T without endorectal coil is 4.2 s for 
20 partitions within 1 selected slab with an in-plane resolution of 1.6 x 1.6 mm, using 
the above-mentioned TWIST and parallel imaging techniques. Signal is acquired 
during the course of 5 min in which the contrast agent bolus passes through the 
prostate, extravasates and partially washes out again. 
Adequate temporal sampling is necessary for accurate estimation of pharmacokinetic 
parameters to reduce overlap between malignant and benign tissue (75–77). There is 
ongoing debate on the imaging parameters needed for optimal spatial and temporal 
resolution to yield the highest diagnostic performance for DCE-MRI of the prostate, 
and even within one site there existed a variation in temporal resolution from 5.8-18 
s over 4 MR scanners, depending on field strength and vendor (67).
Prostate MRI and MRSI – Use 
of Different Coils
Prostate MR at clinical field strengths (up to 3 T) is usually performed with at least 
a pelvic phased array coil for signal reception. The number of channels in the pelvic 
phased array coil is of importance for parallel imaging possibilities. The European 
Society of Urogenital Radiology recommends the use of a 8- to 16-channel pelvic 
phased array coil for all prostate MR exams (36), and current instrumental setups 
can contain even more coil elements. 
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In addition to an external phased array coil, an endorectal coil for local signal reception 
or a combination of the two can be used. The combined use of an endorectal coil and 
pelvic phased array coil integrates the high SNR of the prostate from the endorectal 
coil with the wide field of view (FOV) of the pelvis from the pelvic phased array coil 
(Fig. 2.2). This results in higher staging accuracy and image quality at 1.5 T with the 
same imaging parameters (11,78,79). 
The necessity of an endorectal coil for prostate MR is heavily discussed, since it 
causes discomfort for the patient, it requires additional MR scanner time and trained 
personnel for insertion and evaluation of the correct position, and it is expensive. 
Moreover, the SNR changes dramatically with distance from the coil conductors 
because of the inhomogeneous receive profile of the endorectal coil. This profile, 
if uncorrected for, is strongly visible in MR images (Fig. 2.2A,B,D,E), but can be 
reduced by applying a normalization filter, which equalizes signal intensities 
across the image at the cost of larger noise at larger distances from the coil (80). 
Bowel motion can introduce stronger artifacts when the endorectal coil is present, 
but can be suppressed by injections of glucagon and/or butylscopolaminebromide. 
If only the endorectal coil is used for MRI, the strongly localized sensitivity can 
be used to decrease the FOV of the images series, enabling high spatial resolution 
with reasonable scan matrices, as is essentially done in MRSI of the prostate. With 
large prostates, the anterior part of the transition zone of the prostate might suffer 
from lower sensitivity of an endorectal coil only when pushing towards the limits of 
spatial resolution in the posterior peripheral zone. If this high anatomical detail is of 
less importance, one could choose to use the SNR gain of moving to 3 T to eliminate 
the use of the endorectal coil as part of the coil setup (Fig. 2.2G-I). 
Although it is difficult to compare images with and without endorectal coil at 
different field strengths in an objective and/or quantitative way, it has been observed 
that images obtained with a pelvic phased array coil alone at 3 T show comparable 
image quality to those obtained with both a pelvic phased array and endorectal coil 
at 1.5 T (19,81,82). In addition to this, the two different coil setups gave rise to equal 
numbers of motion and coil-related artifacts. This might imply that, if the time for 
inserting the endorectal coil and evaluating its position had been used as additional 
measurement time in a 3 T exam without an endorectal coil, the 3 T images could 
overall be superior to the 1.5 T images with endorectal coil, if patient and bowel 
motion is negligible over longer scan times. It was however also shown that MRI and 
MRSI with an endorectal coil outperformed MRI and MRSI with an array coil at 3 T in 
terms of image quality, staging performance and prostate cancer localization (20,52), 
and the combination of an endorectal with an array coil at 3 T increased SNR and 
image quality with respect to the same setup at 1.5 T (15,83). Due to the possibility 
of remaining coupling of the transmit body coil with the endorectal coil, the allowed 
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SAR deposition when using an endorectal coil is only half that of the setup without 
endorectal coil. At 3 T, this occasionally prolongs scan times of T2W-image series, 
as repetition times need to be prolonged when the physiques of individual patients 
demand a lot of RF power to attain refocusing pulses. 
In the above-mentioned studies, an inflatable endorectal coil was used (Medrad, 
Bayer HealthCare Medical Care, Indianola, PA, USA), where the inflated balloon 
helps to maintain appropriate positioning of the coil in the rectum. At 3 T, the inner 
balloon of the endorectal coil is often inflated with a substance resembling tissue 
susceptibility (e.g. liquid perfluorocarbon or barium sulfate), since inflation with 
air can cause large susceptibility artifacts, deteriorating prostate MRI and MRSI 
quality (84). Prostate MRI studies with a rigid type of endorectal coil have also been 
described (85,86). These rigid coils deform the prostate shape to a smaller extent 
than the inflatable coils, which can improve treatment planning (85). The rigid coils 
provide approximately a 2.5-fold higher SNR than inflatable coils near the peripheral 
zone midline, but a more dramatic lateral decrease in sensitivity is noted with the 
rigid coils as compared with the inflatable coils (86). The hard plastic of the rigid coil 
does not distort the magnetic field by itself, but bowel motion is less reduced than 
with an inflatable coil (86). 
Outlook Towards Ultra-High 
Field
The step from 1.5 to 3 T greatly increased the number of opportunities for prostate MR 
and opened up the possibilities of multiparametric MRI for detection, localization, 
staging and risk stratification of prostate cancer. Increasing the magnetic field 
strength further may bring additional benefits in answering these clinical questions. 
Ultra-high field MR is of particular interest for imaging and spectroscopy techniques 
that are SNR limited at the clinical field strengths of 1.5 or 3 T, such as non-proton 
imaging and spectroscopy.
However, to be of any clinical value, anatomical prostate imaging with T2W-MRI 
should also be of good quality at ultra-high field strengths, which is technically 
demanding. The ability to produce a homogeneous image is impaired by dielectric 
resonance effects and related transmit field (B1
+) heterogeneities (87). Additionally, 
the power requirements and amount of RF absorbed in the body increase both 
roughly proportional to B0
2 and SAR predictions become more complex due to the 
dielectric effects (88).
At 4 T, B1
+ inhomogeneities become apparent in prostate images (89). Phase inco-
herence (destructive interference of the B1
+ field) at the location of the prostate 
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results in a locally low SNR, i.e. signal drop-out. To overcome signal drop-out at the 
location of interest, transmit-receive (transceiver) surface array coils can be used in 
combination with a driving scheme to adjust the phase (and magnitude if necessary) 
of the transmitting elements within the array. With this technique, referred to 
as RF field focusing or B1
+ shimming, the RF field can be tailored to increase B1
+ 
homogeneity in the prostate. At 7 T the B1
+ patterns become even more complex 
and spatially distorted, and any set of B1
+ phases and magnitudes of the different 
coil elements will produce in some spatial locations significant losses in combined 
B1
+ magnitude (90,91). However, it is possible to maximize B1
+ phase coherence and 
thus B1
+ magnitude within any chosen, relatively small, region of interest such as 
the prostate by a patient specific driving scheme to adjust phases (90,92). With this 
technique it is feasible to obtain 7 T T2W-TSE images with high SNR of the full 
prostate region with transceiver array coils only (Fig. 2.4). 
Other coil configurations to perform prostate imaging at 7 T were investigated as 
well (93,94). A transceiver endorectal coil provided improved peak transmit and 
receive B1 but reduced B1 homogeneity compared with a transceiver external surface 
array. The rapid decrease of B1
+ with increasing distance from the coil limits the 
advantage of peak B1
+ performance and severely compromises anatomical imaging 
with conventional RF pulses (93,95). Specifically tuned adiabatic pulses, insensitive 
to B1 non-uniformity and designed to remain in a so-called superadiabatic regime, 
which provides substantially less constraints to the B1 and RF power deposition, 
can be used to improve image quality with a transceiver endorectal coil (96). The 
transceiver endorectal coil is especially very suited for spectroscopic imaging studies 
because of the high B1
+ close to the coil. To overcome the large B1
+ inhomogeneities and 
to reduce or prevent chemical shift displacements artifacts 3D 1H MRSI sequences 
for 7 T are semi or fully adiabatic (semi-LASER or LASER) (94,95,97). In comparison 
with a PRESS sequence, a semi-LASER sequence has two more refocusing pulses, 
giving more freedom to manipulate the strongly coupled spin systems of citrate and 
spermine. Optimal citrate detection is possible at an echo time as short as 56 ms, 
which minimizes signal degradation due to T2 relaxation (Fig. 2.3C). The chemical 
shift dispersion at 7 T allows the design of chemical shift selective pulses that can 
effectively refocus spermine spins, which can be added to the semi-LASER sequence 
to obtain maximum signal from all metabolites of interest in the prostate (98). In 
addition to field- and TE- related increase in SNR this is a great advantage of 7 T 
1H MRSI with respect to 1.5 or 3 T 1H MRSI. At 7 T, the sensitivity of MR of nuclei 
other than protons may become high enough to be of clinical relevance. Preliminary 
results of phosphorus spectroscopic imaging of the prostate at a relevant spatial 
resolution in a clinically acceptable measurement time with a 31P endorectal loop coil 
have been described (99).
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The best coil configuration to image the prostate at 7 T that has been presented so 
far is the combination of a transceiver surface array with a receive only endorectal 
coil (93). This coil setup combines the homogeneous B1
+ of the shimmed array coil 
with the high sensitivity of the endorectal coil to obtain optimal image quality. As 
described earlier, filling the inner balloon of the endorectal coil with perfluorocarbon 
strongly reduces susceptibility artifacts.
Before coil and sequence performance can be tested in an in vivo exam at 7 T, 
extensive safety validations are necessary. At ultra-high fields, the application 
of RF over time is generally not limited by whole-body average (global) SAR 
but rather by local SAR (90,100). The short RF-wavelength of the excitation and 
refocusing pulses leads to very significant flip angle and electric field variations, 
causing local hot-spots in SAR inside the body. Numerical computations of the RF 
field distribution and the corresponding SAR can be performed by using detailed 
computer-aided design models of the coil(s) and the tissues in the FOV of the coil(s). 
Figure 2.4 - Anatomic images of the lower abdomen of a healthy volunteer acquired with an 8-channel 
transceiver coil at 7 T. A, B: Full FOV gradient echo images before (A) and after (B) B1+ shimming. 
C, D: Full FOV TSE images before (C) and after (D) B1+ shimming. As expected, the TSE acquisition is 
more sensitive to the inhomogeneous B1
+ as demonstrated by the low SNR and absence of the expected 
contrast (C). Successful TSE imaging was not possible until after the transmit phases were adjusted by 
focal B1
+ shimming. Source: (90).
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A numerical model can also be extended with thermal parameters (heat capacity, 
thermal conductivity, metabolism and blood perfusion) of the tissues in the model 
to calculate local temperatures by applying the Pennes bioheat-transfer equation. 
All models have their limitations, by assuming electrical and thermal properties and 
tissue dimensions, but they are generally considered conservative regarding safety. 
Moreover, to confirm the computer simulations, temperature measurements are 
often performed in a phantom.
According to the SAR and temperature computations it is not allowed to perform 
prostate 1H MRSI with adiabatic pulses with an external transceiver surface array 
coil. Moreover, to perform T2W-TSE imaging with this coil, the pulse durations 
of the excitation and refocusing pulses need to be prolonged and the flip angle of 
the refocusing pulses needs to be brought back to 150°. Nevertheless, TSE imaging 
at 7 T currently remains strongly limited by SAR, which prevents us from taking 
full advantage of the increased SNR. Despite this limitation, it is possible to obtain 
very useful T2W images within 100 s with transceiver surface coils only (Fig. 2.5). 
Compared with the currently highest clinical standard (an endorectal coil at 3 T), 
T2W-MRI with an external transceiver coil array at 7 T is not providing the same 
image quality yet, although many of the anatomical details are very well visible at 
7 T too (Fig. 2.6). The contrast of peri-prostatic tissue appears very different at 7 T, 
because of low excitation and refocusing flip angles outside the B1
+ shimmed area 
with different chemical shift artifacts (different pulse lengths), diminishing contrast 
between muscles, lipids and bones. The combination with a receive only endorectal 
coil can further increase the resolution within the prostate (93). To date no literature 
on prostate DWI or DCE-MRI at 7 T exists, and the exploration and application of 
new MR techniques at 7 T for the prostate are still very much in their infancy.
Figure 2.5 - T2W-MRI at 7 T of the prostate of a 58-year-old patient with prostate cancer. In coronal (A), 
sagittal (B) and axial (C) planes the prostate is very well depicted. After B1+ shimming with the external 
transceiver coil array, sufficient power could be delivered to the prostate in this 98 kg patient for adequate 
refocusing pulses in the TSE train. In-plane resolution 0.7 x 0.7 mm, at least 20 slices (thickness 3 mm) 
were acquired in all directions within 2 min acquisition time each. The endorectal coil was not used for 
proton signal reception.
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Discussion 
The increase of magnetic field strength for clinical purposes has always been a 
matter of debate, yet it is occurring and will become a clinical reality. The majority of 
prostate MR studies published in scientific literature at the moment are performed at 
3 T. Many of these studies comprise a single-center setting, include a small number 
of subjects and investigate the performance of one specific MR technique for one 
specific diagnostic problem (detection, localization, staging, risk assessment). The 
same holds for 1.5 T studies, and all the different study designs make it very difficult 
to compare the performance of 1.5 versus 3 T. Moreover, it is not always clear from 
the study description if MR protocols have been optimized with technologies such 
as parallel imaging. Soon after the clinical introduction of 3 T, a couple of small 
studies compared 1.5 T prostate MR directly with 3 T prostate MR. These studies 
showed the potential of 3 T MR in prostate cancer staging, because of the increase 
in spatial resolution. Additionally, prostate MR using only a phased-array coil was 
found to be feasible at 3 T. This provided the opportunity to image patients who 
are unable or unwilling to undergo an endorectal coil examination, but is also used 
today to decrease cost and increase patient through-put of prostate cancer MR. In 
the early days of 3 T prostate MR it was not expected that tumor lesion detection or 
localization would profit from the increase in field strength because of the nearly 
field-independent tissue contrast of T2W images. In this prediction, the combination 
with other functional MR techniques described in this review (DWI, DCE-MRI and/
or MRSI) was not taken into account, and with the sensitivity at 3 T, this combination 
can now be made in a routine examination within a reasonable time. This so-called 
Figure 2.6 - Axial T2W TSE images at 7 T (A) and 3 T (B) of a 69-year-old patient with prostate cancer 
(weight 100 kg), at approximately the same level in the prostate near the apex. 7 T images were acquired 
in 1 min 53 s with the external transceiver coil array after B1
+ shimming, whereas 3 T images were acquired 
in 5 min using an abdominal array and an endorectal receive coil. A region suspicious for prostate 
cancer is visible in the right anterior aspect of the central gland on both scans (arrows). This region was 
confirmed to be Gleason 4+4 prostate cancer on MR-guided biopsy. Note the difference in appearance of 
peri-prostatic tissues between the two images. The endorectal coil at 7 T was not used for proton signal 
reception.
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multiparametric MRI approach has emerged during the last couple of years (8,101). 
It appeared that MR of the prostate is not easy, as none of the functional techniques 
by itself provided a satisfying accuracy in detecting or localizing cancer in the 
prostate. In general, the more of these imaging techniques are combined, the better 
the tumor detection accuracy seems to be. For example, recent data have shown that 
by combining T2W-MRI, DCE-MRI and MRSI a positive predictive value of almost 
80% can be reached for tumor detection, about 40% higher than for each technique by 
itself (102). Adding DWI even resulted in positive predictive values reaching 100% 
in a different study of the same group (103). Similar results were obtained in other 
groups (104,105), and multiparametric MRI was also found to be a valuable tool in 
risk stratification of prostate cancer (106). These results show the complementary 
information that is obtained by the different sequences in multiparametric MRI, 
suiting the diversity in prostate cancer types. However, large multi-center studies 
with state-of-the-art multiparametric MRI and pathological correlation should be 
performed to evaluate the value of multiparametric MRI more rigorously, and to 
define the exact added value of the individual imaging techniques.
The opportunities of the higher sensitivity at 3 T resulted in innovative ideas to 
first adapt, but later improve and accelerate pulse sequences, which occurred in 
parallel with improvements to coil designs. Most of this knowledge could also be 
translated back to 1.5 T, opening up the possibility of multiparametric MRI at this 
field strength as well. In the end the step from 1.5 to 3 T is not a golden egg. After 
some adaptations, for most of the functional techniques the move from 1.5 to 3 T is 
‘just’ an increase in sensitivity. If pursued to full extent, good multiparametric MRI 
should be possible at 1.5 T too, albeit with somewhat less resolution and somewhat 
longer examination time. 
Perhaps the choice of field strength is not the most important one: the choice of 
whether or not to perform an MR exam for the subject with (suspicion of) prostate 
cancer is the most critical one. With its proven ability to identify suspicious regions 
for MR-guided or directed biopsies to detect the disease, its ability to very accurately 
stage local disease, its possibilities to visualize the location and extent of the disease, 
and its promise for in vivo assessment of tumor aggressiveness, an MRI of the prostate 
should not be denied to any person with suspicion for prostate cancer. It has even be 
suggested that multiparametric MRI should be performed before taking biopsies in 
men with raised PSA levels, in order to select for biopsy those with significant cancer 
that requires treatment and to reduce the number of unnecessary biopsies carried 
out (107,108). Addressing the concerns of overtreatment of the general population of 
patients with prostate cancer, new treatment options for the patient with confirmed 
disease are in the pipeline, but these definitely need an accurate and trustworthy 
representation of the exact extent and aggressiveness of the tumor in the organ. With 
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an often very slow progression of the disease, the best measure for validating MRI of 
prostate cancer is the correlation with detailed histopathology of resected prostates 
or MR-guided biopsy specimens as surrogate endpoints of the disease. The choice 
for a specific coil (combination) and scanning protocol should mainly be determined 
by the clinical question posed (36). 
With the fast development of prostate MRI at 3 T (and reverse-engineering to 
1.5 T) the urological field needs to redefine existing measures. For example, one 
of the most significant improvements of 3 T prostate MRI is the increase in spatial 
resolution, enabling the high local staging accuracy and the detection of minimal 
capsular invasion (implying stage T3 disease). The prognostic implications of 
minimal capsular invasion are unclear to date. Men with minimally invasive disease 
may do equally well after surgery as those with cancers confined to the gland. It will 
be important to investigate the clinical effect of minimal capsular invasion in order 
to prevent patients with allegedly inoperable (extracapsular) disease from being 
withheld curative surgery. Studies in this field cannot use surrogate endpoints: the 
presence of distant metastatic disease because of extracapsular extension needs to be 
confirmed by long-term follow-up of the patient.
A better understanding of progression of local prostate cancer and when it 
metastasizes requires a more fundamental approach to investigating the disease. 
Perhaps this is where MR of the prostate at ultra-high field can contribute, as to 
date it is not clear if increasing the field strength beyond 3 T will increase the benefit 
of clinical prostate MR any further. The number of technical challenges present 
at ultra-high field strength currently hampers quick acquisition without artifacts. 
The opportunities of the ultra-high field, additional SNR and increased spectral 
dispersion, are nevertheless very appealing, and new strategies to perform imaging 
and spectroscopy are currently being explored. Separating transmit and receive 
coils, increasing the power for the individual transmit channels, the use of different 
transmit modes within one acquisition, and an on-line assessment of deposited 
SAR in combination with phase and amplitude B1
+ shimming are just some of the 
technical innovations that will push this field forward in the coming years.
Conclusion
Technically, prostate MR would probably not have been where it is at the moment, 
without the emerging use of 3 T MR systems. From a method to determine the 
presence of extracapsular prostate cancer, it is becoming a multifunctional tool in the 
management of prostate cancer. The different techniques from the multiparametric 
MR approach have all benefited from the step from 1.5 to 3 T, to varying extents. The 
use of an endorectal coil at 3 T is not as important as it was on 1.5 T to obtain high-
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quality images and spectroscopy, and the choice for a specific coil (combination) 
and scanning protocol should mainly be determined by the clinical question 
posed. Prostate MR at 7 T is still in its infancy but can, in addition to providing 
new opportunities to fundamentally study prostate cancer, also result in reverse-
engineering of essential technical improvements to lower field strengths, analogous 
to what the step from 1.5 to 3 T invoked.
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Abstract 
Objective: To assess the feasibility of prostate 1H MR spectroscopic imaging (MRSI) 
using low-power spectral-spatial (SPSP) pulses at 7 T, exploiting accurate spectral 
selection and spatial selectivity simultaneously. 
Methods: A double spin-echo sequence was equipped with SPSP refocusing pulses 
with a spectral selectivity of 1 ppm. Three-dimensional prostate 1H MRSI at 7 T was 
performed with the SPSP-MRSI sequence using an 8-channel transmit array coil and 
an endorectal receive coil in three patients with prostate cancer and in one healthy 
subject. No additional water or lipid suppression pulses were used. 
Results: Prostate 1H MRSI could be obtained well within specific absorption rate 
(SAR) limits in a clinically feasible time (10 min). Next to the common citrate 
signals, the prostate spectra exhibited high spermine signals concealing creatine and 
sometimes also choline. Residual lipid signals were observed at the edges of the 
prostate because of limitations in spectral and spatial selectivity.  
Conclusion: It is possible to perform prostate 1H MRSI at 7 T with a SPSP-MRSI 
sequence while using separate transmit and receive coils. This low-SAR MRSI 
concept provides the opportunity to increase spatial resolution of MRSI within 
reasonable scan times.  
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Introduction
Proton magnetic resonance spectroscopic imaging (1H MRSI) can be used as part 
of a multiparametric MRI prostate examination at 1.5 or 3 T in prostate cancer 
management (1). In vivo MR spectroscopy measurements provide biochemical 
information about tissues, and with localized MRSI techniques spatial variations 
in metabolite levels can be studied. The metabolites commonly reported in prostate 
1H MRSI are choline compounds, polyamines, creatine, and citrate. Prostate cancer 
usually shows increased total choline (tCho) levels and decreased citrate levels 
compared with normal prostate tissue (2,3). Polyamine levels are also known to 
change in prostate cancer (4,5), but this change is harder to detect in vivo due to 
spectral overlap with tCho and creatine (4,6). Ratios of prostate metabolite levels have 
been linked to clinically important factors such as prostate cancer aggressiveness 
(7) and recurrence after radiotherapy treatment (8). However, MRSI acquisitions 
are time-consuming at field strengths of 1.5 and 3 T, while spatial resolution is 
limited. Because spectroscopy directly benefits from increases in the signal-to-noise 
ratio (SNR), which could be traded for shorter acquisition times or higher spatial 
resolution, effort has been put into performing prostate 1H MRSI at a field strength 
of 7 T (9–11). 
The most common method for prostate 1H MRSI is point-resolved spectroscopy 
(PRESS). Water and lipid signals are suppressed by either additional dual-frequency 
selective pulses (so-called BASING (12) or MEGA pulses (13)), or by incorporation 
of spectral selectivity in the refocusing pulses (14–16). Next to this, outer volume 
saturation (OVS) slabs are placed around the prostate to further decrease periprostatic 
lipid signal contamination (17,18). The MR body coil is used for excitation and external 
phased-array coils around the pelvic area are used for signal reception, sometimes 
in combination with an endorectal receive coil. Translation of these concepts to 7 T 
is not straightforward. First, attaining homogeneous and sufficiently high transmit 
radiofrequency (RF) amplitude (B1
+) in deeper parts of the body is challenging (19). 
Second, the high chemical shift separation at 7 T in combination with the limited 
bandwidth of slice-selective pulses in PRESS would result in severe chemical shift 
displacement artifacts and lipid signal contamination. Finally, the high number 
of RF pulses in the sequence and the quadratic increase of specific absorption rate 
(SAR) with magnetic field strength would lead to long acquisition times.
These challenges have partly been circumvented by using endorectal transceiver coils 
for 1H MRSI of the prostate at 7 T (9–11,20). The inhomogeneous B1 field of such coils 
requires the use of B1
+ insensitive pulses to prevent non-uniform spin excitations over 
the prostate. Using LASER-type (localization based on adiabatic selective refocusing) 
pulse sequences with MEGA pulses (9–11), accurate localization of the spectra is 
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possible, but water and lipid suppression still suffer from the inhomogeneous B1
+ 
field. Moreover, the high RF power deposition of these sequences requires long 
repetition times (TR; 2-3s) to stay within SAR limits, resulting in unacceptably long 
acquisition times.
An external transmit array coil may present an interesting alternative for this approach. 
Using such a coil array in combination with RF shimming can yield homogeneous 
yet lower B1
+ fields within the prostate. Homogeneous B1
+ fields obviate LASER-type 
sequences, and B1
+ is still sufficiently high to allow the use of conventional pulses 
of long duration, demanding less RF power (21–23). The transmit array coil can be 
combined with a receive-only endorectal coil, ensuring high local SNR within the 
prostate (22). This allows high-resolution prostate imaging (22) and it is particularly 
attractive for prostate 1H MRSI. 
To return from the complicated high-power multi-pulse approach of transceiver 
surface coils at 7 T to the basics of conventional PRESS, we investigated the use 
of spectral-spatial (SPSP) refocusing pulses at 7 T (24). These pulses are capable 
of both volume and frequency selection and have been incorporated in the PRESS 
localization for prostate 1H MRSI at 1.5 and 3 T to suppress water and lipids (14–
17). The spectral selectivity of such pulses eliminated the need for additional water 
suppression pulses at clinical field strengths. The larger chemical shift separation 
at 7 T facilitates more accurate spectral selection and may make lipid suppression 
pulses redundant as well. This would bring the number of RF pulses per TR to three, 
which is well feasible at 7 T in terms of SAR. An additional advantage of SPSP pulses 
is the large bandwidth of the RF subpulses played during each gradient lobe, which 
minimize chemical shift displacement artifacts in spatial selectivity.   
An important aspect in spectral interpretation is prior knowledge about the peak 
shapes of coupled spin systems. It is well known that citrate peak shapes change 
with sequence timing and field strength (15,25), but less attention has been paid 
to the shape of spermine, the most abundant polyamine in the prostate (4,26). 
Because two groups of spermine resonate within the spectral region of the lipids, 
J-coupling evolution of spermine is affected by the spectral selectivity of the SPSP 
pulses. This J-modulation can be refocused with spectrally-selective pulses, similar 
to heteronuclear experiments in which heteronuclear J-coupling is refocused by 
applying a 180° pulse to only one nucleus (27). Complete refocusing results in fully 
in-phase signal at the beginning of the acquisition, independent of the total echo 
time (TE), maximizing the spermine signal at 3.1 ppm. 
The aim of this work is to assess the feasibility of prostate 1H MRSI using SPSP 
pulses at 7 T with separate transmit and receive coils. We present the SPSP pulse and 
sequence design, study the effect of the pulse sequence on the coupled spin systems 
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of interest, and examine the performance of the new sequence in phantom and in 
vivo experiments. 
Methods
MRSI Pulse Sequence and RF Pulse Design
A double spin-echo MRSI sequence was designed with an asymmetric slice-selective 
excitation pulse and two SPSP refocusing pulses (Fig. 3.1A). Crusher gradients were 
positioned around the SPSP pulses of this ‘SPSP-MRSI’ sequence. 
The single-band linear-phase SPSP pulse was designed in MATLAB (The 
Mathworks, Natick, MA) using the Shinnar-Le Roux algorithm (28,29). To avoid 
the need for additional lipid suppression pulses, a sharp transition band between 
citrate and lipids was required. The transition bandwidth was therefore set to 0.3 
ppm, with the passband for the metabolites of interest ranging from 3.4 to 2.4 ppm 
and the stop band starting at 2.1 ppm (Fig. 3.1B). These requirements together with 
the severe B1
+ limitations within the prostate resulted in a pulse length of 35.22 ms. 
Variable rate selective excitation (VERSE) was used to reduce RF peak power 
requirements (30), finally generating a peak RF amplitude of 11 μT. The SPSP pulse 
Figure 3.1 - A: Sequence timing diagram of double spin echo sequence using spectral-spatial (SPSP) 
refocusing pulses. No water or lipid suppression pulses are incorporated. The phase encoding gradients 
are combined with the spoilers after the 2nd SPSP pulse. B,C: Characteristics of the SPSP pulse. Spectral 
selectivity (B) and simulated SPSP profile (C). Cho, choline; Cit, citrate; Cr, creatine, Spm, spermine.
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consisted of 65 subpulses, each with a design time-bandwidth product of 2. With 
a subpulse duration of 392 us, this would correspond to a subpulse bandwidth of 
approximate 5.1 kHz. However, after applying VERSE to meet the constraints in 
B1
+, the stretched subpulses had an approximate time-bandwidth product of 1.61, or 
subpulse bandwidth of 4.1 kHz. The SPSP pulse design also employed a correction 
for the non-uniform sampling in excitation k-space to further reduce chemical 
shift misregistration (31,32) (Fig. 3.1C). Gradient hardware parameters limited the 
minimum slice thickness in the directions of the SPSP pulses to 37 mm.
An 8 ms minimum-phase slice-selective pulse with a bandwidth of 1200 Hz was 
used for excitation. The minimum TE of the SPSP-MRSI sequence was 88 ms, echo 
delay τ1 was kept constant at 21.45 ms. 
Hardware
Measurements were performed on a 7 T whole-body MR system (MAGNETOM, 
Siemens Healthcare, Erlangen, Germany). An 8-channel 1H transceiver body-array 
coil with meander-type microstrip elements (33) was used in combination with a 
1H receive-only endorectal coil. To produce an endorectal coil suitable for 7 T, 
the capacitors and cables of a commercially available 3 T inflatable 1H endorectal 
coil (Medrad, Pittsburgh, PA) were replaced to tune and match the coil to the 1H 
frequency at 7 T (297 MHz). An active series detuning circuit was added to ensure 
safety during transmit. The endorectal RF coil was interfaced to the MR system 
using a home-built receive switch with an integrated small-band low-noise amplifier 
(Advanced Receiver Research, Burlington, CT). The array coil was driven by eight 
1 kW amplifiers, and the RF power deposited by each individual channel was 
monitored using an in-house developed RF supervision platform (34). 
Safety of the Coil Setup  
The presence of a local, detuned endorectal coil and its cabling might alter the electric 
and magnetic field distribution of the 8-channel array transmit field. The safety of 
the coil setup was assessed by numerical simulations of these field distributions and 
by additional phantom, workbench, and in vivo measurements. The 1H receive-
only endorectal coil used in the current study was detuned during transmit and 
has the same dimensions, wiring, and cable routing as a transceiver 31P endorectal 
coil used in a previous study (35). Therefore, results of the numerical simulations 
and phantom experiments of the 8-channel array transmit field could be used from 
that study. In these simulations, the 8-channel array coil did not generate relevant 
elevations of the local B1
+ field and SAR distribution close to the endorectal coil and 
cables, which would indicate RF coupling. The phantom experiments involved 
B1
+ and temperature mapping, as well as temperature measurements with fiber 
optic temperature sensors, while transmitting with the 8-channel array coil. The 
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maximum allowed transmit power determined from these experiments was 48 W 
per 6 minutes (leading to a maximum 10 g averaged SAR of 15 W/kg). To justify 
the use of previous safety data obtained with a slightly different setup, RF coupling 
of the detuned receive-only 1H endorectal coil with each element of the 8-channel 
array coil was measured using a network analyzer. In these measurements, the 
endorectal coil was placed within a body-sized phantom filled with sugar-solution 
resembling body fluid (with respect to electrical conductivity and permittivity) 
to load the array coil, which was positioned around the phantom. The endorectal 
coil was moved throughout the phantom to assess differences in RF coupling with 
respect to positioning. Next to direct RF-coupling, common mode currents possess a 
patient safety risk. The possible presence of common mode currents was assessed by 
touching and repositioning the cables while monitoring the tuning, matching, and 
RF-coupling. Finally, an in vivo temperature measurement was performed with the 
current coil setup, for which fiber optic temperature sensors were placed close to the 
top capacitor of the endorectal coil, its feed point, and on the rod that enclosed the 
connecting wires. 
Modulation of Coupled Spin Systems
The modulation of the spectral shape of citrate and spermine with TE was simulated 
with NMR-Sim (Bruker, Billerica, MA). The strongly coupled AB spin system 
of citrate (4 MR-visible protons) was modeled with a chemical shift difference of 
0.15 ppm (45 Hz at 7 T) and a J-coupling constant of 15 Hz (36). Spermine has 10 
-CH2- groups, which give rise to three multiplets in a 1D pulse-acquire spectrum 
(Fig. 3.2). The protons of the four -CH2- groups not connected to the amine groups 
are visible at 1.8 and 2.1 ppm, whereas the six others all resonate around 3.1 ppm 
and are never resolved individually in vivo. The protons at 3.1 ppm are all scalar 
coupled via a three-bond J-coupling to the protons either resonating at 1.8 ppm or 
to those resonating at 2.1 ppm, with J-couplings of 6.86, 7.07 and 7.14 Hz (37). This 
is considered a three-spin system in product operator formalism. However, the two 
–CH2- groups at 1.8 ppm are also strongly coupled to each other with a J-coupling 
of 7.27 Hz (37). 
In case of a double spin-echo sequence equipped with hard 90° and 180° pulses, the 
evolution under J-coupling of spermine can be described using the product operator 
formalism. After the initial 90y° excitation RF pulse, the magnetization starts at Ix and 
-ignoring the strong J-coupling between the 1.8 ppm groups- the evolution follows 
(38):
I
1x
 cos2(πJt) + 2I
1y
I2z sin(πJt)cos(πJt) + 2I1yI3z sin(πJt)cos(πJt) - 4I1xI2z2I3zsin2(πJt)         [3.1]
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where t = 2[τ1+ τ2], with τ1 and τ2 the echo delays in a PRESS sequence, and J = 
6.86, 7.07 or 7.14 Hz, depending on the resonance considered. Based on this, no 
in-phase (Ix) magnetization is predicted to occur at TE = 71 ms, and maximum in-
phase magnetization at TE = 142 ms. To investigate the difference between hard and 
spectrally-selective refocusing pulses on the J-modulation of spermine, simulations 
were run with a double spin-echo sequence equipped with a hard 90° and either 
hard 180° or spectrally-selective 180° pulses (duration 15 ms, refocusing bandwidth 
= 300 Hz) at TE = 60, 71, 80, 88, 100, 110, 120, 135, 142, 150, 170, 190 and 213 ms with 
fixed τ1 (21.45 ms). T1 and T2 relaxation were neglected in the simulations, the ratio 
between spermine (20 MR visible protons) and citrate (4 MR visible protons) in the 
simulations was 1:1. The modulation of citrate and spermine with TE using the SPSP-
MRSI sequence was also assessed with phantom experiments on a 7 T animal MR 
system (ClinScan, Bruker, Billerica, MA), with citrate and spermine concentrations 
of 90 mM and 18 mM, respectively. Based on these simulation and phantom results, 
subsequent experiments were performed at TE = 135 ms.
SPSP-MRSI Phantom Experiments 
Since local variations in B1
+ over the prostate may remain after RF shimming 
(coefficients of variation of 15% have been reported (39)), the sensitivity of the SPSP 
Figure 3.2 - Molecular structure of spermine, together with its simulated pulse acquire 1H MR spectrum 
for 7 T. The proton spins with chemical shifts of 2.1 and 1.8 ppm couple to the proton spins at 3.1 ppm with 
J-coupling constants of 6.86, 7.07 and 7.14 Hz. The two –CH2- groups at 1.8 ppm are strongly coupled to 
each other with a J-coupling of 7.27 Hz (37). The line-styles of the arrows indicate the resonance frequency 
of signals from protons in the boxes with corresponding line-style. 
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pulses to B1
+ was investigated. The effect of variations in B1
+
 on the spectral shape of 
the SPSP pulse was investigated using Bloch simulations implemented in MATLAB. 
The effect of B1
+ on spectra acquired with the SPSP-MRSI sequence was studied in a 
small phantom containing choline, creatine, and citrate on the 7 T Bruker Clinscan 
MR system (30-cm body coil diameter), to guarantee a spatially homogeneous B1
+. 
The localization performance and the sensitivity of SPSP-MRSI to the combined 
effects of B0 and B1
+ variations were assessed in a phantom setup resembling the 
in vivo situation (Fig. 3.5A) on the human 7 T MR scanner. Water and metabolite 
spectra were obtained after optimized B0 and RF shimming and flip angle (FA) 
calibration. Subsequently, the RF shim was purposely changed to a generate an 
asymmetric B1
+ profile over the volume of interest (VOI) and the FA was recalibrated 
to obtain correct FAs on one side of the metabolite fluid compartment. The MRSI 
measurement was then repeated. Absolute B1
+ maps were acquired at both RF shim 
settings using a magnetization-prepared gradient-echo sequence (TR = 5000 ms, TE 
= 5 ms, magnetization preparation FA = 90°, reference FA = 10°) (40).  A B0 map was 
recorded using a dual gradient echo field mapping sequence (TR = 510 ms, TE1 = 
2.04 ms, TE2 = 3.06 ms, FA = 15°).
The maximum SAR of the SPSP-MRSI sequence was measured using the same 
phantom setup. The RF amplitude of the SPSP pulses was set at maximum voltage 
achievable by the system and the excitation pulse voltage was scaled accordingly. 
The relative difference between the spermine signal at 3.1 ppm observed with the 
SPSP-MRSI sequence at 7 T (TE = 135 ms) and with a regular PRESS sequence with 
MEGA pulses and OVS slabs for water and lipid suppression at 3 T (TE = 145 ms) 
was also assessed with the above mentioned phantom (TR 750 ms and 10 s) and in 
relaxation time independent simulations. 
SPSP-MRSI In Vivo Measurements
One healthy volunteer (age, 39 years) and three patients with biopsy-proven prostate 
cancer (ages 65, 67, and 70 years) were included in this study. All measurements were 
carried out in compliance with the local institutional medical ethics committee, and 
written informed consent was obtained from all patients before the measurement.
The subjects were placed in a supine position on the dorsal section of the 8-channel 
array coil after insertion of the endorectal coil. The ventral section of the array 
coil was positioned over the lower abdomen. Peristalsis was suppressed by an 
intramuscular injection of 1-mg Glucagon (GlucaGen Hypokit, Novo Nordisk, 
Bagswærd, Denmark) and 20-mg butylscopolaminebromide (Buscopan, Boehringer, 
Ingelheim, Germany). 
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SAR-monitoring, B0 and B1
+-shimming and FA calibration were performed as 
described previously (23). T2-weighted fast spin echo images covering the entire 
prostate were acquired to provide an anatomical background for the MRSI 
measurements. In short, the parameters for the T2-weighted imaging were: TR 4380–
4690 ms, TE 85 ms, 9 refocusing pulses with FAs of 165° (first refocusing pulse) and 
150° (all other refocusing pulses), matrix 320 x 320, in-plane resolution 0.3 x 0.3 mm, 
20-23 slices with thickness 2 mm, total acquisition time 2:34-2:55 minutes per 
direction. During T2-weighted imaging and MRSI, only the endorectal coil was used 
for signal reception. 
3D SPSP-MRSI of the prostate was acquired with varying settings for frequency 
offset of the SPSP pulses, VOI, field of view (FOV), matrix size, and thus resulting 
total acquisition time (Table 3.1), because of optimization purposes and differences 
in prostate size. In all subjects TE was set to 135 ms and TR to 1000 ms, and the 
SPSP pulses selected slices in the left-right and anterior-posterior directions. An 
elliptical k-space acquisition scheme (41) was applied (1 average) and spectra were 
Hamming filtered (50%). All measurements were performed within SAR limits. 
Results
Safety of the Coil Setup
RF coupling between each channel of the 8-channel array coil and the detuned 
receive-only 1H endorectal coil was negligible (minimum –46 dB), and there was 
no indication for the presence of common mode currents. The in vivo temperature 
measurements showed only a temperature increase that was caused by the direct 
current used to control the detuning circuit. The coil setup was therefore considered 
safe, and the maximum allowed transmit power in vivo could be based on previous 
simulation results (35). The SPSP-MRSI sequence performed at maximum achievable 
voltage used 14% of the allowed transmit power of 48 W. 
Table 3.1 - Settings of SPSP-MRSI in vivo measurements
Subject FOV 
(mm3)
Matrix Real voxel 
size (cm3)
TA 
(min:sec)
VOI 
(mm)
Offseta SPSP 
pulse (Hz)
Relative 
SPSP pulse 
amplitude 
1 70x70x70 10x12x12 0.89 6:59 70x70x70 -570 96 %
2 58x70x70 10x12x12 0.74 6:59 50x50x50 -570 100 %
3 70x60x60 14x12x12 0.47 10:17 70x50x50 -530 100%
4b 58x70x70 10x12x12 0.74 6:59 40x60x60 -530 97%
a Frequency offset from the carrier frequency (water) at 4.7 ppm.
b Healthy volunteer
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Modulation of Coupled Spin Systems
The simulations and phantom measurements of citrate and spermine showed the 
modulation of citrate with varying TE (Fig. 3.3). Citrate intensity was maximal at TE 
= 135 ms in both the simulations and the measurements. The simulations also showed 
the difference in spermine modulation using a PRESS sequence with spectrally-
selective refocusing pulses (Fig. 3.3A) and a PRESS sequence with hard pulses (Fig. 
3.3C). In the former, J-coupling evolution is mostly refocused, resulting in high 
spermine signals at 3.1 ppm at all simulated TEs. The remaining minor differences 
in total signal intensity with TE are caused by the strong coupling between the two 
–CH2- groups at 1.8 ppm. Removing the J-coupling between the two -CH2- groups 
at 1.8 ppm resulted in completely refocused, TE-independent spectra (data not 
shown). The simulation of a sequence with hard pulses showed strong spermine 
signal modulation with TE following the expected J-coupling evolution (Fig. 3.3D). 
The phantom experiments with the SPSP-MRSI sequence confirmed the simulations 
regarding spermine evolution, but in the presence of T2 signal decay. 
SPSP-MRSI Phantom Experiments 
The spectral profile of the SPSP pulse showed increasing variation in refocusing 
efficiency over its bandwidth with decreases in B1
+ (Fig. 3.4A). This effect mainly 
caused signal decrease in spectra measured in a small phantom (Fig. 3.4B). Relative 
peak heights remained similar for the uncoupled metabolites choline and creatine, 
but due to changes in the spectral shape of citrate, the ratio of the peak amplitudes 
of the uncoupled metabolites with this metabolite changed with B1
+. 
The 3D SPSP-MRSI measurements of the phantom setup resembling the in vivo 
situation showed good localization of the spectra (Fig. 3.5B). The metabolite spectra 
presented very low or no water signal and well separated metabolite peaks (Fig. 
3.5C). Intravoxel B0 inhomogeneity caused broader lines and lower amplitudes 
close to the endorectal coil in water spectra (Fig. 3.5B). These effects are also seen 
in the metabolite spectra shown in Figures 3.5D,E. B0 inhomogeneity also caused 
inter-voxel differences in the resonance frequency (Fig. 4D), leading to shifts of the 
spectral profile of the SPSP pulse relative to the metabolite resonances. This led 
to partial suppression of the upfield resonance of citrate at B0 shifts above 40 Hz, 
evidenced by the slight asymmetry of the citrate shape in the bottom two rows of the 
(identical) spectral maps shown in Figure 3.5D,E.
Spectral signal intensities dropped with decreasing B1
+ (Fig. 3.5F). The citrate shape 
was affected at FAs below 80% of the intended FAs (Fig. 3.5G,H). Overall, metabolite 
ratios varied little within the region of optimized RF shim (Fig. 3.5E). 
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Figure 3.3 - Citrate and spermine modulations. Simulated (A) and measured (B) spectra using a PRESS 
sequence with spectrally-selective refocusing pulses at different echo times (TE). C: Simulated spectra 
using a PRESS sequence with hard pulses at different TE. D: Evolution of Ix magnetization of spermine 
in a PRESS sequence with hard pulses, assuming a three spin system (38). In all cases τ1 was fixed at 
21.45 ms, TE=2[τ1+τ2]. Cit, citrate; Spm, spermine.
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Phantom measurements with PRESS-MRSI using MEGA-pulses and OVS slabs 
at 3 T and SPSP-MRSI at 7 T showed their effect on spermine intensity relative to 
choline and creatine intensities (Fig. 3.6). The spermine signal at 3 T is affected by the 
MEGA-pulses, resulting in a different spin evolution with disperse magnetization 
terms at TE. This presents as relatively little spermine signal compared with the 
7 T SPSP-MRSI results. The effect is more pronounced in the T1-saturated spectra 
at TR = 750 ms than in the fully relaxed spectra at TR = 10 s, because of differences 
in T1 relaxation times between the metabolites. The phantom results indicated that 
the T1’s of choline and creatine in solution are longer than those of spermine and 
citrate at both field strengths. The measured spectra are also affected by possible T2 
relaxation time differences, but relaxation-independent simulations showed that the 
disperse spermine signal at 3 T with the PRESS-MRSI using MEGA-pulses at TE = 
145 ms is a factor of 4 smaller compared with its mainly in-phase signal using the 
SPSP-MRSI at 7 T with TE = 135 ms because of the differences in J-modulation with 
the two sequences (data not shown). 
SPSP-MRSI In Vivo Measurements
In vivo measurements of SPSP-MRSI are presented in Figures 3.7 to 3.9. The spectra 
were well localized in the VOI, and within the prostate the metabolites choline, 
spermine and citrate were present (Fig. 3.7A-C). At the edges of the prostate, 
Figure 3.4 - SPSP pulse behavior at different maximum pulse power. A: Simulated dependence of the 
spectral part of the SPSP pulse on the relative B1
+ in the spatial isocenter (1My(f)→180y°→My(f)). B: Effect 
of relative B1
+
 (Vref: reference voltage for 90°-excitation and 180°-SPSP pulses) on spectra measured in a 
phantom containing the prostate metabolites choline, creatine and citrate. The uncoupled metabolites 
choline and creatine show a decrease in signal with decreasing B1
+, the strongly coupled citrate metabolite 
also exhibits a different spectral shape. Cho, choline; Cit, citrate; Cr, creatine.
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Figure 3.5 - Effect of B0 and B1
+ offset on spectral quality in a prostate phantom. A: Phantom with 
dimensions and properties similar to the human abdomen. 1: Hole for endorectal coil. 2: Solution of 
prostate metabolites containing Cho (9 mM), Spm (18 mM), Cre (12 mM) and Cit (90 mM) (4). 3: Tissue 
simulating sugar solution to load the 8-channel array coil. B: Spectral map of water superimposed on 
image of the center part of the phantom showing localization (red box: VOI), coil receive profile, and shim 
effect on water shape. Yellow box: field of view, green grid: interpolated matrix. C: Phantom spectrum 
with symmetrical citrate shape and well resolved resonances of Cho, Spm, and Cre, without water 
residual. D,E: Spectral maps of metabolites (2.1-3.5 ppm, bottom 7 rows of VOI) acquired with optimized 
B0 and B1
+ in the VOI superimposed on a B0 map (D) and on a flip angle map (E), measured using a 
nominal 90° flip angle. F: Spectral map of metabolites (2.4-3.5 ppm) acquired with optimized B0, but 
asymmetric B1
+ (background image) in the VOI. G,H: Zoom of spectra indicated in E and F respectively, 
scaled identically. Percentages indicate the relative flip angles (of 90° and 180° intended) attained at that 
location according to the flip angle maps. Small variations in the spectral shape of citrate remain after 
optimal RF shimming. Cho, choline; Cit, citrate; Cr, creatine; Spm, spermine.
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lipid signals (2.1-2.6 ppm) were sometimes present. It was possible to obtain 
fairly homogeneous B0 over the whole prostate (example in Fig. 3.7D), but spatial 
B1
+ variations across the prostate remained despite RF shimming (Fig. 3.7E). The 
presence of lipids in the spectra could not directly be related to variations in local 
resonance frequency. 
Spermine signals were often high compared with the signals of the other metabolites 
in the prostate (Fig. 3.8). The spectral shape of citrate was as expected from simulations 
and phantom measurements, and was affected by differences in local shim. Because 
of the high and reasonably broad spermine signal, tCho and creatine signals were 
not separately visible in many of the spectra. Figure 3.8C shows a spectrum of a 
region that was marked as a significant cancer lesion on 3 T MR images, but apart 
from SNR it did not show clear differences with the spectra of normal appearing 
prostate tissue (Fig. 3.8D-F). 
Figure 3.6 - Spectra of the same phantom as in Figure 3.5, acquired with a PRESS-MRSI sequence using 
MEGA-pulses and outer volume saturation slabs (TE = 145 ms) at 3 T (A,C) and with the SPSP-MRSI 
sequence (TE = 135 ms) at 7 T (B,D). A,B: TR = 750 ms. C,D: TR = 10 s. The spectra are scaled to maximum 
signal intensity. Cho, choline; Cit, citrate; Cr, creatine, Spm, spermine.
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In the healthy volunteer, elevated tCho signals were observed in the area of the 
urethra and the ejaculatory ducts (Fig. 3.9). In both patient and healthy volunteer 
spectra, a broad resonance around 2.35 ppm with varying height was observed in 
some spectra of the prostate (Figs. 3.8F, 3.9B). The chemical shift position of this 
resonance suggests a lipid origin. 
Discussion
Performing prostate 1H MRSI at 7 T is appealing in terms of SNR and spectral 
resolution and has challenged researchers to develop new pulse sequences and coils 
for this purpose. Unfortunately, the challenges related to ultra-high field strengths 
have increased the complexity of this already rather complicated technique until 
now. In this work, we presented a simple, back-to-basic approach to 7 T 1H MRSI of 
the prostate, which was successfully applied in four subjects. The use of an external 
array coil for signal transmission in combination with RF shimming, an endorectal 
coil for signal reception, and the implementation of SPSP refocusing pulses in a 
Figure 3.7 - Patient data. A: Spectral map of the full field of view on top of a transversal T2W 7 T prostate 
image. The white rectangle indicates the VOI selected by the SPSP pulses. Some lipid signal is present at 
the edges of the prostate. B: Spectrum indicated by the green square in a showing resolved tCho, Spm and 
Cit, and no water residual. C: Spectrum indicated by the red square in a showing lipid contamination. D: 
B0 map. E: Flip angle map, measured using a nominal 90° flip angle. Higher metabolite signals are present 
in the area with higher B1
+
 and closer to the coil wiring because of the coil sensitivity profile. This patient 
was under active surveillance for a Gleason 3+3 tumor (not visible in the image plane). tCho, total choline; 
Cit, citrate; Spm, spermine.
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double spin-echo sequence are the main elements for this low-SAR alternative for 
prostate 1H MRSI at 7 T. 
Although prostate 1H MRSI at 1.5 and 3 T is often performed with PRESS sequences 
equipped with slice-selective pulses for localization and dual-frequency pulses for 
selective water and lipid suppression (18,42,43), studies using SPSP-MRSI type of 
sequences have also been presented (14–16). Contrary to the spectral selectivity of 
the SPSP pulse as the most challenging factor at 1.5 and 3 T, requiring additional 
OVS pulses, the limiting factor at our 7 T system is the available B1
+
 transmit power 
with 8 x 1 kW amplifiers. The B1
+ amplitude in the prostate was considerably lower 
than at clinical field strengths, even after maximizing it with RF shimming. In two 
Figure 3.8 - Patient data. A,B: Spectral maps of the full FOV on top of transversal (A) and coronal (B) 
T2W 7 T prostate images. C-F: Spectra indicated by the colored squares in A and B. The white rectangle 
indicates VOI. The FOV placement in feet-head direction was not optimal because the MRSI could 
be planned on localizers and the transversal T2W-image only because of SAR restrictions. This, in 
combination with a rather large VOI resulted in fold-in of signal, mainly in feet-head direction. Lipid 
signal is present at the edges of the prostate, especially at the ventrolateral sides and at the level of the 
seminal vesicles. Differences in local shim have an effect on the citrate shape. A significant cancer lesion 
is present in the right peripheral zone at the level of the apex, extending from dorsolateral to ventrolateral 
(A). Apart from SNR, no clear differences are observed between a spectrum in the tumor lesion (C) and a 
spectrum on the contralateral side (D). tCho signal is observed in some spectra further away from tumor 
lesion (F). Spectra C, D, and F show signal at 2.35 ppm, which is probably lipid contamination. Spectral 
range: 2 – 3.5 ppm. tCho, total choline; Cit, citrate; Spm, spermine.
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Figure 3.9 - Healthy volunteer data. A: Spectral map on top of a sagittal T2W 7 T prostate image showing 
high metabolite signals throughout the prostate and minimal lipid signal at the edges of the prostate. 
Elevated tCho signals are present around the urethra (B) and the ejaculatory ducts (C). Spectra further 
away from the urethra show low tCho signal (D). The real voxel size is indicated by the yellow dotted 
circle. Spectral range: 2 – 3.5 ppm. tCho, total choline; Cit, citrate; Spm, spermine.
subjects, the required pulse power for the SPSP pulses was not completely reached 
(96 and 97% of required B1
+). This has probably slightly reduced SNR as was shown 
by the phantom experiments.
The use of SPSP pulses for 7 T prostate 1H MRSI is attractive for several reasons, 
despite their B1
+-related limitations. First, SPSP pulses intrinsically have a large 
spatial bandwidth because of the short duration of the subpulses, thus minimizing 
chemical shift displacements. In this study, the spectral-spatial pulse design 
employed a chemical shift misregistration correction to reduce misregistration over 
the spectral passband even further (31,32). Second, the spectral selectivity of the 
pulses allowed full refocusing of citrate, whereas the lipids at 2.1 ppm and below 
fell well within the spectral stopband. This was achieved by designing the pulses to 
have a transition band of only 100 Hz, facilitated by the long pulse duration as well 
as by the high spectral resolution at 7 T. In principle, this eliminates the need for 
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additional lipid suppression pulses or small VOI sizes to avoid contamination from 
periprostatic lipid signals, as was needed at 1.5 and 3 T. 
Nevertheless, lipid signals were sometimes present in the in vivo spectra from tissue 
on the anterior and superior sides of the prostate. This may have been caused by 
lipid protons resonating within the transition band of the SPSP pulses. By setting the 
frequency offset of the SPSP pulses to -530 Hz (-1.8 ppm) with respect to water, the 
transition band was set to range between 2.4 and 2.1 ppm. This was adequate for full 
refocusing of citrate, but may have resulted in partial refocusing of lipid resonances, 
probably originating from α-CH2 methylene protons of the fatty acid chains, which 
have relatively broad resonances at 2.25 ppm (44). The lipid signals exceeded the 
metabolite signals, despite their resonance in the transition band of the pulse. These 
large lipid signals from the periprostatic fat probably also contaminated spectra 
more centrally in the prostate because of the characteristics of the spatial response 
function related to k-space sampling with relatively small matrix sizes (45). Although 
the side lobes of the spatial response function were suppressed by a Hamming filter, 
resonances of varying size and phase were observed in some prostate spectra at 
the resonance position of the lipids within the periprostatic fat. To reduce signals 
from periprostatic fat, OVS pulses could be incorporated before the SPSP-MRSI 
localization within SAR limits at the same TR, but their efficiency would be limited 
by the low B1
+ outside the prostate after RF shimming. A sharper spectral transition 
band of the SPSP pulses may also decrease lipid contamination but would require 
longer pulses. 
The combination of the sensitivity profile of the endorectal coil and the VOI 
localization determined the minimum FOV to avoid fold-in of signals. Because the 
spatial selectivity of the current SPSP pulses is Gaussian-shaped, rather large axial 
VOI sizes were needed to retain maximum signal at the edges of the prostate. This 
restricted the minimum FOV and thus the minimum voxel size achievable within 
reasonable acquisition times. To benefit optimally from the increased SNR at 7 T, fast 
encoding approaches in combination with SPSP-MRSI can be explored.  
An important implication of the spectral selectivity of the refocusing pulses 
employed in this work is the intrinsic refocusing of the J-coupling evolution of 
spermine because only the 3.1-ppm group of spermine is refocused by the SPSP 
pulses. Without additional strong couplings present, this would lead to an in-phase 
signal of spermine at 3.1 ppm, independent of TE. The spectral shape of the 1.8 ppm 
spermine resonance in high resolution spectra is however indicative for the presence 
of non-equivalent spins (46), and the existence of a strong coupling between these 
protons has also been shown in theoretical calculations (37). The strong J-coupling 
slightly affects the refocusing effect, but the signal of spermine at 3.1 ppm was 
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mostly absorptive at different TEs. The other polyamines present in prostate tissue, 
spermidine and putrescine, show structurally and spectrally close resemblance 
to spermine (46). It is therefore expected that J-coupling refocusing also occurs in 
these metabolites. The concentrations reported for these polyamines are however 
5 to 10 times lower than spermine concentrations, and thus provide only a minor 
contribution to the in vivo polyamine resonance. This seems to hold for both normal 
and prostate cancer tissue; no significant differences in their concentrations were 
found between these tissues (4). 
The appearance of the in vivo 7 T spectra, showing large spermine signals, is clearly 
different from that of lower field prostate spectra. The signal intensity of spermine 
with respect to tCho and creatine is, next to the J-coupling refocusing effect, also 
affected by differences in T1 relaxation times of the prostate metabolites between 
field strengths. The T1 relaxation times of tCho and creatine have been found to 
increase from 3 T to 7 T in the human brain (47,48), with T1 values of ~1.3 s and ~1.8 s 
at 7 T, respectively. The reported T1 value of tCho in the prostate at 3 T was similar 
to that of brain at 3 T, that is, 1.1 s (36). Our phantom results showed a relatively 
short T1 of spermine with respect to choline and creatine at both field strengths. 
At the short TRs employed for in vivo measurements, tCho and creatine are partly 
saturated, whereas spermine and citrate appeared at almost full intensity. Our 
results suggest that the concentration ratio between polyamines and citrate in vivo 
lies between 1:2 and 1:4, which is in line with high-resolution magic angle spinning 
(HR-MAS) results from prostate tissue (49). For in vivo quantification of polyamines 
it is essential to take into account their J-modulation behavior, without this it is very 
likely to underestimate the polyamine concentration.
The very large spermine signal at TE = 135 ms in the 7 T in vivo spectra (often 
exceeding citrate signal intensities) was unexpected with regard to its reported T2 
relaxation time as short as 53 ms at 3 T (50). It would be of interest to measure T2 
values of spermine in vivo, which would be possible with the SPSP-MRSI sequence 
because of its J-coupling refocusing property. This feature has also been used to 
measure T2 values of γ-aminobutyricacid (GABA) in human brain (51). However, 
the effect of the strong coupling between the two –CH2- groups of spermine at 1.8 
ppm has to be taken into account in these measurements. 
The potential benefit of SPSP-MRSI at 7 T for assessing prostate cancer should be 
investigated in a larger patient cohort. Significant decreases in spermine and citrate 
concentration with increasing tumor grade have been reported in HR-MAS tissue 
studies (5). Although decreases in spermine and citrate in prostate cancer might 
be readily detected in vivo with the SPSP-MRSI sequence, internal referencing 
to discriminate the receive profile of the endorectal coil from metabolite changes 
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would be beneficial for quantification purposes. Because tCho levels are increased 
in prostate cancer, the well-known use of ratios including this metabolite could 
serve to assess prostate cancer and remove coil profile effects (17,26). However, 
not in all prostate spectra tCho signals could be distinguished separately from 
the large Spm signal, complicating this quantification approach. It is expected 
that reductions in voxel size will improve the separate detection of tCho, because 
this will improve intra-voxel B0 homogeneity, narrowing linewidths. Another 
opportunity with this spectrally-selective sequence would be to study metabolite 
resonances closer to water, for example, myo-inositol (3.5, 3.6, 4.1 ppm) and taurine 
(3.4 ppm), but most interestingly the other resonances of ethanolamine (3.8 ppm), 
phosphoethanolamine (4.0 ppm), (glycero)-phosphocholine (3.6-3.9 and 4.3 ppm) 
and choline (3.5 and 4.0 ppm) (52). HR-MAS studies of prostate biopsies showed 
significant differences between prostate cancer and normal prostate tissue in the 
concentrations of these metabolites (49,53,54), whose 3.2 ppm resonances all overlap 
in in vivo spectra (tCho). HR-MAS as well as in vivo 31P MRSI results suggest that 
especially phosphoethanolamine is a major contributor to the in vivo observed tCho 
resonance (53,55).
We conclude that 3D 1H MRSI of the prostate at 7 T is possible using a SPSP-MRSI 
sequence with a multi-channel transmit array coil and an endorectal receive coil. 
In vivo spectra with this low SAR sequence showed all signals of interest in the 
prostate with unexpectedly high spermine signals, because of the intrinsic J-coupling 
refocusing of spermine by the SPSP pulses. 
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Abstract
Objective: To evaluate the technical feasibility of multiparametric magnetic 
resonance imaging (mpMRI) of the prostate at 7 T, assess its image quality and 
compare it with 3 T. 
Methods: Fourteen patients with biopsy-proven prostate cancer (mean age, 65.2 
years; range, 51-71 years) underwent 7 T mpMRI with an external 8-channel flexible 
body array coil and an endorectal coil. High-resolution turbo spin-echo T2-weighted 
(T2W) imaging was performed with an in-plane resolution of 0.3 mm and a slice 
thickness of 2 mm (mean duration 2:18 min). Diffusion weighted imaging (DWI) 
was performed using 5-shot readout-segmented echo-planar imaging at b-values of 
0, 100, 400 and 800 s/mm2 with an in-plane resolution of 1.75 mm (mean duration 
4:06 min). 1H MR spectroscopic imaging (MRSI) was performed using a double 
spin-echo method with slice-selective excitation and two spectral-spatial refocusing 
pulses combined with 3D spatial localization by traditional phase-encoding and/or 
a fast spiral readout at higher resolution (mean real voxel size 0.71 mm3 or 0.52 mm3, 
mean duration 9:03 min or 6:25 min, respectively). Image and spectral quality were 
rated on a 5–point scale by a radiologist and spectroscopist, respectively, and a 
qualitative comparison of the images to 3 T was performed.
Results: Prostate mpMRI at 7 T including at least two out of three different MR 
techniques was obtained at in 13 patients. Overall T2W image quality at 7 T was 
scored as fair (3/5, 38%) to good or very good (4/5 and 5/5, 48%). 24% of the T2W 
image series showed an improvement in structure delineation compared with 3 T. 
Motion artifacts and areas of low SNR, probably related to an inhomogeneous RF 
transmit field, affected 55% and 48% of the image series, respectively. The overall 
image quality of the DWI was scored as fair (3/5, 25%) or (very) good (4/5 and 5/5, 
75%). Ghosting of the rectal wall in the readout direction was the most pronounced 
artifact in DWI (75%). MRSI quality was rated fair or good in 56% of the acquisitions. 
Lipid contamination was the main reason for poor spectral quality.  
Conclusions: mpMRI of the prostate at 7 T is feasible at unprecedented spatial 
resolutions for T2W-imaging and DWI and within clinically acceptable acquisition 
times for high resolution MRSI. The higher spatial resolutions can yield better 
delineation of prostate anatomy, but the robustness of the techniques needs to be 
improved before clinical adoption of 7 T mpMRI.  
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Introduction
Multiparametric magnetic resonance imaging (mpMRI) has been shown to be 
effective for the detection, localization and local staging of prostate cancer (1–4) and 
in guiding prostate biopsies in men with previous negative findings (5). An mpMRI 
prostate protocol consists of high-resolution T2-weighted (T2W) MR imaging and 
at least two functional MR techniques: diffusion-weighted imaging (DWI), dynamic 
contrast-enhanced (DCE) MRI and/or proton MR spectroscopic imaging (1H MRSI) 
(6). 
A number of challenges exist in assessing the prostate with mpMRI, even for 
experienced radiologists reading state-of-the-art 3 T images. It remains difficult to 
distinguish prostatitis from tumor in the peripheral zone (7,8), and identify tumors 
in the transition and central zones (9,10). It has been suggested that morphology and 
texture characteristics are most useful in correctly assigning these cases (11,12), which 
is reflected by the most prominent role for T2W-MRI in the detection of transition 
zone cancers in the latest Prostate Imaging Reporting and Data System (PIRADS 2) 
(13). This advocates for T2W-imaging at a higher spatial resolution. 
Besides detection of the disease aided by PIRADS, mpMRI is increasingly being used 
to assess cancer aggressiveness non-invasively. This can improve risk stratification 
of patients with localized prostate cancer, for example to identify candidates eligible 
for active surveillance (14,15). Current quantitative measures from DWI, DCE-MRI 
and 1H MRSI have potential for this purpose, but still show considerable overlap 
between tumor aggressiveness classes (16,17). Refinements of the functional prostate 
MRI techniques could potentially lead to more specific results, allowing better 
separation of these classes. 
Ultra-high field-strength (7 T and higher) MR systems offer an increased signal-
to-noise ratio (SNR), theoretically enabling improvements in spatial resolution 
of the SNR-limited mpMRI techniques: T2W-MRI, DWI and 1H MRSI. Moreover, 
peak separation in MRSI improves at these field strengths, because of increased 
spectral resolution. Since the peaks of the prostate metabolites choline, spermine 
and creatine are not well separated in 3 T spectra, let alone in 1.5 T spectra, their 
signals are often summed together for quantification (18). With increasing choline 
levels and decreasing spermine levels in prostate cancer, obtaining their individual 
signals may increase the value of 1H MRSI in prostate MR exams. 
Nevertheless, strong radiofrequency (RF) inhomogeneities, high specific absorption 
rates (SAR) and large susceptibility effects present a challenge for prostate mpMRI 
at 7 T. The feasibility of T2W prostate imaging at 7 T with external transmit-receive 
array coils has been demonstrated previously (19–21). Although cancer lesions were 
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visible and image quality was considered satisfactory to good in patients on the 
7 T images acquired with an external array coil (22), image resolution could not 
be improved compared with state-of-the-art 3 T images within similar acquisition 
times. 
The combination of an external transmit array coil with an endorectal receive coil 
increases local sensitivity and allows for reduced fields of view, enabling higher 
resolution prostate images (23). This coil combination also creates opportunities for 
DWI and fast 1H MRSI, with pulse sequences dedicated to overcome the 7 T related 
technical challenges. 
In this study we evaluated the technical feasibility of mpMRI of the prostate at 
7 T including T2W-MRI, DWI and 1H MRSI using the combination of an external 
8-channel transmit array coil and an endorectal receive coil. Moreover, we provide a 
clinical assessment of the image quality of 7 T mpMRI and a qualitative comparison 
with 3 T imaging. 
Materials and Methods
This study was approved by the institutional review board of the University of 
Duisburg-Essen and all patients gave written informed consent. 
Subjects
Fourteen patients with biopsy-proven prostate cancer (mean age: 65.2 years, range: 
51-71 years; median PSA level: 6.2 ng/mL, range: 1.0-11.6 ng/mL; median Gleason 
score: 6) were recruited for this study between September 2013 and October 2014. 
Exclusion criteria were general contraindications to MRI (e.g. cardiac pacemaker) 
and 7 T specific contraindications (presence of surgical clips, stents, or any other 
foreign metallic implant), contraindications to endorectal coil insertion (e.g., prior 
anorectal surgery, inflammatory bowel disease), and claustrophobia. All patients 
underwent a clinical mpMRI staging exam including triplanar T2W-MRI, DWI and 
DCE-MRI at a 3 T MR system prior to the 7 T exam, using a 32-channel phased array 
coil and an endorectal coil (see Table 4.1 for scan parameters). 
Scanner and Patient Setup
Measurements were performed by using a combination of an in-house built receive-
only endorectal coil tuned to 297 MHz (adapted from a commercially available 3 T 
endorectal coil; Medrad, Bayer AG, Leverkusen, Germany) and an in-house built 
8-channel body array coil on a 7 T whole-body research MR system (MAGNETOM 
7T, Siemens Healthcare, Erlangen, Germany). The gradient coil of the MR system 
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was replaced after the first two subjects were scanned. The new gradient coil had 
better linearity, but lower maximum gradient amplitudes and smaller slew rates. 
The endorectal coil was inserted with the patient in the left lateral decubitus 
position. The inner balloon of the endorectal coil was filled with perfluorinated 
fluid (Galden; Solvay Specialty Polymers, Spinetta Marengo, Italy) to a volume 
of approximately 50 mL to minimize susceptibility differences between the 
endorectal coil balloon and the tissue. To reduce peristalsis and motion artifacts, 
patients who had no contraindications received an intramuscular injection of 1 mg 
Glucagon (GlucaGen® Hypokit™, Novo Nordisk, Bagswærd, Denmark) and 20 mg 
butylscopolaminebromide (Buscopan®, Boehringer, Ingelheim, Germany). SAR-
monitoring, magnetic field shimming, RF-shimming and flip angle calibration were 
performed as described previously (19). 
Multiparametric MR Imaging
The full MRI protocol at 7 T included triplanar T2W turbo spin-echo imaging, DWI 
and 3D 1H MRSI. In all these sequences, the external array coil was used for signal 
transmission and the endorectal coil for signal reception. Sequence optimization for 
T2W-MRI at 7 T with only the array coil was presented previously (19), the use of the 
endorectal coil allowed for an increase in spatial resolution (Table 4.1). The number 
of slices was adjusted to cover the full prostate (12-25 slices). 
DWI was performed using a 5-shot readout segmented echo-planar imaging 
sequence, including a 2D navigator echo to correct for non-linear phase-errors (24), 
with b-values of 0, 100, 400 and 800 s/mm2. To minimize echo time, an optimized 
monopolar diffusion encoding scheme was used (25). Sequence parameters are 
stated in Table 4.2. Apparent diffusion coefficients (ADCs) maps were generated 
using all b-values. 
Table 4.1 - Parameters of T2W-MRI sequences at 3 T and 7 T
T2W-MRI 3 T 7 T
TR (msec) 5270-5900 2500-5100a
TE (msec) 99-144 80-85b
Flip angles (°) 90/120 90/150-160c
FOV (mm)
TRA: 180x180
SAG: 138x192
COR: 96x192
96x96
Resolution (mm) TRA: 0.4x0.4SAG,COR: 0.5x0.5 0.3x0.3
Slice thickness (mm) 3.0 2.0
Slice gap (mm) 0 or 0.3 0.4
No. of slices 19-23 10-25
Imaging time (min:sec) 2:16-5:49 1:28-2:59
a  TR and total imaging time depended on number of slices. b TE depended on gradient system. c Refocusing 
flip angle adjusted to 150° after first two patients. Mean number of slices in patients transversal: 21, 
sagittal: 16, coronal: 15. TRA: transversal; SAG: sagittal; COR: coronal.
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Metabolite levels within the prostate were measured using a dedicated 7 T 1H MRSI 
sequence using spectral-spatial pulses for volume selection (26). The spectroscopic 
k-space was filled elliptically using 3D phase-encoding (default Spectral-Spatial: 
SP2 MRSI), and/or using fast angular and temporal interleaved spirals which 
simultaneously encoded the spectroscopic frequency dimension and two spatial 
dimensions by constant density gradient waveforms (27,28) (fast Spectral-Spatial-
Spiral: SP3 MRSI). The third spatial dimension in case of spiral sampling was 
obtained with a phase-encoding gradient resulting in cylindrical 3D coverage of 
the k-space with a stack of spirals. MRSI of the prostate was acquired with varying 
settings for the volume of interest (VOI), field of view (FOV), matrix size, and thus 
resulting total acquisition time (Table 4.3), because of optimization purposes and 
differences in prostate size. Spectroscopic results were interpolated to a 16 x 16 x 16 
or a 32 x 32 x 16 grid by the scanner software, depending on the native resolution of 
the MRSI. MRSI and DWI were performed with the same angulation as transversal 
T2W-MRI. 
Table 4.2 - Parameters of diffusion weighted imaging sequences at 3 T and 7 T
DWI 3 T 7 T
TR (msec) 2700 3300 a or 4200 b
TE (msec) 70 49 a  or 68 b
Flip angles (°) 90/180 90/180
FOV (mm) 168x526 130x130 a or 154x154 b
Resolution (mm) 2.0x2.0 1.4x1.4 a or 1.75x1.75 b
Slice thickness (mm) 3.0 2.0
Slice gap (mm) 0 or 0.3 0.4
No. of slices 20-23 10-20
Imaging time (min:sec) 4:07-4:18 3:08-4:22
a Subjects 1 and 2, strong gradient system. b Remaining subjects, standard gradient system.
Table 4.3 - Parameters of MR spectroscopic imaging using a spectral-spatial (SP2) or spectral-spatial-
spiral (SP3) pulse sequence
Protocol N FOV (mm) matrix Nominal voxel size (mm)
Real 
voxel size 
(mm3)
#NA TA (min:sec)
SP
2
A 1 70x70x58 12x12x10 5.8 x 5.8 x 5.8 0.74 1 7:01
B 1 70x70x70 10x12x12 7.0 x 5.8 x 5.8 0.89 1 7:01
C 1 80x80x67 12x12x10 6.7 x 6.7 x 6.7 1.1 1 7:01
D 4 70x60x60 14x12x12 5.0 x 5.0 x 5.0 0.47 1 10:17
E 1 98x84x84 14x12x12 7.0 x 7.0 x 7.0 1.1 1 10:17
SP
3
A 1 80x80x80 16x16x16a 5.0 x 5.0 x 5.0 0.28 1 3:16
B 5 120x120x72 20x20x12a 6.0 x 6.0 x 6.0 0.48 3 7:16
C 2 160x160x70 23x23x10b 7.0 x 7.0 x 7.0 0.77 3/4 5:04/6:44
N: number of subjects. #NA: Number of averages. TA: Total acquisition time. 
Real voxel size is the effective voxel size after applying a 50% Hamming filter to reduce inter-voxel bleed 
(43). Size of the VOI varied between subjects. a 6 angular and 2 temporal interleaved spirals. b 5 angular 
and 2 temporal interleaved spirals.
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Image Analysis 
The 7 T T2W images, diffusion weighted images and ADC maps of the patients were 
evaluated by a radiologist (J.J.F., 13 years of experience in prostate MRI), blinded to 
patient history. The following characteristics of the transversal T2W images were 
rated on a 5-point scale (‘very good’, ‘good’, ‘fair’, ‘poor’ or ‘very poor’): visualization 
of the peripheral zone, transition zone, seminal vesicles, benign prostatic hyperplasia 
(BPH; if applicable), neurovascular bundles and the urethra; delineation of the 
prostatic capsule and delineation of dominant prostate cancer lesion (if applicable). 
Overall image quality was rated on the same scale for transversal, sagittal and 
coronal T2W images separately. The following characteristics of DWI were scored 
on the 5-point scale: SNR per b-value image, overall image quality of the ADC maps, 
and visibility of BPH and of prostate cancer lesions if applicable. Artifacts in T2W 
images and DWI were rated on a 4-point scale (‘absent’, ‘mild’, ‘moderate’, ‘severe’) 
or as ‘present but not affecting the prostate’ for each available image direction. 
Predefined artifacts can be found in Table 4.4, and single examples of 7 T specific 
artifacts (Supplemental Figures 4.1 and 4.2) were used to instruct the radiologist for 
his reading. The radiologist was asked to report other artifacts as well on the above-
mentioned scale. The endorectal coil line artifact (Fig. S4.1E) was rated as ‘absent’ 
or ‘present’.
A comparison of the 7 T and 3 T images was performed by two readers in consensus 
(M.W.L., spectroscopist with 4 years of experience, B.P. MD with 2 years of 
experience in prostate mpMRI, 100 cases). Structure delineation and image contrast 
Table 4.4 - Image artifacts identified in the 7 T prostate images and their possible causes
Image Type of artifact (Possible) cause 7 T specific?
T2W Image blurring and ghosts of rectal wall and/
or bladder in phase-encoding direction
Motion No
T2W Coil flare, i.e. extremely bright signal close to 
the endorectal coil which drops off rapidly 
further away from the coil
Sensitivity profile endorectal coil No
T2W Focal signal void or alternating bright 
and dark bands from a focal spot close to 
endorectal coil
1: Air bubble in balloon of 
endorectal coil
1: No
2: residual current in endorectal 
coil during transmit a
2: Yes
T2W Areas with low SNR in prostate B1
+ inhomogeneities Yes
T2W Line signal void through seminal vesicles Endorectal coil flux pattern (44) No
DWI N/2 ghosts in phase-encoding direction Eddy currents, susceptibility 
differences, motion
No
DWI Ghosting in readout direction Motion, failure of 2D navigator Yes
DWI Geometric distortion of the prostate between 
b-values
Eddy currents, motion (45) Yes
a Because of a possible small residual coupling between the transmit elements and the receive endorectal 
coil, some current is induced which creates artefacts near the conductor endorectal coil.
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of T2W images and overall quality of ADC maps at 7 T were rated better, similar or 
worse than at 3 T.  
Spectra were evaluated by a spectroscopist (M.W.L.) for the separation of signals 
of citrate, choline, spermine, and creatine, the shape of the citrate signal and the 
presence or absence of water and lipid signals. Overall spectral quality was judged 
on a 5-point scale: ‘very good’, ‘good’, ‘fair’, ‘poor’ or ‘very poor’. If both SP2 and fast 
SP3 MRSI were acquired in one subject, the results were compared using the criteria 
stated above, and on their SNR. 
Results 
Ten subjects successfully concluded the full 7 T mpMRI protocol. One patient aborted 
the 7 T exam before any relevant images could be recorded because of severe back 
pain. In three patients only two out of three different MR techniques were performed, 
Figure 4.1 - Flow chart of mpMRI protocols performed. T2W: T2-weighted MR imaging, DWI: diffusion-
weighted MR imaging, MRSI: MR spectroscopic imaging, TRA: transversal, SAG: sagittal, COR: coronal, 
SP2 MRSI: spectral-spatial MRSI, SP3 MRSI: spectral-spatial-spiral ‘fast’ MRSI.
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twice because of scanner failure, once because B0 shimming was not successful in 
combination with the very small prostate size after transurethral resection (see flow 
diagram in Figure 4.1). The total scan duration varied between 32 min (transversal 
T2W-MRI and DWI only) and 1 hour and 23 min, with an average of 1 hour and 5 
min. Figures 4.2 and 4.3 show examples of full mpMRI exams. Table 4.5 comprises 
the results of the radiological evaluation, the comparison to 3 T and the spectroscopy 
evaluation. The results are elaborated upon in the following sections.
T2-Weighted Imaging
The visibility of anatomical structures was judged fair to good by the radiologist. 
The depiction of the peripheral zone, the urethra, BPH nodules and suspected 
prostate cancer lesions yielded the best scores. Overall image quality was scored as 
fair, good and very good in 38%, 41% and 7% of the image series, respectively, with 
transversal images yielding the highest average score, followed by coronal images 
and sagittal images. The severity of motion artifacts increased from transversal to 
coronal to sagittal images, while the severity of areas of low SNR increased with 
opposite orientation order. This low SNR artifact was usually observed in the right 
anterior prostate base and/or apex, and in two patients from apex-to-base on the 
right anterior side. Motion artifacts and areas of low SNR decreased image quality in 
55% and 48% of the image series, respectively (artifact scored as mild or worse). Mild 
focal signal void artifacts were seen in transversal and sagittal images. Examples of 
the artifacts observed are presented in Figure 4.1. 
The higher spatial resolution of T2W-MRI at 7 T could primarily be appreciated 
in the transversal images, showing better structure delineation than at 3 T in 42% 
of the image series. However, in most (88%) of the 7 T T2W images in the other 
orientations, structure delineation was judged similar to or worse than at 3 T. Image 
contrast was comparable between most 7 T and 3 T T2W images. 
Diffusion Weighted Imaging
The visibility of anatomical structures in the 7 T ADC maps was judged good, and the 
SNR of native b-value images decreased gradually from good to fair with increasing 
b-values. In the anterior part of large prostates the native diffusion images had a low 
SNR, especially the b = 800 s/mm2 images. SNR of the diffusion images was degraded 
in the same areas as reported for the T2W images, artificially increasing the ADC in 
these areas. The overall image quality of the DWI was scored as fair (25%), good 
(67%) or very good (8%). Ghosting of the rectal wall in the readout direction (Fig. 
4.2) was the most pronounced artifact in DWI (scored mild-moderate). Geometric 
displacements and distortions between native b-value images were mainly observed 
in the left-right (phase-encoding) direction and reached a maximum of 3 mm 
between b = 0 and 800 s/mm2 in one patient. This effect resulted in less well-defined 
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Figure 4.2 - Prostate mpMRI of a 65-year old patient. A cancer lesion in the right peripheral zone is visible 
on both the 3 T (A,B) and 7 T images (D-I). A,C: T2W-MRI; B,D: ADC map; E,F: diffusion weighted 
images with b = 0 (E) and right: b = 800 (F); G: spectral map of SP2 MRSI (protocol D); H: spectrum of 
lesion, I: spectrum of normal-appearing contralateral peripheral zone tissue. The lesion appears as a 
hypo intense area in the T2W images and as a focus of restricted diffusion on the ADC maps. The 7 T 
diffusion-weighted b-value images show a strong T2-weighting, masking the effect of the tumor on the 
diffusion. The tumor spectrum shows relative low citrate (Cit) levels with respect to spermine (Spm) 
levels, choline could not be identified because of the large linewidth of Spm. The overall image quality of 
the 7 T transversal T2W images and DWI was rated fair and good, respectively. Structure delineation and 
contrast of the T2W image series as well as the quality of the DWI was judged similar to 3 T. lip: lipids.
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prostate edges in the ADC maps (example in Figure 4.2). This artifact was rated mild 
by the radiologist. Nyquist ghosts were either absent or not affecting the prostate. 
Compared with 3 T, the 7 T ADC image quality was rated better in one patient and 
similar (n=5) or worse (n=6) in the other patients. 
1H MR Spectroscopic Imaging
The overall quality of the spectra varied between subjects, 4 out of 8 SP2 datasets and 
5 out of 8 SP3 datasets were rated fair or better. The main reason for poor spectral 
quality was lipid contamination of the spectra in the region from 2.6-2.3 ppm, 
precluding detection of citrate. The 7 T spectra without lipid contamination looked 
different from 1.5 T or 3 T spectra, with a large spermine signal, concealing the 
choline and creatine signals in many spectra. The spectral shape of citrate (doublet 
of doublets in case of homogenous B0) showed a negative lobe between the main 
Table 4.5 - Rating of quality and artifacts of 7 T mpMRI and comparison to 3 T. The average and standard 
deviation of the rates of all 12 patients is presented. Values between square brackets indicate the 
occurrence of artifacts not affecting the prostate.
T2W-MRI MRSI
Visibility anatomical structures in transversal direction SP2 2.6 ± 1.3
Peripheral zone 3.7 ± 0.8 SP3 2.9 ±0.8
Transition zone 3.6 ± 0.7 
Seminal vesicles 3.4 ± 1.0 (N/A1: 2) DWI
BPH-nodules 3.8 ± 0.7 Visibility anatomical structures in ADC
Neurovascular bundles 3.4 ± 0.7 BPH-nodules 3.9 ± 0.5 
Urethra 4.2 ± 0.6 PCa lesion 4.1 ± 1.0 (N/A: 4)
Prostate delineation 3.6 ± 0.7 SNR per b-value
PCa lesion delineation 3.8 ± 0.4 (N/A: 3) 0 4.0 ± 0.4
Overall image quality 50 3.8 ± 0.5
Transversal 3.8 ± 0.8 400 3.6 ± 0.5
Coronal 3.4 ± 1.0 800 3.4 ± 0.5
Sagittal 2.9 ± 0.9 Overall image quality ADC 3.8 ± 0.6
Artifacts TRA COR SAG Artifacts
Motion related 1.5 ± 0.8 1.9 ± 0.7 2.2 ± 1.0 N/2 ghosts 1.0 ± 0.0 [1]
Coil flare 1.4 ± 0.7 1.1 ± 0.4 1.4 ± 0.7 Ghosting in readout direction 2.5 ± 0.9 [1]
Focal signal void 2.0 ± 1.4 [7] 1.1 ± 0.4 1.8 ± 1.1 [1] Geom. distortion 1.8 ± 0.7
Low SNR areas 2.1 ± 0.9 1.9 ± 1.1 1.3 ± 0.5
Line signal void SV 50%
T2W - Comparison to 3 T Structure delineation Contrast DWI - Comparison to 3 T
TRA COR SAG TRA COR SAG
7 T better 5/12 - 2/10 - - - 7 T better 1/12
7 T similar 6/12 2/7 2/10 10/12 3/7 9/10 7 T similar 5/12
7 T worse 1/12 5/7 6/10 2/12 4/7 1/10 7 T worse 6/12
Scale image and MRSI quality: 1 - very poor 2 - poor, 3 - fair, 4 - good, 5 - very good
Scale artifacts: 1 – absent, 2 – mild, 3 – moderate, 4 - severe
1 Transversal slices did not cover seminal vesicles in two patients.
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doublet in areas with low SNR identified in T2W images and sometimes at the edges 
of the prostate.
Fold-in of signals from outside the FOV was observed in three SP2 datasets, this 
affected spectra in the prostate in one case. With SP3 protocol B and C, no fold in 
of signals was observed, even in case of large prostate sizes which required a large 
VOI (size > 60x60x60 mm). Higher resolution MRSI in a large VOI at still reasonable 
Figure 4.3 - Prostate mpMRI of a 71-year old patient. A cancer lesion in the right peripheral zone is visible 
on both the transversal T2W image (A) and the ADC maps (B) at 3 T and 7 T. Ghosting of the rectal wall 
was present in some slices of the transversal 7 T T2W images, but image quality was rated good and 
overall structure delineation was rated better than at 3 T, contrast was rated similar. The sagittal (C) 7 T 
images showed general image blurring, resulting in a fair score for image quality. Structure delineation 
was rated worse than at 3 T, while contrast was rated similar. Although the 7 T coronal (D) image quality 
was rated very good, the contrast was judged worse than 3 T. E and F show spectroscopic maps of an MRSI 
slice at mid-prostate level using SP2 (protocol C; real voxel size 1.1 mm3) and fast SP3 MRSI (protocol B; 
real voxel size 0.48 mm3), respectively. Lipids are present in the spectra of the peripheral zone close to 
the rectal wall, but the resolution improvement with SP3 improves the number of spectra without lipid 
contamination. G,H: spectra of SP2 and SP3 indicated by the red voxels in E and F respectively. The 
receive profile of the endorectal coil is seen in the SNR distribution of the spectra. Spectra in the area of 
the tumor showed lipid contamination and could not be judged on their metabolite levels. Cit: citrate; 
Spm: spermine.
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SNR could be obtained with SP3 within the same acquisition time (7 min) as the SP2 
acquisition (Fig. 4.3).
Both SP2 and SP3 MRSI were obtained in four patients. They showed similar quality 
in three patients (1 time both good, 2 times both poor), although SNR was generally 
a bit lower in SP3 spectra than in SP2 spectra. In one patient a wrong acquisition 
filter was used for the SP3 data which negatively affected the line shapes (SP3: fair, 
SP2: good).
Possible cancer-related changes were observed in only two patients (Figures 4.2 and 
4.4), one showing decreased citrate levels with respect to the total spermine+choline 
peak, and the other showing increased choline levels in the tumor compared with 
adjacent prostate tissue.
Discussion 
The results of our study demonstrate the feasibility of mpMRI of the prostate at an 
ultrahigh field strength of 7 T for the first time, in a small cohort of patients with 
prostate cancer. T2W-MRI and DWI were performed at unprecedentedly high spatial 
resolutions, and flexible MRSI acquisition in terms of resolution and measurement 
times was presented. Nevertheless, our first experiences with mpMRI at 7 T show 
limitations and challenges as well, currently restricting its clinical application.
T2W-MRI of the prostate at 7 T has been shown before (19,20,22,23), with satisfactory 
to good image quality ratings in patients scanned with an external array coil only 
(22). The SNR gain of a higher magnetic field was not translated into a higher spatial 
resolution in those studies. In our work, an endorectal receive coil allowed for a 
Figure 4.4 - 1H MRSI of the prostate of a 76-year old man with a Gleason 3+4 tumor in the left dorsolateral 
peripheral zone in the apex of the gland. A and C are zoomed regions of the spectral map in B, indicated 
by the colored boxes (A: normal-appearing tissue, C: cancer lesion). Large lipid signals anterior and 
lateral posterior of the prostate are visible in B, concealing citrate or distorting the citrate shape in the 
neighboring prostate spectra, such as in the bottom spectra in A. All prostate spectra show high spermine 
signals, and only in a few spectra in normal-appearing tissue choline could be separately observed. In 
tumor tissue choline signals were present and higher than spermine signals. Cit: citrate; Cho: choline; lip: 
lipids; Spm: spermine.
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smaller field of view, enabling increases in the spatial resolution with full prostate 
coverage in similar acquisition times as at 3 T. The rating of the delineation of 
anatomical structures in T2W images did however not improve with respect to the 
external-array coil only 7 T study, and also a direct comparison of the 7 T and 3 T 
images of the patients only showed a beneficial effect of the higher resolution in 
transversal T2W-MRI in six patients. Possible reasons for not achieving a better 
structure delineation are the areas of low SNR and motion related artifacts which 
were observed in the images. Areas of low SNR most likely resulted from destructive 
interferences in the RF transmit field (B1
+), decreasing the local B1
+ and thus causing 
lower excitation and refocusing flip angles. B1
+ was maximized by RF shimming in 
a transversal slice at the midprostate, improving the B1
+ field in a 3D region around 
this slice. However, RF interference patterns are very complex at 7 T, resulting in a 
high likelihood of signal loss just outside the RF shimmed area (20). This drawback 
of 7 T is especially problematic in patients with a large prostate. 3D volume selection 
using a parallel transmit approach (29,30) may redress this problem, as has recently 
been shown for cardiac MRI at 7 T (31). Motion artifacts (image blurring and coil 
ghosting) are not 7 T specific, and may offset gains in spatial resolution. The motion 
artifacts in coronal and sagittal images were more severe than in the transversal 
images, which might be explained by the direction of the slice-selection and the 
time between injection of antiperistaltic agents and the acquisition of the images. 
Transversal slices contain less moving structures (due to peristalsis and respiration) 
than sagittal and coronal slices and the SAR intensive T2W acquisitions were 
interleaved with the less SAR demanding DWI and MRSI acquisitions to minimize 
the total exam duration. In practice, transversal scans were obtained within 30 min, 
directly after shimming and pulse calibration, while the other T2W acquisitions 
were obtained after 40 min of scanning. At 3 T, all anatomical images can be acquired 
consecutively within a total of 30 min. Automation of the calibration processes at 7 T 
will shorten the total acquisition time and possibly decrease motion artifacts in later 
scans. Whether improved structure delineation using higher resolution T2W-MRI 
could improve prostate cancer detection in challenging cases (e.g. transition zone 
cancer) needs to be investigated in a future study using histopathology as reference 
standard.
To our knowledge, DWI of the prostate at 7 T has not been reported before. Strong 
susceptibility effects and short T2
* relaxation times make this technique particularly 
challenging at 7 T. At clinical field strengths, DWI is typically performed with single-
shot EPI techniques. This technique is very sensitive to susceptibility differences 
because of the limited bandwidth per pixel along the phase-encoding direction, and 
has limitations in the maximum resolution that can be achieved. Parallel imaging 
and multi-shot or segmented EPI techniques have alleviated these shortcomings 
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(32,33), but still suffer from residual problems such as motion-induced phase-errors. 
To achieve a robust non-linear correction for these phase errors, 2D navigators can 
be used (24). The combination of readout-segmented EPI, parallel imaging and 2D 
navigators for motion correction was found to be robust enough for 7 T DWI of the 
human brain and breast (34,35). Our results show that DWI of the prostate at 7 T as 
well, even without the use of parallel imaging. Including a parallel imaging factor 
of two would decrease geometric distortions by half, but the distortions measured 
in our study (max. 3 mm) were comparable to those reported for breast DWI using 
parallel imaging at 7 T with a similar readout-segmented EPI sequence (35). We 
tried to align the b-value images using linear transformations, but this did not 
clearly reduce the bright and dark bands lateral to the prostate that resulted from 
the geometric distortions between the individual b-value images. More advanced 
post-processing methods, accounting for non-linear distortions (36), could be tested 
to improve ADC map quality. This might not even be necessary since the radiologist 
marked the geometric distortion artifact as mild. More severe was the ghosting 
artifact in readout direction. Remarkably, this artifact was not observed before the 
change of the gradient coil, after which the TE of the DWI sequence was increased by 
19 ms. This increase in TE probably degraded the data of the 2D navigator, limiting 
the motion correction.
The main challenge in performing MRSI at 7 T with external transmit coils is to stay 
within SAR limits during the full 3D acquisition while attaining accurate localization 
of the spectra and effective water and lipid suppression. It was shown recently that 
the power deposition of MRSI at 7 T can be kept low using a sequence with spectral-
spatial refocusing RF pulses (26). These RF pulses theoretically obviate the need for 
water and lipid suppression pulses, confining the number of RF pulses per TR to 
three. However, the quality of the MRSI prostate spectra varied among the subjects. 
Especially lipid contamination was found to degrade spectral quality. Effective 
elimination of lipids without affecting citrate resonances requires a homogeneous B0 
field throughout the full VOI, because citrate and the lipid signals are only 0.3 ppm 
apart. The frequency at the edges of the VOI might be several hertz off from the 
carrier frequency within the center of the prostate in case of a large prostate and 
correspondingly large VOI, with higher frequencies leading to more refocusing of 
periprostatic lipids. Other strategies, such as additional frequency-selective lipid 
suppression or outer volume suppression slabs, commonly used at 1.5 and 3 T, may 
be explored to remedy this problem.
The appearance of prostate spectra obtained with the method used here, showing 
high spermine signals, is clearly different from commonly observed spectra at lower 
fields. The reason behind the high spermine signals is the spectral selectivity of the 
refocusing pulses, which refocus the J-coupling between the 1.8 ppm and 3.2 ppm 
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resonances of spermine (26). Larger patient cohorts are needed to study possible 
spectral differences between normal prostate tissue and prostate tumors at 7 T. The 
use of SP3 MRSI is recommended for future MRSI studies, because a spiral readout 
offers more flexibility in terms of the combinations of FOV, resolution and acquisition 
times than conventionally encoded MRSI and therefore offers more opportunities to 
take advantage of the increased SNR at 7 T. Spiral readout trajectories simultaneously 
acquire the frequency dimension and two of the spatial dimensions and can thereby 
accelerate collection of spectroscopic data (27,28). Temporal spiral interleaves were 
used to reach a spectral acquisition bandwidth of 1000 Hz. Several spiral readout 
protocols were tested to find an optimum in resolution, acquisition time and SNR 
of the spectra. Very fast MRSI could be obtained with a small FOV (SP3 protocol 
A, ~3 min), but this protocol suffered from the same fold-in problem as SP2 MRSI 
when using a larger VOI. The protocol with the largest FOV had an intermediate 
acquisition time (SP3 protocol C, ~5 min), but lacked sufficient resolution. In the end, 
the combination of FOV (120 x 120 mm in plane), resolution (real voxel size 0.48 cc), 
SNR and acquisition time (~7 min) in protocol B was judged best for prostate MRSI 
at 7 T. Nominal resolutions of elliptical phase-encoding MRSI and spiral MRSI 
should not be compared directly, because of different definitions of the point spread 
function with the acquisition techniques (28). With a spiral readout it was possible 
to obtain MRSI with a real voxel size slightly below the size of tumors deemed 
clinically significant (0.5 cc) in 7 min, reducing the scan time by 3 min compared 
with conventionally encoded MRSI. 
Current guidelines recommend the use of at least two functional techniques next to 
T2W-MRI in mpMRI (6). The 3 T prostate staging protocols at our institute consist 
of T2W-MRI, DWI and DCE-MRI. The latter technique was not explored in this 7 T 
study since it is not SNR limited at 3 T and therefore expected to benefit less from 
increased field strength than the other techniques (37). A functional technique that 
might be further explored at 7 T in combination with the mpMRI protocol presented 
here is 31P MRSI (38–40). This technique may yield complementary metabolic 
information for tumor characterization (e.g. aggressiveness) (41,42). The current 
external array coil also enables mpMRI examinations without endorectal coil, 
although at somewhat lower resolutions.
This study had several limitations. First, the number of patients was relatively 
low, and histopathological reference data was not available. Secondly, 7 T mpMRI 
results were not complete in all cases. These limitations were considered acceptable 
for an assessment of technical feasibility and an initial evaluation of image quality. 
Unfortunately, a direct comparison of MRSI at 3 T and 7 T was not possible, 
because MRSI was not included in the clinical 3 T mpMRI staging protocol. Direct 
comparisons of SNR between two field strengths are very difficult to interpret 
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because of differences in coil setup, pulse sequences, optimal sequence timing etc., 
and were therefore not performed. 
Although our results are encouraging in terms of technical advancements, showing 
the feasibility of mpMRI at 7 T, this study also revealed particular challenges which 
need to be overcome to truly benefit from the increased SNR at 7 T and enable 
robust full 7 T mpMRI. The main challenges to overcome for high-resolution T2W 
imaging are blurring caused by motion and signal drop-out due to low B1
+. The latter 
challenge can also affect ADC maps by decreasing SNR in native DWI images. A 
slightly lower resolution in DWI may be sufficient for image interpretation and will 
help to increase SNR and optimize ADC maps. MRSI can be performed at clinically 
relevant resolutions within reasonable time with a spiral readout, but is sensitive 
to lipid contamination. The possible clinical application of 7 T mpMRI has to be 
revisited once the main burdens have been taken away by technical improvements. 
Better structure delineation using higher resolutions and better spectral profiling of 
the prostate, improving prostate cancer assessment, is within near reach at 7 T. 
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Figure S4.1 - Typical artifacts in five T2W image series at 7 T.  A,B: Motion induced ghosts of the rectal 
wall affecting the area of the  neurovascular bundles and the peripheral zone (arrows) and an area with 
low SNR caused by B1
+ drop-out (dotted ovals). C: severe motion artifact causing image blurring and 
ghosts throughout the sagittal view of the prostate. D: Signal void close to the endorectal coil wire (star). 
E: Straight line signal void through seminal vesicles (arrows).
Supplemental Figures
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Figure S4.2 - Artifacts in DWI. A-B: Ghosting in readout direction, C-F: Geometric distortion. A: Diffusion 
weighted image of 62 year old patient, b = 0. B: corresponding ADC map. C: T2W reference image of a 51-
year old patient. D,E: Diffusion weighted images at b = 0 and 800 s/mm2 respectively, window width and 
level were optimized for each image. F: ADC map. The blue crosses indicate the same geometric location 
at all images. A distortion of 3 mm is present in the b = 800 s/mm2 images, resulting in a bright and a dark 
band lateral of the prostate of the prostate in the ADC map.
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Abstract 
Objective: Optimization of 31P MR spectroscopic imaging (MRSI) of the human 
prostate at 7 T by the evaluation of T1 relaxation times and the Nuclear Overhauser 
Effect (NOE) of phosphorus-containing metabolites. 
Methods: Twelve patients with prostate cancer and one healthy volunteer were 
scanned on a 7 T whole-body system using a 31P endorectal coil combined with an 
8-channel 1H body array coil. T1 relaxation times were measured using progressive 
saturation in a 2D localization sequence. 31P MRSI was performed twice: once 
without NOE and once with NOE using low-power continuous wave 1H irradiation 
to determine NOE enhancements.
Results: T1 relaxation times of 31P metabolites in the human prostate at 7 T varied 
between 3.0 and 8.3 s. Positive but variable NOE enhancements were measured for 
most metabolites. Remarkably, the 31P MR spectra showed two peaks in chemical 
shift range of inorganic phosphate. 
Conclusion: Knowledge of T1 relaxation times and NOE enhancements enables 
protocol optimization for 31P MRSI of the prostate at 7 T. With a strongly reduced 
31P flip angle (≤ 45°), a 31P MRSI dataset with optimal signal-to-noise ratio per unit 
time can be obtained within 15 minutes. The NOE enhancement can improve fitting 
accuracy, but its variability requires further investigation.
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Introduction
With an increasing number of human ultra-high field MR systems installed during 
the last decade, the study of metabolism in vivo by phosphorus (31P) MR spectroscopy 
has regained interest. A 31P MR spectrum contains information about metabolites 
that play important roles in tissue phospholipid and energy metabolism, and also 
provides a way to measure tissue pH. This makes 31P MR spectroscopy an excellent 
technique to study human cancers (1,2). However, due to the inherently low 
sensitivity of in vivo 31P MR spectroscopy, it is very little used to study human cancers 
and has no role in prostate cancer research. Clinical prostate cancer management 
is increasingly based on a multiparametric MR imaging approach (3). A typical 
multiparametric MR imaging protocol consists of a combination of anatomical (T2-
weighted) MR imaging, diffusion-weighted imaging, dynamic contrast-enhanced 
MR imaging and/or 1H MR spectroscopic imaging (MRSI). 
Human 31P MR spectroscopy studies at clinical magnetic field strengths of 1.5 to 3 T 
are limited by sensitivity and spectral resolution. This results in long acquisition 
times, demands for large voxels, and can cause considerable overlap in metabolite 
resonances. Earlier 31P work of the human prostate with an endorectal coil at 2 T, 
without any localization apart from the coil reception profile, showed separate 
resonances for phosphocreatine (PCr), adenosine triphosphate (ATP), and inorganic 
phosphate (Pi), but could not separate resonances related to phospholipid metabolism: 
phosphoethanolamine (PE), phosphocholine (PC), glycerophosphoethanolamine 
(GPE) and glycerophosphocholine (GPC) (3,4). These individual metabolites are of 
particular interest as their mutual ratios and levels have repeatedly been linked to 
malignancy in cell studies and tissue samples (5–7) and also recently in vivo in the 
human brain (8).
1H-decoupling can improve the sensitivity of in vivo 31P MR spectroscopy at clinical 
field strengths (9,10). Decoupling during signal acquisition removes the effects of the 
weak heteronuclear 31P-1H scalar couplings of the phosphomonoesters (PE and PC) 
and phosphodiesters (GPE and GPC), transforming their spectral appearances from 
triplets into singlets. This results in both spectral simplification and higher intensities 
of these resonances. Decoupling can be combined with low-power radiofrequency 
(RF) irradiation on water protons during the relaxation delay to generate a Nuclear 
Overhauser Effect (NOE) (11,12). The low-power RF irradiation saturates the 1H 
spins, that is, their energy levels involved will get equally populated, which can lead 
to an increased steady-state magnetization of the 31P nuclei due to dipolar relaxation 
(10,13). 
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An increase in magnetic field strength is directly beneficial for spectroscopy purposes, 
but it also poses some challenges on performing an in vivo MR examination of the 
abdomen. To localize 31P MR spectra accurately, proper anatomical MR images 
need to be acquired first.  Recently, we showed that anatomical imaging and 3D 
31P MRSI of the prostate can be performed safely at 7 T with a combination of an 
8-channel 1H transmit/receive (TxRx) coil setup and a 31P TxRx endorectal loop 
coil (14). We also demonstrated the feasibility of 3D 31P MRSI within a clinically 
acceptable measurement time at 7 T. The 31P MR spectra obtained from the prostate 
of a healthy volunteer revealed separate resonances for PE and PC. However, none 
of the sensitivity enhancement strategies known from the clinical field strengths (1H 
decoupling and NOE) were employed. Decoupling would theoretically improve the 
line width of the 31P resonances; however, the 31P-1H couplings in PE, PC, GPE and 
GPC are in the order of 6 to 7 Hz (15), which is below the minimum line width of 
the uncoupled metabolite PCr that could be reached in the prostate by shimming at 
7 T (~20 Hz) (14). Alternatively, NOE generation may well be beneficial for 31P MRSI 
at 7 T. 
Different pulse sequences have been employed to generate an NOE (16,17). In a 
frequently used technique, continuous wave NOE, water protons are continuously 
irradiated at low power during the full repetition time (TR), except for a short period 
of signal acquisition at the 31P frequency. Due to the low-power aspect, continuous 
wave NOE may be employed within the specific absorption rate (SAR) limits of 
transmitting RF power at a field strength of 7 T. In a pioneering 31P MRSI study of the 
human brain at 7 T, all 31P metabolite resonances showed a positive NOE, with the 
largest enhancements observed for PE (43.8 %) and GPE (43.6 %) and the smallest 
enhancement for the ATPs (9.9-11 %) (18). 
Another aspect to consider for optimal 31P MRSI sensitivity is the combination of 
excitation flip angle and TR. This is determined by the T1 relaxation times of the 31P 
metabolites, which are highly dependent on field strength but also vary between 
metabolites and between tissues. Once T1 relaxation times are known, the flip 
angle at a given TR can be optimized, and the steady-state signal intensities of the 
different metabolites can be incorporated into absolute quantification strategies of 
these signals.  
The objective of this work was to develop an optimized protocol for in vivo 31P MRSI 
of the prostate at 7 T and to characterize in vivo 31P MR spectra of the prostate. T1 
relaxation times of the separate phosphorus-containing metabolites were measured 
in vivo and signal enhancement of these metabolites due to continuous wave NOE 
was evaluated. 
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Methods
Hardware
Measurements were performed on a 7 T whole-body research MR system 
(MAGNETOM 7T, Siemens Healthcare, Erlangen, Germany). A 31P TxRx endorectal 
coil tuned to 120.3 MHz was used in combination with an 8-channel 1H TxRx array 
coil with meander elements (19). A thorough safety validation of the coil combination 
was presented recently (14).
Subjects
All measurements were carried out in compliance with the local institutional medical 
ethics committee, and written informed consent was obtained from all subjects 
before measurements. 
Twelve patients with biopsy-proven prostate cancer (mean age, 66.1 years; range, 58-
72 years; median prostate-specific antigen (PSA) level; 9.7 ng/mL; range, 5.3-29.7 ng/
mL) and one healthy volunteer (32 years) participated in this study. All patients 
underwent a clinical MR staging exam with an endorectal coil on a 3 T MR system 
prior to the measurement at 7 T. 
Subject Preparation
The subjects were placed in supine position on the dorsal array of the 8-channel 
array coil after insertion of the endorectal coil. The inner balloon of the endorectal 
coil was inflated with inert perfluoropolyether liquid (Fomblin, Solvay Solexis, 
Bollate, Italy) to minimize susceptibility differences between the prostate and the 
inner balloon. Then, the ventral array of the 8-channel array coil was positioned 
over the lower abdomen. Peristalsis was suppressed with intramuscular injections of 
both 1 mg of glucagon (GlucaGen; Novo Nordisk, Gentofte, Denmark) and 20 mg of 
Butylscopolaminebromide (Buscopan, Boehringer-Ingelheim, Ingelheim, Germany). 
MR Measurement Protocol 
The MR protocol included magnetic field (B0) phase-map shimming to optimize the 
B0 homogeneity, transmit radiofrequency field (B1+) shimming to maximize 1H phase 
coherence in the prostate, and localized flip angle calibration (20). B1+ shimming and 
flip angle calibration is essential for both obtaining artifact-free T2-weighted fast spin 
echo images of the prostate and efficient continuous wave RF irradiation for NOE. 
The T2-weighted images (echo time [TE] = 71 ms; TR = 3000-3640 ms; resolution 
0.75 x 0.75 x 3 mm) provided an anatomical background for the 2D 31P T1 relaxation 
measurements and the 3D 31P MRSI NOE enhancement measurements. 
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2D 31P MR Spectroscopy – T1 Measurements
Progressive saturation T1 measurements of 31P metabolites were performed in six 
patients using a 2D localization sequence (TE = 30 ms) consisting of a non-slice-
selective adiabatic excitation pulse (90° BIR-4 pulse (21), duration 8 ms, bandwidth 
≈ 1500 Hz, frequency offset= +3 ppm from PCr), and two pairs of adiabatic full-
passage (AFP) slice-selective refocusing pulses (22) (duration = 5 ms; bandwidth ≈ 
5100 Hz; offset frequency = +360 Hz) (Fig. 5.1). Crusher gradients were positioned 
symmetrically around the AFP pulses. Slice selection by the AFP refocusing pulses 
was done in the left-right and the head-feet direction, with dimensions matched to 
the prostate size in these directions. Localization in the anteroposterior direction 
depended on the 31P coil sensitivity profile. As the sensitivity of the loop coil 
decreases with distance from the coil, most of the metabolite signal originates from 
the posterior part of the prostate (2-3 cm from the endorectal coil) (Fig. 5.2). Six 
measurements with different TRs were obtained with the following order: 2 s, 16 s, 
12 s, 8 s, 6 s and 4 s. This specific order of the different TRs was chosen to stay within 
local SAR limits of the 31P endorectal coil while keeping the total acquisition time 
as short as possible (11 min 32 s). The number of averages as well as the number of 
preparation scans, that is, scans without signal acquisition, to establish steady state 
varied with the different TRs (Table 5.1). 
Figure 5.1 - Diagram of the 2D localization pulse sequence used for T1 determination. An initial non-
slice-selective adiabatic BIR-4 90° pulse is followed by two pairs of slice-selective adiabatic full-passage 
(AFP) 180° refocusing pulses. A spin echo is produced at TE = 30 ms. Crusher gradients are positioned 
around the first AFP pulse in z-direction (Gz), around the second AFP pulse in x-direction (Gx), around 
the third AFP pulse in y-direction (Gy) and around the final AFP pulse in all 3 orthogonal directions.  
BIR: B1-insensitive rotation, RF: radiofrequency, Acq: acquisition. 
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3D 31P MRSI – NOE Measurements
NOE measurements were performed in seven patients and one healthy volunteer. 
For 31P MRSI, a pulse-acquire sequence was used with an 8 ms adiabatic excitation 
BIR-4 pulse (21) with a flip angle of 45° (γB1 = 960 Hz at a distance of 2.5 cm from the 
coil inside the prostate; bandwidth ≈ 1500 Hz). The full field of view (FOV) of the 
endorectal coil was spatially encoded (FOV 120 x 120 x 120 mm; matrix of 10 x 10 x 
10; 4 averages), with weighted k-space sampling using a Hamming window. After 
3D apodization of k-space with a Hamming filter, the true voxel size increased, but 
signal contamination from neighboring voxels was suppressed. The true shape and 
size of a voxel are best approximated by a sphere with a radius of 1.78 times one-
half the original voxel size (23). Therefore, the nominal voxel size of 12 x 12 x 12 mm 
resulted in a real spherical voxel volume of 5.1 cm3. The acquisition bandwidth was 
set to 5000 Hz. TR was set to 1500 ms, and the total MRSI acquisition took 9 min 51 s. 
To determine the NOE enhancements, the 31P MRSI measurement was performed 
twice. In one of these measurements, the 1H spins of water were saturated during 
Figure 5.2 - Sagittal (A) and transversal (B) prostate T2-weighted MR images showing the localization 
of the T1 pulse sequence by slice-selective adiabatic full passage pulses in head-feet (H-F) and left-right 
(L-R) direction (straight lines) and by the coil sensitivity profile (curved dotted line) in anterior-posterior 
(A-P) direction. B: bladder; C: endorectal coil. The maximum A-P prostate size was 5.5 cm in these images.
Table 5.1 - Progressive saturation acquisition protocol
Scan 
number
TR (s)
Number of 
averages
Number of 
preparation scans
Acquisition time 
(min)
1 2 32 6 1.16
2 16 6 2 2.08
3 12 8 2 2
4 8 12 4 2.08
5 6 16 4 2
6 4 24 6 2
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the full TR (except during 204 ms signal acquisition) using low-power continuous 
wave irradiation shaped by 20 blocks of 57.2 ms with a pause of 6 ms in between 
blocks (γB1+ = 20 Hz). To establish steady state, 4 preparation scans (without signal 
acquisition) preceded the MRSI sequence. 1H SAR was monitored using a custom-
built online RF supervision system (14,24). On average 23% of the allowed power 
over 6 min was used during the NOE measurements. 
The theoretical maximum NOE enhancement, ηmax, for 
31P metabolite resonances is 
given by the relation ηmax= 0.5(γ1H) / (γ31P) = 1.24, where γ1H and γ31P are the gyromagnetic 
ratios for 1H and 31P respectively. The real NOE enhancement (η) can be obtained 
from the longitudinal magnetization of 31P spins during 1H irradiation (INOE) and 
without irradiation (I0), since INOE = I0(1 + η). The NOE enhancement per metabolite 
in this study was therefore calculated by 
 η =         [5.1]
Phantom Experiments
In a phantom setup resembling the in vivo setup (Fig. 5.3A), the NOE enhancement 
efficiency of continuous wave RF irradiation was determined by measuring Pi signal 
in phantom experiments while varying the irradiation power settings (γB1+ = 0, 10, 
20, 34 and 50 Hz). The phantom is a large container with a cylindrical hole through 
it for positioning of the endorectal coil. The container is subdivided into smaller 
chambers that can separately be filled with a sugar solution resembling body fluid 
(with respect to electrical conductivity and permittivity) to mimic body load. A 
smaller chamber in the center of the phantom was filled with urine with a large 
Pi signal. B0 and B1+ shimming and flip angle calibration were performed, and the 
B1+ variation in the Pi phantom was comparable to the average variation in the in 
vivo experiments (15%). The effect of magnetic field inhomogeneities on the NOE 
efficiency was evaluated by applying a transmit offset of -100 Hz from the water 
frequency (4.7 ppm) at every power setting. An absolute B1 map was acquired using 
a gradient echo magnetization preparation sequence (TR = 5000 ms; TE = 5 ms; flip 
angle magnetization preparation = 90°; flip angle reference = 10°) (25) and a B0 map 
using a gradient echo field mapping sequence (TR = 510 ms; TE1 = 2.04 ms; TE2 = 
3.06 ms; flip angle = 15°). 
Data Analysis
T1 relaxation times were determined by fitting the function Mz (TR) = M0 (1 – e -TR/T1) 
to the progressive saturation data using a least squares fit. 
For each subject of which two 31P MRSI datasets were collected to determine the 
level of NOE enhancement, two non-neighboring voxels representing prostate tissue 
signal(irradiated spectrum) - signal(reference spectrum)
signal(reference spectrum)
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were selected based on the overlay of the spectroscopic matrix on the T2-weighted 
images (regardless of zonal anatomy or cancer presence due to the large voxel size) 
(Fig. 5.4A). The 31P spectra of the selected voxels were fitted with Metabolite Report, 
a work-in-progress package from Siemens Healthcare. Metabolite Report performs 
automated, prior knowledge based, complex fitting in the time domain and has 
previously been applied to 1H spectroscopy data (26). In the fitting procedure, PC, 
PE, GPC and GPE were each modeled as a triplet with 3 single Lorentzian peaks 
with a constrained separation according to their JPH coupling constants (6 to 7.1 Hz) 
(15) and line amplitudes in a 1:2:1 ratio. The line widths of the single peaks were 
constrained to the line width of PCr, which was also fitted with a Lorentzian line 
shape. The line width constraint also held for two Gaussian peaks that fitted Pi. 
The γ and α resonances of ATP were fitted with a Gaussian line shape; J-coupling 
between these resonances was neglected. A limited frequency range for fitting was 
defined per metabolite. 
Both a quantitative evaluation of the fitting results and a visual quality control were 
performed. Quantitatively, only metabolite fits with a Cramer-Rao lower bound 
(CRLB) below 30% were considered reliable. A spectroscopist qualitatively checked 
the spectra by visual inspection of the original spectra and the fitting results. If a 
metabolite peak was visually present and its fit was assigned to the correct resonance, 
Figure 5.3 - NOE phantom experiments. A: Transversal view of the phantom with a solution containing 
Pi in a small container on top of the endorectal coil and sugar solution in the outside containers to load 
the 8-channel 1H array coil. The blue box in the spectroscopic grid indicates the area analyzed for NOE 
enhancements, B1 and B0. B: NOE enhancements (η) of Pi when applying continuous wave irradiation 
on-resonance and -100 Hz off-resonance at variable transmit powers. C: Absolute B1 map measured using 
a nominal 90° flip angle. D: B0 map.
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giving a minimal residue, the fitting result was accepted. Only metabolites that 
passed both quality checks were used to determine NOE values. 
The consistency of absolute changes in metabolite ratios between voxels due to NOE 
enhancements was determined by the Pearson correlation between metabolites 
ratios without and with NOE. The effect of a NOE enhancement on the quality of the 
fit was assessed by the Pearson correlation between the NOE values of all metabolite 
fits and the difference in CRLB with and without NOE. 
Results
High-quality 31P MR spectra were obtained in all subjects (see Fig. 5.4 for one 
example). The full width at half maximum line width of PCr in the selected voxels 
of the 31P MRSI datasets ranged from 9.0 to 19.0 Hz (mean ± SD: 12.5 ± 3.0 Hz). 
Resonances of PE, PC, Pi, PCr, γATP and αATP were present and well resolved in most 
prostate 31P data, although the limited excitation bandwidth in the T1 measurement 
prevented T1 determination of αATP and βATP. In the MRSI spectra, the βATP 
intensity was strongly attenuated or not present due to the limited bandwidth of 
the excitation pulse. GPC and GPE signals were low or absent in most spectra, even 
with NOE (Fig. 5.4). In many spectra, two peaks resonated with some overlap in 
the chemical shift range of Pi. The peak at approximately 5.4 ppm possibly reflects 
Pi in an environment of pH 7.6, whereas the peak at approximately 4.9 ppm may 
represent Pi in a pH environment of 7.1. Because of the limited signal-to-noise ratio 
(SNR) the Pi peaks could not be reliably fitted in some spectra. With the used spatial 
resolution, no obvious differences in metabolite ratios between tumor and normal 
prostate tissue were observed in the 31P MR spectra. Only three tumor lesions were 
larger than 1.5 cc (measured using 3 T multi-parametric MRI data), and the largest 
lesion occupied less than 40% of a 31P voxel volume.
T1 values were calculated from the amplitude of metabolite signals in the 5 
consecutive progressive saturation experiments (Table 5.2 and Fig. 5.5). The shorter 
T1 relaxation time of PCr (4.1 ± 0.4 s) compared with those of PE and PC (7.6 ± 1.5 s 
and 5.9 ± 1.3 s respectively) is clearly noticeable from the relaxation curves in Figure 
5.5B and 5.5C. T1 values of the two peaks assigned to Pi were significantly different 
from each other (P<0.01, paired t-test). 
The phantom experiment showed positive NOE enhancements at all power levels for 
Pi when continuous wave power was applied on-resonance (Fig. 5.3B). A downfield 
100 Hz offset in transmit frequency resulted in decreased NOE enhancement. The 
enhancement level did not correspond with local B0 or B1 inhomogeneities within 
the phantom (Fig. 5.3CD). 
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In vivo, all metabolite resonances except those of ATP showed positive NOE 
enhancements, with the enhancement for PE reaching 44% (Table 5.2). In particular, 
PC and both Pi resonances showed large variation in NOE enhancements (Fig. 5.6). 
The variation in metabolite levels between all voxels was similar with and without 
NOE (Fig. 5.7A), whereas variation increased in the metabolite ratio containing the 
low-SNR metabolite of PC (Fig. 5.7B). Metabolite ratios change because of differences 
in NOE enhancement between metabolites (Fig. 5.7B) and this change is consistent 
between voxels for the ratios PE/PCr and PCr/γATP (R2 = 0.64, P = 0.0002 and 
R2 = 0.71, P < 0.0001, respectively), but not consistent for the ratios PE/PC and PC/Pi1 
(R2 = 0.23, P = 0.07 and R2 = 0.11, P = 0.42, respectively) (Fig. 5.7D). The quality of the fit 
improved with an increase in NOE enhancement (R2 = 0.43, P < 0.0001, see Fig. 5.7C). 
Three out of nine metabolites (PE, Pi1 and PCr) were fitted with greater accuracy 
Figure 5.4 - NOE voxel selection, 31P spectral quality and effect of NOE on 31P spectra of the prostate. A: 
Coronal T2-weighted prostate MR image of a patient with prostate cancer. The green grid on top of the 
image represents the interpolated spectroscopic matrix. The dashed red circles indicate the real voxel 
sizes of the selected blue voxels for NOE analysis. B: Spectral map of four voxels outlined by the dotted 
yellow line in A indicating the general spectral quality of 31P MRSI with NOE in prostate (TR = 1500 ms, 
TA = 9 min 51 s, spectral range: -9 to 9 ppm). C and D: 31P spectra of the upper selected voxel in A without 
NOE (C) and with NOE (D). The spectra are scaled identically to show NOE enhancements. The spectra 
were time-domain filtered with a Lorentzian filter of 30 Hz.
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Figure 5.5 - T1 measurements. A: Example 31P spectra of the whole prostate during a T1 progressive 
saturation measurement. B,C: Fitting of T1 31P relaxation curves of PE, PC and GPC (B) and PCr, yATP 
and both Pi resonances (C) in one patient. Individual points represent normalized measured signal at a 
certain TR. The spectra were time-domain filtered with a Lorentzian filter of 30 Hz.
Table 5.2 - Apparent in vivo T1 relaxation times (s) and NOE enhancements (%) of 31P metabolite 
resonances in the human prostate at 7 T obtained in this study, and literature values of brain, muscle and 
breast tissue 
PE PC Pi (pH≈7.4)
Pi 
(pH≈7.1) GPE GPC PCr γATP αATP
Prostate
T1 (s) 7.6 ± 1.5 5.9 ± 1.3 4.6 ± 1.9 6.5 ± 2.4 8.3 5.9 ± 1.7 4.1 ± 0.4 3.0 ± 0.9 NM
N 6 6 5 5 1 4 6 4
NOE (%) 44 ± 22 14 ± 34 45 ± 60 16 ± 40 6a 8 ± 9 20 ± 17 -6 ± 19 -9 ± 32
N (n) 8 (16) 8 (15) 8 (8) 4 (5) 1 (2) 4 (4) 8 (16) 8 (15) 8 (16)
Brain (18)
T1 (N=9) 4.8 ± 1.0 NM 3.2 ± 0.5 4.1 ± 1.2 4.0 ± 1.3 3.4 ± 0.3 1.3 ± 0.2 1.3 ± 0.1
NOE (N=6) 44 ± 8 29 ± 9 16 ± 8 44 ± 21 25 ± 12 24 ± 2 10 ± 3 11 ± 9
Calf muscle (27)
T1 (N=8) 3.1 ± 0.9 (PME) 6.3 ± 1.0 6.0 ± 1.1 (PDE) 4.0 ± 0.2 3.3 ± 0.2 1.8 ± 0.1
Breast (28)
T1 (N=6) 4.7 ± 1.2 5.6 ± 0.8 NM NM NM NM NM NM
N: number of subjects included in analysis; n: number of voxels with approved metabolite fit included in 
analysis; NM: not measured; PME: phosphomonoesters; PDE: phosphodiesters; T1 and NOE values: mean ± SD. 
a NOE determined from only 2 voxels, individual values: -6% and 17%.
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(significantly smaller CRLB, paired t-tests) with NOE in comparison to without 
NOE, whereas none of the metabolite fits decreased significantly in accuracy due to 
NOE generation (Table 5.3). Example metabolite maps of PE with and without NOE 
of one subject are presented in Figure 5.8, not corrected for B1 profile. The general 
increase in PE signal in this slice clearly shows the NOE enhancement within the 
prostate. 
Discussion
In this study, we determined the in vivo apparent T1 relaxation times at 7 T of 31P 
metabolites present in the human prostate. Knowledge of the T1 times can be used to 
design clinical scanning protocols with optimal SNR, and is essential for any attempt 
to quantify these metabolite levels. The sensitivity of 31P MRSI of the prostate may be 
further increased by irradiation of water protons, giving rise to NOE enhancement. 
The high spectral quality allowed thorough characterization of the 31P MR spectra 
of the prostate. 
Figure 5.6 - NOE enhancements (η) per voxel of 
31P metabolites in the prostate at 7 T. Variation in 
NOE enhancements is probably caused by fitting 
inaccuracies not intercepted by quality control, 
for example, due to low SNR of the specific 
metabolite.
Table 5.3 - Fitting accuracy (Cramer-Rao Lower Bound (CRLB) %, mean ± SD) without and with NOE.
CRLB (%) PE PC Pi1 Pi2 GPE GPC PCr γATP αATP
No NOE 4.7±1.6 7.2±2.6 25.9±7.1 23.1±9.9 7.0±3.1 13.2±1.4 7.9±3.5 8.5±2.3 10.2±3.3
With NOE 3.2±0.6 7.2±4.0 20.3±4.5 22.5±7.0 6.7±1.1 14.0±3.7 6.2±2.0 8.8±1.8 10.7±1.9
P-value 0.0004 0.96 0.035 0.80 0.85 0.72 0.006 0.54 0.40
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All 31P T1 times measured at 7 T were longer compared with reported values 
for prostate at 2 T (PCr: 1.1 s; phosphomonoesters (mainly PE and PC): 2.6 s; 
phosphodiesters (mainly GPE and GPC): 1.2 s; Pi: 1.5 s; γATP: 1.3 s) (4). A number 
of studies reported apparent T1 relaxation times in other human tissues at 7 T 
(18,27,28). These are included in Table 5.2. The T1 relaxation times of PE in human 
brain, muscle and breast at 7 T were shorter compared with prostate T1 times found 
in this study. T1 values of Pi, GPE, GPC and γATP in prostate were comparable to 
muscle, but longer than in brain (18,27). Only PCr showed comparable values in 
these three different tissues at 7 T. The only human study reporting T1 values for PC 
at 7 T showed a similar T1 in breast as we obtained in prostate (28). PCr and γATP 
T1 relaxation times measured in this study were partly contaminated by signals 
from the smooth muscle of the rectum because of the 2D localization technique. This 
Figure 5.7 - Effects of NOE enhancement (η) on variation in the data (A,B) and on fitting accuracy (C). The 
absolute values (in arbitrary units [a.u.]) of PE, PCr and γATP without and with NOE are displayed in 
(A), the metabolite ratios PE/PCr, PCr/γATP and PE/PC without and with NOE are displayed in (B). The 
NOE enhancement did neither result in increased variation of the metabolite values nor of the ratios of 
PE/PCr and PCr/γATP. The spread in the absolute values is mainly caused by the sensitivity profile of the 
endorectal coil. The NOE enhancement (all metabolites lumped) correlates negatively with the difference 
in CRLB of metabolite fits with and without NOE (C), indicating that the higher SNR obtained with a 
positive NOE enhancement improves fitting accuracy. The scatterplot of metabolite ratios (D) shows the 
level of consistency of ratios without and with NOE enhancement. The PE/PCr and PCr/γATP ratios 
without and with NOE correlated significantly, but this was not true for the PE/PC and PC/Pi1 ratio.
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might explain their similarities with the relaxation times reported for muscle tissue. 
Because the signals of PE, PC, GPE and GPC were absent or very low in muscle, the 
obtained T1 relaxation times of these metabolites can be regarded purely prostatic.
The relatively long apparent T1 relaxation times of 31P metabolites in prostate tissue 
at 7 T and the limitations in total acquisition time require a trade-off between TR 
and accompanying flip angle and matrix size when performing 31P MRSI. The Ernst 
angles corresponding to the calculated T1 values of PCr, PE and PC at a TR of 1500 
ms were 46°, 35° and 39° respectively. With the current settings of the MRSI (45° flip 
angle, TR = 1500 ms), partial saturation of all metabolites was induced, but SNR per 
unit time was close to optimal.
There are two major, competing, mechanisms known to influence the relaxation 
of 31P nuclei: dipolar interactions and chemical shift anisotropy (CSA) (29). Theory 
predicts that dipolar relaxation leads to an increase in T1 relaxation times with 
increasing field strength in tissues. On the other hand, CSA decreases T1 relaxation 
times and becomes increasingly important at higher field strengths, with 1/T1 being 
proportional to B02 in case of pure CSA relaxation (13,29). In human studies where 
31P T1 relaxation times at two different field strengths were compared directly, it 
was shown that muscle and brain T1 times decrease from 3 or 4 T to 7 T (27,30), 
indicating the increased presence of CSA at 7 T in vivo. CSA also reduces the T2 
relaxation times of 31P metabolites, and the effect of CSA on T2 is dependent on 
field strength with 1/T2 ~ B02, whereas T2 relaxation by dipole-dipole interactions is 
nearly field-independent (13). Bogner et al. reported 24% to 53% shorter T2 times in 
human muscle at 7 T compared with 3 T, suggesting that CSA played a significant 
role at 7 T but did not become the dominating relaxation mechanism (27). 
Although it was not the primary goal of this study to investigate the contributions 
of CSA and dipolar interactions on T1 times, the NOE results obtained here also 
Figure 5.8 - Metabolite maps of PE superimposed on the corresponding T2-weighted MR image. A: 
No NOE, B: with NOE. Numbers are arbitrary representations of the fitted signal integral, and the 
interpolated spectroscopic imaging matrix is shown. The endorectal coil B1 profile is clearly visible, as 
PE signal intensity is higher close to the coil. In nearly all voxels, PE signal intensity is enhanced by NOE.
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provide information about dipole-dipole contribution to the relaxation mechanism 
(29,31). The maximum NOE factor, , is only attainable in molecules with very fast 
rotational motion under pure 31P-1H dipolar relaxation. The NOE values found in this 
study are far below this theoretical optimum, which is expected because of violation 
of both conditions. The rotational motion of metabolites in vivo is expected to be 
in the intermediate range, and CSA relaxation competes with dipolar relaxation. 
Nevertheless, we still observed a positive NOE value for all metabolites, except 
for γATP and αATP. The contribution of CSA relaxation in ATPs may therefore be 
larger than it is for the other metabolites in the prostate. However, this can only be 
confirmed with measurements of NOE and T1 at different field strengths, which was 
beyond the scope of this study.
The observation of a positive NOE enhancement for all metabolites in the prostate 
except the ATPs is in line with previously published NOE data from 31P metabolites 
in human brain at 7 T (18). However, the values observed in our study showed larger 
variation. This may have resulted from the limited bandwidth of continuous wave 
irradiation used to saturate water, which makes NOE efficiency vulnerable to B0 
inhomogeneities, as shown by the phantom experiments. The in vivo 1H shim of 
~30 Hz might have prevented complete water saturation; however, the local spatial 
variations in B0 in the selected voxels were maximal 10 Hz on 1H. The spatial variations 
in B0 present in the phantom experiment were larger than 10 Hz, but even those did 
not have a visible effect on the NOE enhancements. Therefore, it was expected that 
the small bandwidth characteristic of continuous wave irradiation only contributed 
minimally to the observed variation in NOE enhancements. 
The phantom study also showed that continuous wave NOE enhancement of Pi 
reached a steady state from a γB1+ of 20 Hz. The dependence of NOE enhancement on 
RF power needs to be taken into account when performing in vivo NOE-enhanced 
31P MRSI at 7 T. Severe distortions of B1+ can occur at this field strength, which can 
lead to signal drop-out in MR images, but also to variation in NOE enhancement. In 
this study, B1+ was maximized in a small region of interest, namely the prostate, by a 
dedicated B1+ phase shimming approach (32). The variations of B1+ within the organ 
were small (≈15%). Because the selected voxels to examine NOE fell well within 
the patient-specific B1+ shim regions and the phantom experiments showed minimal 
local variation in NOE at a 1H γB1+ of 20Hz (±15%), the variation in NOE values 
was expected not to be caused by B1+ inhomogeneities either. The minimal effects of 
the mentioned disadvantages of continuous wave irradiation - its small bandwidth 
and B1+ dependence - on NOE generation in this study can also be derived from 
Figure 5.7A and B, which shows similar variation in absolute metabolite levels and 
ratios with and without NOE. Variation in NOE enhancements was largest for both 
Pi peaks and PC, metabolite peaks with relatively low SNR and, especially for Pi, 
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pH dependence of the chemical shift. These factors possibly result in larger fitting 
inaccuracies for these peaks, and also for those of GPE and GPC, than for the other 
metabolite peaks. Since the NOE calculation is based on two fit values, the observed 
variation in NOE might well have been caused by fitting inaccuracies of signals with 
low intensity.
Due to the SNR increase in case of a positive NOE, the fitting accuracy of the 
metabolites was expected to increase. The strong correlation between NOE values and 
the difference in CRLB with and without NOE (Fig. 5.7C) confirmed this hypothesis. 
Because three metabolites (PE, Pi1 and PCr) showed a significant increase in fitting 
accuracy with NOE, whereas none of the other metabolites was fitted significantly 
worse, acquiring spectra with NOE would be beneficial in terms of overall fitting 
accuracy. γATP and αATP had a slightly negative NOE, but the maximum CRLBs of 
the fits of these metabolites with NOE were 11.9% and 13.9% respectively, which is 
well below the quality threshold of 30%. 
Non-NOE-enhanced and NOE-enhanced metabolite ratios containing signals with 
higher SNR (PE, PCr, γATP) showed a strong correlation. High R2 values for this 
correlation point to a consistent change between enhanced and non-enhanced ratios, 
rather than to a variability in ratios due to within voxel NOE-enhancement differences 
between metabolites, although the latter cannot be excluded. The observed variation 
in NOE enhancements of the phospholipid metabolites is likely a combination of 
true variability (unknown cause) and a result of low SNR. The reproducibility of 
NOE-enhanced metabolite ratios and non-NOE-enhanced metabolite ratios should 
be assessed to determine if the SNR gain due to NOE enhancement is ultimately 
beneficial or not. Reproducibility measurements are also needed to determine the 
minimum detectable changes due to prostate abnormalities (33).
A number of remarkable differences were present between the 7 T 31P MR spectra 
of the prostate obtained by in vivo MRSI in this study, 31P spectra acquired at lower 
field strength and high-resolution NMR spectra from prostate extracts. The near 
absence of signals in the phosphodiester region in the 7 T MR spectra of the prostate 
was in marked contrast with the phosphodiester region of low field strength in vivo 
31P MR spectra (including prostate spectra) (3,4,34). Those showed a high and broad 
peak in the phosphodiester region, which was generally assigned to GPC and GPE 
together, that is, free cytosolic compounds. A number of observations, however, 
including reduction of this peak at higher field strengths, indicated a substantial 
contribution of large, mainly immobile membrane phospholipids to the resonance 
in the phosphodiester region at low field strengths (35–39). The relaxation of these 
large compounds is determined principally by CSA, elucidating the broadness of 
this peak at low field strengths and the reduction of signal in this spectral region at 
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field strengths above ~7 T. The phospholipids would only be apparent as a baseline 
hump in high field strength spectra due to the CSA-induced quadratic increase of 
line width with B0 (13). The signals remaining in the phosphodiester region at higher 
field strengths would result from small molecules that only experience minor CSA 
relaxation. In the 7 T prostate 31P spectra that showed two peaks in the phosphodiester 
region, the chemical shifts of these peaks corresponded well with those of GPE and 
GPC. The clean observation of metabolite resonances can be regarded as another 
advantage of higher magnetic field strengths next to increases in SNR and chemical 
shift dispersion.
The ratios between the different metabolites in our spectra resemble 31P high-
resolution NMR results of prostate tissue extracts more closely than 1H high-
resolution magic angle spinning (HR-MAS) results of intact prostate tissue. The near 
absence of GPE and GPC in the in vivo spectra was also noticed in 31P high-resolution 
NMR spectra of perchloric extracts of prostate tissue (40,41). This contrasts with the 
1H HR-MAS spectra, which showed clear signal of the phosphodiesters, whereas 
PC was nearly undetectable. The ratio between PE and PC observed in vivo differed 
from in vitro observations, in which PE was more abundant than PC, especially in 
the 1H HR-MAS spectra (~6x in 31P high-resolution NMR spectra, 30-250x in 1H HR-
MAS spectra) (6,40–42). The differences between in vivo and in vitro results suggest 
metabolite content changes during extraction and in vitro measurements.
In nearly all 31P MR spectra of the prostate obtained in this study, two peaks were 
present in the chemical shift range of Pi. Because the exact chemical shift of Pi is pH 
dependent, the two peaks may represent Pi in two compartments with different 
pH. The significant difference in T1 relaxation times of the two peaks assigned to 
Pi also suggests separate environments. Histologically, the normal human prostate 
consists of three major tissue compartments: stromal (45%), epithelial (21%), and 
acinar luminal (34%) (43). The luminal space contains the citrate rich prostatic fluid 
(44). The pH of prostatic fluid showed a strong correlation with the citrate content 
(45,46), being slightly acidic (pH<7) in healthy prostates, but ranging up to pH=8 in 
diseased prostates (45,47). Prostatic epithelial pH was recently measured by confocal 
microscopy to be around 7.0 in rats and dogs (48), whereas the pH of fibromuscular 
stroma has not been reported, to our knowledge. Some studies from the previous 
century reported very low Pi concentrations in prostatic fluid (49,50), which would 
exclude the prostatic fluid as possible contributor of Pi to one of the peaks in this 
chemical shift range. In this case, the two peaks observed in the Pi chemical shift 
range in the 7 T MR spectra of the prostate might originate from stromal and the 
epithelial cells; however, the pH difference between these compartments would be 
unexpectedly large (pH 7.6 versus 7.1). It is also possible that other metabolites are 
present in this chemical shift range. A known confounder in the Pi spectral region 
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is 2,3-diphosphoglycerate, a metabolite present in human blood. Whereas the 
concentration of this metabolite in blood is high (~3 mM (51)), the blood volume 
in the prostate is small (<10% (52,53)), strongly reducing the likelihood of the 
presence of 2,3-diphosphoglycerate in the prostate spectra. Editing techniques such 
as polarization transfer, which suppresses signals from uncoupled 31P nuclei (e.g., 
Pi), should be explored to improve assignment of resonances in the in vivo 31P MR 
spectra of the human prostate. 
With an optimized 31P MRSI protocol, the next step is to study cancer-related changes 
in prostate metabolism at 7 T. The data of the patients included in the current study 
was not analyzed in detail for possible differences between tumor and normal 
prostate tissue because of the lack of proper histopathological standards, but clear 
visual changes were not yet observed. The patients presented with mainly small and 
low-aggressive tumors, and it is likely that partial volume effects may have obscured 
differences in 31P metabolite levels. In the previous in vivo studies at 1.5 and 2 T, an 
increase of phosphomonoesters in prostates with tumor compared to prostates of 
non-diseased young individuals was found (3,4,34). However, the signal in those 
studies was localized by the coil profile only, resulting in spectral contamination 
of periprostatic tissue; and the limited spectral resolution resulted in overlap of the 
resonances of PE, PC, Pi, GPE and GPC. The observed differences between tumor 
and normal tissue could therefore very well be the result of different coil positioning, 
age-dependent enlargement of the prostate or spectral quantification errors. In ex 
vivo prostate 1H HR-MAS and 31P NMR studies, the individual levels of PE, PC, 
GPE and GPC and their mutual ratios have been related to prostate malignancy 
(6,40–42), so it is to be expected that these changes could also be captured in vivo by 
31P MRSI at 7 T in a larger patient cohort with detailed localized histopathology as 
a gold standard.
Conclusion
High quality 31P MRSI of the human prostate at 7 T can be obtained within a clinically 
acceptable measurement time (acquisition time ≈ 10-15 min at TR ≤ 1.5 s). A strongly 
reduced flip angle (≤ 45°) is required to optimize SNR per unit time, because T1 
relaxation times for 31P metabolites were found to be relatively long. The signals of 
some 31P metabolites present in the prostate can be enhanced by irradiating the water 
resonance to obtain a NOE. The NOE enhancement can improve fitting accuracy, but 
further research is required to determine if NOE is ultimately beneficial for further 
interpretation of 31P MRSI data. The in vivo 31P MR spectra of the prostate showed 
differences in metabolite ratios compared with those obtained by in vitro NMR, and 
presented with two peaks in the chemical shift range for Pi. 
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Abstract
Objective: The aim of this study was to identify characteristics of phosphorus (31P) 
spectra of the human prostate and to investigate changes of individual phospholipid 
metabolites in prostate cancer through in vivo 31P magnetic resonance spectroscopic 
imaging (MRSI) at 7 T.
Materials and Methods: In this institutional review board–approved study, 15 
patients with biopsy-proven prostate cancer underwent T2-weighted MR imaging 
and 3D 31P MRSI at 7 T. Voxels were selected at the tumor location, in normal-
appearing peripheral zone tissue, normal-appearing transition zone tissue and 
in the base of the prostate close to the seminal vesicles. 31P metabolite ratios were 
determined and compared between tissue types. 
Results: Signals of phosphoethanolamine (PE) and phosphocholine (PC) were 
present and well resolved in most 31P spectra in the prostate. Glycerophosphocholine 
(GPC) signals were observable in 43% of the voxels in malignant tissue, but in only 
10% of the voxels in normal-appearing tissue away from the seminal vesicles. In 
many spectra, independent of tissue type, two peaks resonated in the chemical shift 
range of inorganic phosphate, possibly representing two separate pH compartments. 
The PC/PE ratio in the seminal vesicles was highly elevated compared with the 
prostate in 5 patients. A considerable overlap of 31P metabolite ratios was found 
between prostate cancer and normal-appearing prostate tissue, preventing direct 
discrimination of these tissues. The only two patients with high Gleason scores 
tumors (≥ 4+5) presented with high PC and GPC levels in their cancer lesions.
Conclusions: 31P MRSI at 7 T shows distinct features of phospholipid metabolites 
in the prostate gland and its surrounding structures. In this exploratory study, no 
differences in 31P metabolite ratios were observed between prostate cancer and 
normal-appearing prostate tissue possibly because of the partial volume effects of 
small tumor foci in large MRSI voxels. 
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Introduction
Prostate cancer is the most frequently diagnosed malignancy among men in the 
Western world, and it is the second leading cause of cancer-related death within 
this population (1,2). Because of prostate-specific antigen (PSA) testing and 
improvements in treatments, the current incidence-to-mortality ratio of prostate 
cancer is approximately 8:1. This striking discrepancy between the incidence rate 
and the mortality rate is not just a sign of effective treatment, but it is also a marker 
for the high detection of clinically insignificant cancers due to PSA testing: many 
men are diagnosed with a disease that, in their case, had better remained undetected 
(3,4).
It has been shown that with a combination of anatomical and functional magnetic 
resonance (MR) techniques, referred to as multiparametric MR imaging (MRI), 
accurate information can be obtained about the presence, location and stage of 
local prostate cancer (5,6). These MR examinations can be performed at clinical 
magnetic field strengths of 1.5 to 3 T (7). Diffusion-weighted MR imaging, proton 
(1H) MR spectroscopic imaging (MRSI) and dynamic contrast-enhanced MR 
imaging at 3 T even showed promising results in their correlation with prostate 
cancer aggressiveness (8–10). An accurate assessment of aggressiveness is essential 
to choose and improve treatment planning of individual patients and thus 
reduces overtreatment. Because histopathology of biopsied tissue is still the gold 
standard for identifying the presence and aggressiveness of prostate cancer (11), 
multiparametric MRI can identify tumor-suspicious regions to target biopsies. 
Replacing the traditional 8-to-12-needle ultrasound-guided biopsy procedure with 
an multiparametric MRI-guided biopsy reduces the number of needles and provides 
a better representative sample of the tumor, correctly identifying the true Gleason 
score in 88% of the patients (as opposed to 55% in schematic biopsy procedures) (12). 
One of the functional MR techniques, 1H MRSI, probes prostate metabolism. It has 
revealed that citrate levels decrease in prostate cancer, while total choline levels 
increase (13–15). Whereas the spectral peak of citrate directly represents the citrate 
intermediate in the Krebs cycle, the choline peak observed in 1H MRSI does not 
represent a single metabolite. Its increase in prostate cancer, but also in other tumors, 
has been mainly attributed to the increases in the phosphorus-containing compounds 
contributing to the total choline peak: phosphoethanolamine (PE), phosphocholine 
(PC), glycerophosphoethanolamine (GPE) and glycerophosphocholine (GPC) 
(16–21). The phosphomonoesters PC and PE are both precursors and degradation 
products of the membrane phospholipids; the phosphodiesters GPC and GPE are 
degradation products only (22). Levels of the individual membrane phospholipid 
precursor and degradation products reflect the turnover of the phospholipid pool, 
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which is expected to change in cancer cells because of their aberrant phospholipid 
metabolism (16,18,21,23).
Approximately 2 decades ago, these specific changes in phosphomonoester 
and phosphodiester levels were studied in prostate cancer by in vivo 31P MR 
spectroscopy at 1.5 and 2 T (24,25). A number of these studies showed an increase 
of phosphomonoesters in prostates with tumor compared with prostates of healthy 
individuals. However, the combination of a low magnetic field strength with a low 
intrinsic sensitivity of 31P compelled long acquisitions, and poor anatomic localization 
of the signals resulted in contamination of the spectra by signals from periprostatic 
tissues. Moreover, the low spectral resolution prohibited distinction between the 
phosphomonoesters PE and PC and between the phosphodiesters GPE and GPC. 
Distinguishing these metabolites is of particular interest because their mutual ratios 
and their individual levels have repeatedly been linked to malignancy in cell studies 
and tissue samples (17,18,21,26,27). 
A higher magnetic field strength is directly beneficial for 31P MR spectroscopy in terms 
of signal-to-noise ratio (SNR) and spectral resolution (28,29). Recently, the feasibility 
of in vivo 31P MRSI together with adequate anatomical background imaging of the 
prostate at 7 T was shown (30,31). The 31P spectra of a healthy volunteer presented 
clearly distinguishable signals from the phosphomonoesters PE and PC, but very 
low or no signal in the phosphodiester spectral region. 
To identify further characteristics of 31P spectra of the human prostate and its 
surrounding tissues and to investigate changes of individual phospholipid 
metabolites in prostate cancer in vivo, 31P MRSI was performed in patients with 
prostate cancer at 7 T. 
Materials and Methods
Patients
All measurements were carried out in compliance with the local institutional medical 
ethics committee, and written informed consent was obtained from all patients 
before the measurement. 
Fifteen patients with biopsy-proven prostate cancer (mean age, 65 years; range, 56-
72 years, median PSA level, 6.5 ng/mL; range, 4.7-15.8 ng/mL) participated in this 
study. All patients underwent a clinical multiparametric MRI staging examination 
with an endorectal coil on a 3 T MR system prior to the 7 T examination. The 3 T MR 
images were evaluated by one of four different radiologists with 1, 8, 10 and 17 years 
of experience in prostate MR. 
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From six patients, exact localization of pathology was present: whole-mount section 
histopathology from three patients after radical prostatectomy, and histopathology 
of MR-guided biopsy with in vivo needle position confirmation in three patients. All 
tumor findings were graded according to the 2005 International Society of Urological 
Pathology Modified Gleason Grading System (32). Systematic transrectal ultrasound 
(TRUS) biopsy histopathology results were available in all cases, but completeness 
of data varied. For the patients without exact localization of pathology (n = 9), the 
Gleason score was reported for all positive biopsies (n = 22) and the number of 
positive biopsies out of the total number of biopsies taken was known in 7 cases; the 
localization (left/right), in 8 cases; the level (apex/mid/base), in only 1 case; and the 
percentage of tumor core within the biopsy in 2 cases.  
Hardware
Measurements were performed on a 7 T whole-body MR system (MAGNETOM, 
Siemens Healthcare, Erlangen, Germany). A 31P transmit-receive endorectal coil 
tuned to 120.3 MHz was used in combination with an 8-channel 1H transmit-receive 
body array coil with meander elements. A thorough safety validation of this coil 
combination has recently been published (30).
Patient Preparation
The patients were placed in supine position on the dorsal array of the 8-channel 
array coil after insertion of the endorectal coil. The ventral array of the 8-channel 
array coil was positioned over the lower abdomen. Further details about patient and 
coil preparation as well as quality checks of the coils have been published previously 
(30). 
MR Measurement Protocol 
The MR protocol included static magnetic field (B0) phase-map shimming to optimize 
the B0 homogeneity, and transmit radiofrequency field (B1
+) shimming to maximize 
the achievable B1
+ amplitude within the prostate (33). B1
+ shimming is essential both 
for obtaining artifact-free T2-weighted fast spin echo images of the prostate and for 
efficient signal enhancement of the 31P MRSI by the nuclear Overhauser effect (NOE) 
(31,34). The T2-weighted images (repetition time [TR] = 3000-3640 ms; echo time = 
71 ms; resolution = 0.75 x 0.75 x 3 mm) (31) provided an anatomical background for 
the 3D 31P MRSI measurements.
31P MRSI was performed with a pulse acquire sequence. An adiabatic excitation 
BIR-4 pulse of 8 ms with a flip angle of 45° (γB1 = 960 Hz within the prostate at a 
distance of 2 cm from the coil; bandwidth ≈ 1500 Hz) in combination with a TR of 
1500 ms ensured close-to-optimal SNR per unit time (34). The full field of view of the 
endorectal coil was covered (field of view = 120 x 120 x 120 mm; matrix = 10 x 10 x 
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10 [n = 12] or 12 x 12 x 12 [n = 3]), resulting in effectively spherical voxel volumes of 
5.1 cm3 and 3.0 cm3 after apodization with a Hanning filter of the k-space weighted 
sampling (35). The acquisition bandwidth was set to 5000 Hz and the corresponding 
acquisition times were 9 min 51 s or 17 min 44 s. 
In 12 patients, an NOE was generated by applying low-power continuous wave 
1H irradiation (n = 7) or WALTZ-4 1H irradiation (n = 5) during the full TR (except 
during 204 ms signal acquisition) to saturate the 1H spins of water (34). 
31P MRSI Voxel Selection 
On the basis of histopathological information and/or the radiological report of 
the 3 T clinical prostate examination of each patient, a radiologist-fellow (E.K.V.) 
and a spectroscopist (M.W.L.) selected spectroscopy voxels in consensus. For this 
purpose, the voxel matrix of the spectroscopic examination was projected over 
the T2-weighted 7 T MR images. In cases where whole-mount histopathology was 
available, spectroscopy voxels were selected by visually matching the MR images 
with the histopathology slices. In cases where histopathology data of MR-guided 
biopsy or TRUS-guided biopsy were available, voxel selection was guided by the 
annotations made as part of the clinical radiology report of the 3 T images. The 
voxels were assigned as representing tumor tissue, a cancer-suspicious region on 
MR, mainly normal-appearing peripheral zone (PZ) tissue and mainly normal-
appearing transition zone (TZ) tissue. Care was taken that the voxels assigned to 
mainly normal-appearing tissue did not overlap with the tumor or the MR-visible 
tumor lesion, but contamination from other prostate tissues or periprostatic tissue in 
these voxels was allowed. A maximum of five non-neighboring voxels were selected 
per patient, with no more than 2 voxels within the same tissue type. An additional 
voxel was selected in the base of the prostate (PZ or TZ) close to the seminal vesicles, 
if this was possible without violating the non-neighboring restriction. This allowed 
the assessment of the influence of phospholipid metabolite levels of the seminal 
vesicles on the prostate spectra. High total choline levels in these vesicles are a 
known confounder in 1H MRSI of the prostate (36). A matrix grid shift was carried 
out if this improved the volume representation of voxels of interest. 
One patient was under active surveillance after a systematic TRUS biopsy finding 
with a Gleason score of 3+3, but two consecutive 3 T MR images in two years showed 
no MR-visible lesion. Only normal-appearing PZ and TZ voxels were included from 
this patient in the analysis.
For all voxels representing tumor tissue or a cancer-suspicious region on MR, the 
tumor volume was either determined from histopathology by the pathologist or 
measured on the T2-weighted or diffusion-weighted images from the clinical 3 T 
multiparametric MRI examination by the radiologist-fellow (E.K.V.). Voxels selected 
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as tumor tissue containing a tumor smaller than the clinically deemed relevant size 
(37) of 0.5 cm3 were discarded for further analysis. 
Data Analysis
The 31P spectra of the selected voxels were fitted with Metabolite Report (Siemens 
Healthcare, Erlangen, Germany). Metabolite Report performs automated, prior 
knowledge based, complex fitting in the time domain and has previously been 
applied to 1H spectroscopy data (38). In this procedure, PE, PC, GPE and GPC were 
each modeled as a triplet with three single Lorentzian peaks with a constrained 
separation according to their JPH coupling constants (6 - 7.1 Hz) (39) and line 
amplitudes in a 1:2:1 ratio. The line widths of the single peaks were constrained to 
the line width of phosphocreatine (PCr) which was also fitted with a Lorentzian line 
shape. The line width constraint also held for two Gaussian peaks that fitted the two 
peaks in the inorganic phosphate (Pi) chemical shift region. The γ and α resonances 
of adenosine triphosphate (ATP) were fitted with a Gaussian line shape; J-coupling 
between these resonances was neglected. 
Both a quantitative evaluation of the fitting results and a visual quality control 
were performed. Quantitatively, only metabolite fits with a Cramér-Rao lower 
bound (CRLB) below 30 % were considered reliable. Because only little overlap 
exists between 31P resonances, this minimum CRLB for 7 T 31P spectra was set less 
stringent than the generally used CRLB threshold of 20% for the more complex 
signals in 1H spectra. A spectroscopist (M.W.L.) qualitatively checked the spectra by 
visual inspection of the original spectra and the fitting results. If a metabolite peak 
was visually present and phased correctly, and its fit was assigned to the correct 
resonance, giving a minimal residue, the fitting result was accepted. The fitted 
amplitude of metabolite peaks that passed both quality checks was used for further 
analysis. If no signal was visually present for a metabolite peak, its fitted amplitude 
was set to zero. Metabolite resonances with wrong phasing or a wrong fit (CRLB > 
30 % or visual) were not used for further analysis. 
Metabolite ratios were calculated for all selected voxels. The denominator of the 
ratio was a single phospholipid metabolite amplitude, a sum of phospholipid 
metabolite amplitudes, or the γATP amplitude. For the three patients from whom 
non-NOE enhanced data were recorded, metabolite amplitudes were corrected by 
NOE factors determined in prostate at 7 T (34), before calculating metabolite ratios. 
Metabolite amplitudes were not corrected for partial saturation caused by T1 effects.
Metabolite ratios of the selected voxels in tumor, normal-appearing PZ, normal-
appearing TZ and close to the seminal vesicles were visualized in scatterplots. A 
distinction was made between voxels containing more and less than 20% of tumor 
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volume. A comparison between the tissues was performed visually. The limited 
number of voxels per tissue type precluded a detailed statistical analysis. 
Transversal, sagittal and coronal color maps of metabolite levels and ratios were 
generated with MATLAB R2012a (MathWorks, Natick, MA, USA) using the fitting 
results of Metabolite Report to visualize within prostate and between patient 
differences. Metabolite maps of PCr and γATP were inspected on the eligibility of 
these metabolites to serve as an internal reference. The CRLB criterion for reliable 
fitting was also applied to these metabolite maps. 
Assuming that both resonances in the chemical shift region of Pi represent Pi in 
two different compartments, the pH of these compartments was calculated in tumor 
and normal-appearing prostate tissue with the modified Henderson-Hasselbach 
relationship (pK = 6.77, δHA = 3.23 ppm and δA = 5.70 ppm) (40).  
Results
The 7 T examination was tolerated well by all patients, and no adverse events 
occurred. In total, 21 voxels representing tumor tissue were selected, of which 
13 voxels contained a tumor volume larger than 0.5 cm3 (confirmed tumors with 
Gleason score of 2+3 [n=1], 3+3 [n=7], 3+4 [n=2], 4+5 [n=1], 5+4 [n=1] and cancer-
suspicious regions on 3 T [n=1], Gleason grade 2 was assigned to 1 of multiple tumor 
foci on whole-mount section histopathology). The tumor volumes varied from 0.6 
to 3.35 cm3 (mean ± SD: 1.47 ± 0.71 cm3). By assuming that the tumor lay completely 
Figure 6.1 - Images taken from a 70-year-old patient with prostate cancer. A: Transversal spectral map of 
31P MRSI in the cancer-free base of the prostate superimposed on a T2-weighted image. The green grid 
represents the interpolated MRSI matrix, the dotted yellow circle indicates the true voxel size (5.1 cm3). 
B: 31P spectrum (white) and fit of the spectrum generated by Metabolite Report (red) together with the 
fitted baseline (blue) of the voxel indicated in A.
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within the voxel, the volume percentage of tumor within the voxel varied from 11.8 
to 100 % (mean ± SD: 33.4 ± 23.9 %). Only four patients presented with 1 or more 
large (>1.5 cm3) tumors. In normal-appearing PZ and TZ tissue, 12 and 19 voxels 
were picked, respectively. In addition, 13 voxels were selected in the base of the 
prostate just below the seminal vesicles.
Resonances of PE, PC, Pi, PCr, γATP and αATP were present and well resolved in 
most voxels. The βATP intensity was strongly attenuated or not present because of 
the limited bandwidth of the excitation pulse. The GPC and GPE signals were low 
or not present in most spectra. Figure 6.1 shows an example of spectral fitting in one 
patient. 
The spectral quality in the selected voxels was generally good, but in voxels at a 
farther distance from the endorectal coil, the SNR was insufficient and/or the 
adiabaticity of the excitation pulse broke down, the latter leading to a distorted 
phase and unreliable amplitude of the metabolites farthest from the center of the 
pulse (PE, PC, αATP). For each tissue type, the number of metabolite resonances 
with detectable signal and whose fit passed both quality checks is presented in Table 
6.1. 
A considerable overlap was observed between metabolite ratios in prostate cancer 
and normal-appearing prostate tissue (Fig. 6.2). No clear differences were observed 
between tumor voxels containing less or more than 20% of tumor volume. It was, 
however, noted that the signals of the phosphodiesters, especially GPC, were more 
often detected in malignant tissue (Table 6.1). High PC levels were observed in the 
tumor region of one patient with a large (1.9 cm3) Gleason score 5+4 lesion confirmed 
Table 6.1. - Acceptably fitted metabolite resonances in 31P MR spectra of the prostate
Tissue type
Tumora PZ TZ Near SV
Total # of 
voxels 13 12 19 13
PE 11 (85%) 9 (75%) 17 (89%) 10 (77%)
PC 12 (92%) 10 (83%) 16 (84%) 10 (77%)
Pi1 5 (38%) 7 (58%) 5 (26%) 2 (15%)
Pi2 7 (54%) 7 (58%) 7 (37%) 3 (23%)
GPE 2 (15%) 1 (8%) 0 3 (23%)
GPC 6 (46%) 2 (17%) 1 (5%) 3 (23%)
PCr 12 (92%) 12 (100%) 19 (100%) 12 (92%)
γATP 12 (92%) 11 (92%) 16 (84 %) 11 (85 %)
αATP 8 (62%) 10 (83%) 13 (68%) 10 (77%)
PC + GPC 6 (46%) 2 (17%) 1 (5%) 3 (23%)
Pi1 + Pi2 5 (38%) 6 (50%) 2 (11%) 1 (8%)
Values show the absolute (number of voxels) and relative (number of voxels/total number of voxels 
x 100%) presence of metabolite signal with a good spectral fit. a All tumor voxels, including cancer-
suspicious regions on 3 T multiparametric MRI. PZ: peripheral zone, TZ: transition zone, SV: seminal 
vesicles.
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at prostatectomy (Fig. 6.3). Another patient with an MR-visible lesion (1.5 cm3) 
assigned by the radiologist as highly aggressive, and with a Gleason score of 4+5 on 
the same side of the prostate (TRUS biopsy), showed especially high GPC levels in 
the lesion (Fig. 6.4). Moreover, γATP was elevated in this lesion, which was not the 
case in the highly aggressive tumor (Gleason 5+4) of the aforementioned patient. 
The PCr metabolite maps showed high PCr levels in the smooth muscle surrounding 
the prostate and low PCr levels within the prostate itself in all patients. The 
γATP metabolite maps showed considerable variation between the patients. In 
some patients, this metabolite was equally distributed over the prostate and the 
surrounding tissues: the γATP map closely resembled the endorectal coil receive 
profile. In other patients this was not case (Fig. 6.5). 
The PC/PE ratio in voxels near the seminal vesicles varied largely between the 
patients (Fig. 6.6). Highly elevated PC levels were observed in and near the seminal 
Figure 6.2 - Metabolite ratios in prostate cancer (PCa), normal-appearing peripheral zone (PZ) and 
transition zone (TZ) tissue, and near the seminal vesicles (SV). No clear differences between the tissues 
are observed. v/v %: tumor volume in percentage of voxel volume; tPLM: total phospholipid metabolites 
(PE+PC+GPE+GPC).
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Figure 6.3 - Images taken from a 68-year old patient with four cancer foci in the prostate. A and B: 
Metabolite maps of the PC/γATP ratio superimposed on T2-weighted images of the prostate. A: Coronal 
slice. B: Transversal slice. C: Sagittal T2-weighted image indicating slice locations of A and B. D: Pathology 
slices indicating the cancer foci with Gleason scores: 1, 5+4; 2, 3+4(+5); 3, 2+3; 4, 3+3. Elevated PC/γATP 
levels are present at the location of the highly aggressive tumor (1, volume of 1.9 cm3) on the right side 
of the base of the gland. A slight elevation of PC/γATP is visible in the tumor with the tertiary Gleason 
grade 5 component in the PZ of the apex of the gland (2, volume 0.5 cm3). Levels of GPC were below the 
detection limit in this patient.
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Figure 6.5 - Metabolites involved in energy metabolism. Metabolite maps overlaid on the transversal 
T2-weighted images show the distributions of PCr and γATP in the prostates and surrounding smooth 
muscles of two patients (A and B). The endorectal coil receive profile affects the observed distributions. 
Color bars display arbitrary units of metabolite signal amplitude. Levels of PCr are low in the prostate 
and high in the smooth muscle. The γATP distribution in patient A seems to represent the coil receive 
profile quite well and could therefore serve as an internal reference. However, the γATP distribution in 
patient B does not follow the coil receive profile with larger γATP signals present in periprostatic tissue. 
No clear cancer-related changes in the 31P signals were observed in these patients.
Figure 6.4 - Images taken from a 72-year old patient with prostate cancer (Gleason score: 4+5; volume: 
1.5 cm3) in the PZ on the right side of the gland. The tumor lesion is indicated by white arrows on the 
transversal T2-weighted image. Metabolite maps overlaid on the same transversal T2-weighted image 
show elevated GPC and γATP levels in the lesion. The T2-weighted image and PCr map indicate that 
the endorectal coil was slightly tilted to the left in this patient. Assuming similar PCr levels in the 
smooth muscles surrounding the prostate, signal intensity differences originate from coil receive profile. 
Colorbars display arbitrary units of metabolite signal amplitude.
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vesicles in five patients. In patients with less elevated PC levels in and near the 
seminal vesicles, the PC/PE ratio in the prostate itself was well below unity (~0.5), 
but a remarkable elevation of the ratio was observed on both lateral sides of the 
prostate from base to midgland (Fig. 6.7). 
Two peaks in the chemical shift region of Pi were visually present in 14 spectra 
(25 %). If both peaks in the chemical shift range of Pi indeed originated from Pi, the 
peak resonating at approximately 5.4 ppm (Pi1) would reflect a pH environment of 
~7.6, whereas the peak at approximately 4.9 ppm (Pi2) would represent Pi in a pH 
environment of ~7.1 (Fig. 6.8). No differences in pH were found between prostate 
cancer and normal-appearing prostate tissue. The Pi1/Pi2 ratio showed a trend of 
higher values in prostate cancer compared with normal-appearing prostate tissue 
(Fig. 6.2). 
Figure 6.6 - Illustration of increased PC in seminal vesicles. Sagittal T2-weighted images of prostates from 
two patients with metabolite maps of the PC/PE ratio overlaid. The first patient (A) shows relatively small 
increases of PC in the seminal vesicles, contrary to the second patient (B) who has high levels of PC in the 
seminal vesicles, as expressed by the PC/PE ratio. No clear cancer-related changes in the 31P signals were 
observed in these patients.
Figure 6.7 - Increased PC/PE in periprostatic tissue. Transversal T2-weighted images of prostates from 
two patients with metabolite maps of the PC/PE ratio overlaid. In both patients, the PC/PE increased 
towards the lateral sides of the prostate. No clear cancer-related changes in the 31P signals were observed 
in these patients (slice with tumor location not shown).
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Discussion
In this explorative 7 T study, 3D 31P MRSI was used to probe phospholipid metabolites 
in the human prostate in vivo, revealing new characteristics of (peri-)prostatic tissue. 
In our patient cohort, large overlap in metabolite ratios was found between prostate 
cancer and normal-appearing tissue and 2 aggressive tumors showed distinctive 
metabolic patterns. 
In contrast to our in vivo study, several ex vivo studies showed significant differences 
between malignant and benign prostate tissue samples or extracts by 31P high-
resolution nuclear magnetic resonance (NMR) or 1H high-resolution magic angle 
spinning (HR-MAS), both in absolute metabolite concentrations and in metabolite 
ratios (26,27,41). An overall increase in the concentration of the phospholipid 
metabolites in prostate cancer has been reported in the quantitative 2D 1H HR-
MAS studies, with the largest increase in PC (up to 10 times in low-grade cancer 
and 28 times for high-grade cancer), followed by GPE and GPC (up to almost 7 
times) and finally PE (up to 2 times) (17,18). The ratios of PC/GPC and PC/PE were 
significantly higher in malignant versus benign prostate tissue samples, where 12 of 
the 15 cancer samples had Gleason scores 3+3 or 3+4 (17). We could confirm neither 
the large increases in metabolite levels nor the differences in metabolite ratios in 
vivo. Only the increased detection of GPC in malignant tissue in vivo possibly 
corresponds with these 1H HR-MAS findings. In 31P high-resolution NMR studies, 
significant relative increases and decreases in GPE and PE, respectively, were found 
in malignant tissue compared with benign prostate tissue (26,41). These findings do 
Figure 6.8 - pH calculated from the chemical shifts of 
two peaks presumably originating from Pi in selected 
voxels in prostate cancer (PCa), normal-appearing 
PZ tissue, normal-appearing TZ tissue and near the 
seminal vesicles (SV). No clear differences in pH 
between the tissues are observed.
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not directly correspond with our in vivo results; however, a decreasing trend in the 
PE/(PE+PC+GPE+GPC) ratio in tumor (Fig. 6.2) may be recognized.
The elevation of phospholipid compounds in cancer has historically been attributed 
to increased cellular proliferation and the corresponding need for increased levels of 
phospholipid and fatty acid metabolites. However, prostate cancers tend to be slow-
growing cancers, in which these metabolite demands might not be so profound. 
A number of studies investigating the relation between prostate cancer cellular 
proliferation rate, cell density and phospholipid metabolite levels have shown 
conflicting results (16,18,42,43). The observed changes in phospholipid metabolites 
in cancer may be attributable to a real alteration of the phospholipid metabolism 
and to morphological changes. In the 1H HR-MAS and 31P NMR studies of prostate 
biopsies, some phospholipid metabolites also varied with the Gleason score of the 
samples (18,26,44). Keshari et al. reported significantly higher GPC levels in high-
grade (Gleason score ≥ 4+3) compared with low-grade (Gleason score ≤ 3+4) prostate 
cancer, whereas PC+GPC provided the best discrimination between low- and 
high-grade prostate cancer, mainly because of the significant increase in GPC (18). 
Komoroski et al. also showed a significant correlation between the GPC/PC ratio 
and the Gleason score (26). Because GPC and GPE were often below the detection 
limit in our acquisitions, the ratios containing these metabolites in their numerator 
or denominator were often zero or infinite and could not be assessed for a possible 
correlation with Gleason score. Moreover, the limited number of patients with 
exact localization of histopathology in this study prohibited a detailed analysis of 
correlation between phospholipid metabolites and Gleason score. 
The ratios comprising PC and/or GPC in tumor did not deviate from normal-
appearing prostate tissue over our whole patient cohort, but the data of the only 2 
patients with higher Gleason scores tumors suggested that PC and GPC levels might 
be related to aggressive prostate cancer. If so, performing 31P MRSI at 7 T in addition 
to multiparametric MRI could clinically be considered to improve diagnosis, but 
it could also tell us something about the metabolites involved in the development 
of the disease. A larger patient cohort with men presenting with a wider range 
of Gleason scores, undergoing prostatectomy or biopsy under MR guidance, is 
essential to study if GPC and PC can be considered in vivo markers for prostate 
cancer aggressiveness. Also, their relation with total choline levels to be measured 
by 1H MRSI in vivo should be studied. 
Aside from the visually observed changes in the two patients with aggressive tumors, 
overlap in various metabolite ratios was found between the tissue categories. The 
overlap between malignant and benign voxels can be attributed to the variability of 
the cancer percentage with the voxel volumes (18). In a publication of Swanson et 
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al., it was reported that tissue samples should contain at least 20% of prostate cancer 
before differences in total choline or GPC+PC could be observed compared with 
benign tissue using 1D 1H HR-MAS (42). It is very likely that partial volume effects 
also caused the variation in metabolite ratios in our study, and possibly obscured 
differences between benign and malignant prostate tissue. In 9 of 13 of the voxels 
assigned as tumor, the percentage of cancer was estimated to be less than 30% and, 
in 3 voxels, it was even less than 20%. This could have resulted in a significant 
underreporting of the potential value of in vivo 31P MRSI. 
Next to the partial volume effect induced by the small tumors in combination 
with the large voxel size in this study, the overlap in metabolite ratios between 
tissue types in our study may have resulted from partial volume contamination 
of tissue surrounding the prostate such as the seminal vesicles, smooth muscles, 
periprostatic fat and neurovascular bundles. Some spectral features of 31P spectra of 
those surrounding tissues were remarkably different from those within the prostate. 
The PCr levels in the prostate were low compared with the surrounding smooth 
muscles (Fig. 6.5), which corresponds with the low density (20%) of smooth muscle 
cells within the prostate (45) but possibly also illustrates the difference in fluctuating 
energy demands of these tissues. The phospholipid metabolite levels were also 
different between the prostate and the surrounding tissues, with high signals of the 
phosphomonoesters, especially PE, in the prostate compared with smooth muscle 
and higher PC/PE ratios in the tissues surrounding the prostate (Fig. 6.7). The 
elevation of the PC/PE ratio in the seminal vesicles in a number of patients was even 
more pronounced and affected spectra in the base of the prostate strongly because 
of voxel bleed (Fig. 6.6). High total choline levels in and surrounding the seminal 
vesicles and the ejaculatory ducts are also a known confounder in 1H MRSI, and 
because of a misassignment in an initial 1H NMR study of seminal vesicle fluid (46), 
it is often believed that GPC levels are elevated in these structures (36). We can now 
confirm more recent 1H NMR results of seminal vesicle fluid that it concerns high 
PC levels instead (47). 
When comparing relative concentrations of phospholipid metabolites in the in vivo 
31P MR spectra of the prostate with those in 1H HR-MAS spectra of prostate samples, 
remarkable differences were present. In benign 1H HR-MAS spectra, PC was nearly 
undetectable, GPC and GPE had comparable concentrations and PE had the highest 
concentration of all phospholipid metabolites. In the in vivo 31P MR spectra of benign 
prostate tissue, both PE and PC were always far more abundant than GPE and GPC, 
and the PC/PE ratio ranged between 0.2 and 1.2. Saturation effects cannot explain 
these differences with HR-MAS, because 31P T1 relaxation times of PE, PC, GPE and 
GPC in vivo at 7 T are all in the same order (~6-8 seconds) (34). The differences 
between in vivo and in vitro results may originate from metabolite content changes 
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during extraction and in vitro measurements. However, the metabolite ratios in 31P 
NMR spectra of perchloric extracts of human prostate tissue resembled our in vivo 
spectra more closely, showing a near absence of GPE and GPC (26,41). Perhaps, the 
1H HR-MAS procedure and data analysis were not fully optimized to accurately 
quantify these metabolites. 
In nearly all in vivo 31P MR spectra of the prostate with high enough SNR, two 
peaks were visible in the chemical shift range of Pi. These may represent Pi in 
two compartments with different pH: one approximately at pH 7.1 and one with 
a remarkably high pH of 7.6. Histologically, normal-appearing human prostate 
tissue consists of 3 major compartments: stromal (45%), epithelial (21%), and acinar 
luminal (34%) (48). In the healthy prostate, citrate is produced within the epithelial 
cells and is ultimately secreted to become a major constituent of prostatic fluid, 
which is stored within the luminal space (49). The pH of prostatic fluid showed a 
strong correlation with the citrate content (50,51), being slightly acidic (pH < 7) in 
healthy prostates but ranging up to a pH of 8 in diseased prostates (50,52). Some 
studies from the previous century reported very low Pi concentrations in prostatic 
fluid (53,54), which would exclude the prostatic fluid as a possible contributor of 
Pi to one of the peaks in this chemical shift range, but this should be reinvestigated 
with modern techniques. Prostatic epithelial pH was recently measured in rats 
and dogs by confocal microscopy to be approximately 7.0 (55), whereas the pH of 
fibromuscular stroma has, to our knowledge, not been reported. It is expected to 
have a pH comparable to that of epithelial tissue because of its cellular structure. 
The trend of higher levels of Pi in a compartment with a pH of 7.6 compared with 
the compartment with a pH of 7.1 in prostate cancer (Fig. 6.2) also needs further 
investigation. It might represent a difference in volume and/or Pi concentration 
of the pH-7.6 compartment. The presence of other metabolites instead of Pi in this 
chemical shift range can also not be ruled out yet. It would be of great interest to test 
the prostatic fluid of patients undergoing a 31P MRSI examination at 7 T on pH and 
Pi concentration. 
All the previous observations regarding metabolite and pH variations in the prostate 
and the surrounding tissues are attributed to the increased spectral resolution and 
sensitivity at 7 T, allowing 31P MRSI and separation of all signals in the spectrum. 
In the in vivo 31P MR spectroscopy studies of the prostate at 1.5 and 2 T, the signal 
was localized by the coil profile only and PE, PC, Pi, GPE and GPC signals could not 
be separated (24,25). These studies reported metabolite ratio differences between 
diseased and healthy individuals, which could very well be the result of different coil 
positioning, age-dependent enlargement of the prostate, or spectral quantification 
errors. 
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In the current MRSI data, we did not use the PCr signal for signal normalization 
throughout the prostate to compare benign and malignant prostate tissue. Large 
PCr signals from the surrounding muscles contaminated the spectra of voxels at the 
lateral sides of the prostate. Also, the γATP signal did show variations throughout the 
prostate in some cases that were not attributable to the coil receive profile only and 
could therefore not be regarded as a good internal reference. To be able to compare 
phospholipid metabolites with PCr ratios at different locations in the prostate, the 
contamination from smooth muscle needs to be decreased by reducing the voxel size 
of the MRSI, which would also be beneficial for studying smaller tumors. At a higher 
spatial resolution, the partial volume effects will be reduced, potentially allowing 
discrimination of tumor and normal-appearing tissue based on 31P metabolite levels. 
This will be clinically challenging because longer acquisition times are not a realistic 
option. Improvements on the endorectal coil design would be necessary to enhance 
sensitivity, and new acquisition techniques should be implemented to sample the 
field of view with a larger number of phase encode steps within an acceptable 
acquisition time. Apart from this, absolute quantification of the metabolite signals 
could be considered. This would require the incorporation of a reference compound 
in the endorectal coil and a correction for the coil receive profile. 
To improve SNR in the current study, we generated NOE signal enhancements by 
saturating the water protons during the 31P MRSI experiment in 12 patients. The 
NOE phenomenon results from dipolar relaxation and is frequently used in 31P 
MR spectroscopy studies (56–58). NOE signal enhancements of the metabolites 
involved in phospholipid metabolism were measured up to 43% in the prostate at 
7 T (34). The increased SNR generated by NOE improved the fitting accuracy of the 
metabolite amplitudes, but variations in enhancement level may affect metabolite 
ratios. Differences in NOE enhancements between tumor and normal-appearing 
tissue have not been reported before, to our knowledge, but can be considered as 
another potential cause of overlap in the data presented here. However, metabolite 
ratios of NOE-enhanced spectra did not show more variation than ratios of spectra 
without NOE. In the current patient group, the overlap between tumor and normal-
appearing prostate tissue also existed in the non-NOE-enhanced data (not shown).
Overall, ultra-high field 31P MRSI for studying the prostate gland, its surrounding 
tissues, and, possibly, prostate cancer is promising but challenging. In vivo 
phospholipid levels in the prostate were established and were clearly different from 
ex vivo 1H HR-MAS observations. The GPC and GPE signals were low and mostly 
detected in tumor tissue, and the PC/PE ratio in vivo ranged between 0.2 and 1.2. 
Seminal vesicles can contain large amounts of PC. There is evidence for the existence 
of 2 separate pH compartments within the prostate, whose relative contributions 
tend to change in prostate cancer. Case examples illustrated that PC and GPC levels 
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may be related to prostate cancer aggressiveness, but, generally, differences in 31P 
metabolite ratios between prostate cancer and normal-appearing tissue were not 
observed, possibly because of partial volume effects. 
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Abstract 
Objective: An often employed strategy to enhance signals in 31P MR spectroscopy 
is the generation of the nuclear Overhauser effect (NOE) by saturating the water 
resonance. However, concerns exist regarding the considerable variation reported 
in NOE enhancement values per metabolite. NOE would add uncertainty to the 
data, negating the SNR gain it generates. We hypothesized that variation in NOE 
enhancement values is not due to variability in the NOE itself, but that it is attributable 
to measurement uncertainties in the values used to calculate the enhancement.  If 
true, the expected increase in SNR with NOE would improve the repeatability of 
31P MR spectroscopy measurements. To verify the hypothesis, a repeatability study 
of native and NOE-enhanced 31P MRSI was performed in the brain of 7 healthy 
volunteers at 7 T. 
Methods: The repeatability coefficient (RC) and the coefficient of variation in 
repeated measurements (CoVrepeat) were determined per method, and the 95% limits 
of agreement (LoA) between native and NOE-enhanced signals were calculated. 
The variation between the methods, defined by the LoA, is at least as great as that 
predicted by the RC of each method. The sources of variation in NOE enhancements 
were determined using variarance component analysis. 
Results: The CoVrepeat was generally better in the NOE-enhanced data, because 
of the signal increase with NOE. The LoAs could be explained by the RCs of the 
individual methods for the majority of the metabolites, generally confirming our 
hypothesis. Variation in NOE enhancement was mainly attributable to the factor 
repeat, but between-voxel effects were also present for phoshpoethanolamine and 
(glycero)phosphocholine. CoVrepeat and fitting accuracy were strongly correlated and 
improved with positive NOE. Between-voxel variations in NOE enhancement might 
be due to local spatial differences in dipolar relaxation time.
Conclusions: Our results generally indicate that NOE just enhances the signal of the 
metabolites, improving the repeatability of metabolite measurements. Additional 
variability due to NOE was minimal. These findings encourage the use of NOE-
enhanced 31P MRSI. 
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Introduction
Phosphorus (31P) MR spectroscopy is a non-invasive technique to study tissue 
metabolism under various physiological and pathophysiological conditions. 
Human organs and tissues frequently investigated using 31P MRS include the liver 
(1,2), skeletal muscle (3,4), the heart (5) and the brain (6,7), and studies concerning 
the prostate (8), the placenta (9), and breast (10) have also been reported recently. 
Metabolic changes can be followed over time with dynamic 31P MRS, and MR 
spectroscopic imaging (MRSI) allows the two- or three-dimensional mapping of 
metabolites to study their spatial distribution.
The low intrinsic sensitivity of in vivo 31P MRS and MRSI however impedes the 
regular use of these techniques. Obviously, advances in radiofrequency (RF) coil 
design and increases in magnetic field strength have been embraced to gain 31P 
sensitivity enabling reduced overall acquisition times or increased spatial resolution. 
Sensitivity of 31P spectra can also be improved by adding proton (1H) irradiation to 
the MR sequence (11–13). Proton irradiation may activate two physical mechanisms: 
decoupling and the nuclear Overhauser effect (NOE). 
The first process, proton decoupling, is particularly useful at clinical field strengths 
(1.5-3 T), where the line width of the resonances of interest after shimming can be of 
similar size as the weak heteronuclear 31P-1H J-couplings (5-7 Hz). Without proton 
decoupling the coupled metabolites split into doublets or triplets, giving rise to broad 
resonances and spectral overlap. Many metabolites present in an in vivo 31P spectrum 
contain one or more weak 31P-1H J-couplings, i.e. phosphoethanolamine (PE), 
phosphocholine (PC), glycerophosphoethanolamine (GPE), glycerophosphocholine 
(GPC), 2,3-diphosphoglycerate, α-adenosine triphosphate (αATP) and nicotinamide 
adenine dinucleotide (NAD+ and NADH). The improvement in spectral resolution 
obtained by decoupling reduces the spectral overlap of the 31P metabolites and 
thus allows better peak assignment and consequently better spectral quantification. 
Decoupling can be achieved by applying high-power broadband proton irradiation 
during 31P signal acquisition, creating high specific absorption rates (SAR) at higher 
field strengths. 
The second process of signal improvement, the NOE, uses low-power proton 
irradiation to saturate the water resonance in between 31P signal acquisitions.  The 
saturated water protons can increase the steady-state magnetization of the 31P nuclei 
through dipolar interactions, resulting in enhanced 31P metabolite signal intensities. 
In vivo enhancements up to 80% have been reported (14), which encourages the use 
of NOE-enhanced 31P MRS or MRSI. Because NOE requires considerably less power 
than decoupling, it is also suited for higher magnetic field strengths. 
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Absolute NOE enhancement values depend on the extent to which the dipolar 31P-
1H interaction mediates T1 relaxation of the 
31P spins (15). The enhancement values 
therefore vary between metabolites, and are dependent on the mobility of the 
metabolites in the tissue and magnetic field strength (14,16–22). Sufficient saturation 
of the water resonance is essential to maximize the NOE enhancement (12,13), and 
needs to be optimized for each sequence. At ultra-high magnetic field strengths it 
is even more important to determine the minimum transmit RF amplitude (B1
+) for 
constant NOE, because of the known spatial inhomogeneities in the B1
+ field (22). 
The in vivo NOE signal enhancement indeed seemed very beneficial initially (14), but 
considerable spread was later reported in NOE enhancement values per metabolite, 
even if the measurements were calibrated well (19,20,22). This has raised concerns 
that NOE might add variation to the 31P data, negating the gain in signal-to-noise 
ratio (SNR). We hypothesized that spread in NOE enhancement values is not due to 
variability in the NOE itself (i.e. non-constant NOE enhancements because of natural 
variation or inadequate NOE calibration), but that it is attributable to measurement 
uncertainties in the values that are used to calculate the NOE enhancement. If true, 
this would argue for the use of NOE as the SNR is expected to increase, which would 
potentially decrease measurement uncertainties. To test this hypothesis repeated 
measurements with both methods, i.e. native, non-enhanced 31P MRS/ MRSI and 
NOE-enhanced MRS/ MRSI are needed. The measurement uncertainties of the 
two methods, measured by their repeatabilities, limit the amount of agreement 
possible between the two methods, and thus define a minimum variation in NOE 
enhancement values per metabolite (23). 
Ultimately, one wishes to answer the question whether or not to use NOE in 31P 
MRS/MRSI studies in any tissue at any field strength. Because of the dependency of 
NOE enhancements on dipolar relaxation processes and saturation efficiency, spatial 
variations in NOE enhancement might be possible, and this may be dependent on 
the tissue type and state (healthy and diseased) and the field strength. To reduce 
complexity regarding all these issues, the research question in this study was 
narrowed down to the possible beneficial effect of NOE on 31P MRSI of the human 
brain at 7 T. To answer this question we performed repeated measurements of native 
31P MRSI and NOE-enhanced 31P MRSI in the brain of healthy volunteers at 7 T. 
Experimental
Hardware
Measurements were performed on a 7 T whole-body MR research system 
(MAGNETOM, Siemens Healthcare, Erlangen, Germany). An 8-rung high-pass 
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quadrature birdcage coil tuned to 31P (120.3 MHz) was used (24), which was designed 
to fit within a homebuilt 8-channel 1H array head coil with meander elements (25). 
The safety of the coil combination was assessed previously (24). 1H MR imaging and 
1H saturation for NOE generation was performed with an add-on system for RF 
shimming, which also performed real-time SAR monitoring on both the 1H and the 
31P channels (26,27). 
Subjects
Seven healthy volunteers (6 male, 1 female, mean age 30 years, range 21-39 years) 
participated in this study. The study was conducted in accordance with all guidelines 
set forth by the approving institutional review board, and signed informed consent 
was obtained from all subjects before the measurements. 
NOE Generation
To ensure efficient water saturation for NOE, a wideband alternating-phase low-
power technique for zero residual splitting (WALTZ-4, historically used for 
decoupling) (28) was adopted. The WALTZ-4 train was applied during the full TR, 
except during the 31P RF pulse and the 204 ms of signal acquisition. The durations of 
the individual pulses of one WALTZ sub-train were 2.5, 5.0 and 7.5 ms, with 2.5 ms 
pauses in between segments, requiring 14 WALTZ-4 trains of 90 ms each per repetition 
time. The minimum power needed to generate constant NOE enhancements for this 
setting of WALTZ-4 was determined to be 30 Hz in previous phantom experiments 
(partly presented in (22)).
MR Measurement Protocol 
Anatomical images for planning of the 3D 31P MRSI measurements were acquired 
using a magnetization prepared 3D T1-weighted gradient echo (MPRAGE) 
Figure 7.1 - Overview of preparation steps for native and NOE-enhanced 31P MRSI and data analysis 
in one subject. A: Transversal absolute 1H B1+ map after B1+ calibration to obtain at least 90° flip angles 
in the posterior part of the brain, allowing minimally 30 Hz NOE power. B: Sagittal MPRAGE image. 
The location of the absolute 1H B1
+ map is indicated by the red line and the slice selection for flip angle 
calibration of 31P is indicated by the white lines. The yellow arrows indicate signal dropout due to low 
B1
+. C: Transversal MPRAGE images with the spectroscopic grid as an overlay. The voxels indicated in 
blue were used for data analysis. The approximate real voxel size is indicated by the yellow dotted circle.
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sequence. Magnetic field (B0) phase-map shimming was performed to optimize the 
B0 homogeneity in the posterior region of the brain. 
1H transmit RF amplitude (B1
+) 
was maximized in the same region using RF shimming. The amplitude of WALTZ-4 
pulses to generate a constant NOE was set to reach at least 30 Hz in the posterior 
part of the brain by using absolute B1
+ maps (Fig. 7.1A). These maps were acquired 
using a magnetization prepared gradient echo sequence (TR = 5000 ms, TE = 5 ms, 
magnetization preparation flip = 90°, excitation flip angle = 10°) (29). 
Flip angle calibration for 31P was performed using a slice-selective pulse acquire 
sequence (6 ms excitation pulse, TR = 15 s), selecting a 40 mm thick slice through 
the posterior brain (Fig. 7.1B). The amplitude of the RF pulse was varied between 
shots to find the maximum magnitude of the phosphocreatine (PCr) peak. This 
maximum was assumed to correspond to 90° excitation, and all 31P RF amplitudes in 
the subsequent MRSI sequences were scaled relative to this value.
For the 3D 31P MRSI measurements, a pulse acquire sequence was used with a 300 
μs block pulse for excitation (flip angle = 45°) and a TR of 1500 ms. The field of view 
(FOV) was set to 240 x 240 x 240 mm and the 3D phase encoding matrix to 12 x 12 
x 8, creating isotropic dimensions in the transverse plane. The delay between the 
excitation pulse and the start of data acquisition was 410μs. An elliptical k-space 
acquisition scheme was applied (1 average) and k-space was Hamming filtered 
(100%). The nominal voxel size of 20 x 20 x 30 mm is therefore enlarged to a ellipsoid-
shaped voxel volume of approximately 38 cm3 (30). The MRSI acquisition of 7 min 
48 s was repeated four consecutive times. The first and third MRSI acquisitions 
were obtained without 1H irradiation (native), the second and the fourth with 1H 
irradiation to generate the NOE. 
Data Analysis – Voxel Selection and Spectral Fitting
Three non-neighboring MRSI voxels were selected per volunteer (Fig. 7.1C). Care 
was taken to select only voxels that received a minimum 1H B1
+ of 30 Hz in the case 
of NOE generation, that were situated completely within the brain, and that showed 
good spectral quality in all four MRSI datasets. Different voxel locations were 
chosen per volunteer. The average B1
+ in each selected voxel was estimated using 
the absolute B1
+ map.
The 31P spectra of the selected voxels were fitted with Metabolite Report, a work in 
progress package from Siemens Healthcare (Erlangen, Germany). Metabolite Report 
performs automated, prior knowledge based, complex fitting in the time domain 
and has previously been applied to 7 T 31P spectroscopy data of the prostate (8). The 
spectral resonances PE, PC, GPE, GPC, inorganic phosphate (Pi), α-, γ-, β-ATP and 
NAD+/NADH were fitted using Gaussian lineshapes, while PCr was fitted with a 
Lorentzian lineshape. Prior knowledge of the relative peak frequencies and the 31P 
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J-coupling patterns in the ATPs was used. The line widths of PE, PC, GPE, and GPC 
were assumed to be the same and thus constrained to each other. The quality of 
the spectral fit was assessed using the Cramér-Rao lower bound (CRLB) values and 
qualitatively by visual inspection by spectroscopist. The CRLB values of the fits with 
and without NOE were compared using a paired t-test per metabolite. 
Only metabolite fits with a CRLB below 30% were considered reliable. The original 
spectra and the fitting results were visually inspected, and if a metabolite peak was 
visually present and its fit was assigned to the correct resonance, giving a minimal 
residue, the fitting result was accepted. Only metabolites which passed both quality 
checks were used in further analyses. 
The NOE enhancement (η) per metabolite in each selected voxel was calculated by 
  η =       [7.1] 
with NOEenhrepeat and nativerepeat representing the mean metabolite peak integral of the 
two repeated measurements using NOE-enhanced and native MRSI respectively.
Theory of Repeatability and Method Comparison
To be able to answer our research question, we used an approach presented by Bland 
and Altman to assess the agreement between two methods of clinical measurement 
(23). The term ‘agreement’ might be misleading here, since a difference between the 
native and NOE-enhanced method is expected because of the NOE enhancements 
for most metabolites. However, the agreement between methods, or the lack of it, 
has two components: the bias, i.e. the mean difference between the methods, and the 
random variation. The random variation is at least as great as that predicted by the 
repeatability of each method, but may be larger because of heterogeneity between 
individual measurement units (e.g. subjects, but in this study individual voxels as 
well). For correct interpretation of the measure of agreement between methods it is 
thus essential to first determine the repeatability of each individual method. 
Statistical Analyses of Repeatability and Method 
Comparison
Useful measures for the repeatability of a method are the repeatability coefficient 
(RC) and the coefficient of variation in repeated measurements (CoVrepeat). The RC 
defines the width of the interval within which we expect the absolute difference 
between two measurements with the same method to lie in 95% of the cases. It 
is defined as √(2) ∙ 1.96 ∙ σrepeat= 2.77 ∙ σrepeat, where σrepeat is the standard deviation 
of repeated measurements. Once the RCs are known for two methods, their 
repeatability intervals (2*RC) can be directly compared to the interval of the 95% 
limits of agreement (LoA) between the two methods (see below), allowing to assess 
NOEenhrepeat - nativerepeat
nativerepeat
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how much of the observed variation between the methods can be explained by the 
repeatability of the individual methods (23).
In the present work, σrepeat was estimated for each metabolite and each method (native 
and NOE-enhanced) by decomposing the total observed variance into the factors 
‘between-subject’, ‘between-voxel’ (or ‘within-subject’), and ‘repeat’ (or ‘within-
voxel’):
  σ2tot = σ
2
between-subject + σ
2
between-voxel + σ
2
repeat    [7.2]
This was done by fitting a 3-level no-predictors linear mixed model to the data of 
each metabolite and method, in which ‘subject’ and ‘voxel’ were treated as level-3 
and level-2 random intercepts, respectively. 
The CoVrepeat is a normalized measure of σrepeat to study relative repeatability: 
  CoVrepeat=  ∙100%,      [7.3]
with μ the mean of the metabolite integrals of all voxels and repeated measurements, 
without or with NOE (μnative and μNOEenh). The native and NOE-enhanced CoVrepeat were 
determined per metabolite and for metabolite ratios, using standard rules for error 
propagation. A relation between quality of the metabolite fits and the repeatabilities 
of the metabolites was explored by the Pearson correlation between CRLB and 
COVrepeat. 
The agreement between native and NOE-enhanced 31P MRSI was quantified using 
their 95% limits of agreement (LoA). The interval of 95% LoA is determined by 
the overall bias between the two methods (d) and the variation around this mean 
difference, expressed by the standard deviation of the differences (σd):
 95% LoA = d ± 1.96 ∙ σd     [7.4]
The LoA were calculated using NOEenhrepeat and nativerepeat (the mean integrals of the 
two repeated measurements per voxel with each method). The overall bias d was 
estimated using 
 d =  NOEenhrepeat - nativerepeat  ,     [7.5]
where the brackets denote the average over all voxels. Since we include all data 
in calculating the agreement, using the two repeated measures for NOEenhrepeat and 
nativerepeat , the observed standard deviation of the differences between pairs of means 
of repeated measures Sd needs an adaptation to attain the standard deviation of the 
differences between the methods σd (23):
 σ2d= S2d +                +     [7.6]
σrepeat
μ
σ2repeat_native
2
σ2repeat_NOEenh
2
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The 95% LoA and the repeatability intervals were compared for each metabolite. If 
these ranges are similar, then the (lack of) agreement is fully explained by the (lack of) 
repeatability. If the range of the 95% LoA is considerably wider than the repeatability 
intervals of the individual methods, then (some) additional heterogeneity exists 
between the individual voxels and subjects in NOE enhancement (i.e. NOE would 
introduce additional signal variation). 
The presence of NOE-induced additional signal variation between voxels and 
subjects was also assessed by variance components analysis of measured NOE 
enhancements, using the same model as described above (Eq. 7.2). 
The effect of NOE on the peak integrals of individual metabolites was tested 
for significance using similar 3-level mixed models as above, with ‘NOE’ as an 
additional fixed factor. To test whether the minimum 1H power criterion of 30 Hz for 
constant NOE was sufficient in vivo, linear mixed models of the NOE enhancements 
of the individual metabolites were constructed, which included local B1
+ as a 
fixed covariate. The possible effect of local B1
+ on NOE enhancement was assessed 
using these models. Statistical test outcomes with p-values < 0.05 were considered 
significant. 
Results
All subjects completed the full scan protocol, without having to repeat any 
measurements. The minimum power condition of 30 Hz for NOE was reached 
in every subject in the posterior part of the brain (example in Figure 7.1). All 
measurements could be performed within the simulation-based SAR limits (15W/6 
min into the coil), governed by local SAR limits and an additional 40% safety margin. 
The power on the 1H channel had the highest contribution to the total SAR. High 
quality spectra were obtained throughout large parts of the brain, but to meet the 
30 Hz criterion on 1H, only voxels from the posterior brain region were selected for 
quantification. The βATP intensity was strongly attenuated or not present because 
it was outside the effective bandwidth of the excitation pulse and it was therefore 
excluded from further analysis. The PC and NAD resonances were sometimes only 
visible as a small shoulder on the right side of respectively PE or αATP. An example 
of a spectral fit is presented in the supplementary material. 
Small variations in spectral patterns between repeated measurements using the same 
method were observed, and NOE enhancements could also be observed visually 
(Fig. 7.2). For all metabolites except αATP the fitting accuracy was significantly better 
in the NOE-enhanced 31P MRSI data than in the native 31P MRSI data (Table 7.1). 
From 378 metabolite signals (7 volunteers ∙ 2 measurements ∙ 3 voxels ∙ 9 signals) 
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Figure 7.3 - Nuclear Overhauser Effect (NOE) 
enhancements (η) per voxel of 31P metabolite 
resonances in human brain at 7 T. NOE enhancement 
resulting from the first and second set of native and 
NOE-enhanced measurements are shown in black 
and red, respectively.
Table 7.1 - NOE enhancements (η, mean ± SD) and fitting accuracies (Cramér-Rao Lower Bound (CRLB) 
%, mean ± SD) of native and NOE-enhanced spectra.
PE PC Pi GPE GPC PCr γATP αATP NAD
η 0.39±0.22 0.19±0.31 0.21±0.20 0.30±0.22 0.36±0.20 0.22±0.05 0.07±0.07 0.00±0.05 0.21±0.23
CRLB 
native 9.4±1.7 20.2±5.8 13.2±2.6 15.0±3.4 11.0±2.7 3.3±0.8 2.4±0.4 2.9±0.7 26.5±7.4
CRLB 
NOEenh 6.8±1.0 16.7±4.1 10.8±1.8 11.7±2.6 8.1±1.8 2.7±0.6 2.3±0.3 2.8±0.7 21.2±5.5
p-value <0.001 0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.56 <0.001
Figure 7.2 - Example of repeated spectra of the same voxel in one volunteer using native 31P MRSI 
(left, native) and using NOE-enhanced 31P MRSI (right, NOEenh). Variations between the individual 
measurements per method are visible, and the NOE-enhanced spectra show a clear increase in signal 
for several metabolites. PE: phosphoethanolamine, PC: phosphocholine, Pi: inorganic phosphate, GPE: 
glycerophosphoethanolamine, GPC: glycerophosphocholine, PCr: phosphocreatine, γ- and α-ATP: γ- 
and α-adenosine triphosphate, NAD: nicotinamide adenine dinucleotide
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in the native 31P MRSI data, 15 metabolite fits had a CRLB above 30% (PC: 2, NAD: 
13), while from 378 signals in the NOE-enhanced 31P MRSI data, this occurred 2 
times (PC: 1, NAD: 1). None of the metabolite signals with a CRLB below 30% was 
discarded by visual inspection. 
NOE enhancement factors varied between metabolites (Table 7.1, Fig. 7.3), with 
mean enhancements up to 39%. The fitted 31P metabolite integrals were significantly 
higher (p≤0.003) using NOE for all metabolites except αATP. PE, PC, Pi, GPE, GPC 
and NAD showed considerable variation in NOE enhancement between the voxels, 
but outliers did not result from the same voxels. 
The repeatability coefficients of native and NOE-enhanced 31P MRSI were comparable 
for all metabolites except for GPE and NAD (Fig. 7.4A). GPE was considerably less 
repeatable with NOE, whereas NAD was better repeatable with NOE. Because of 
the signal increase with NOE, the CoVrepeat (relative repeatability within voxels) was 
better in the NOE-enhanced data for PE, PC, Pi, GPC, PCr, and NAD (Table 7.2, 
Fig. 7.4B). Similarly, the relative repeatability of metabolite ratios containing these 
metabolites improved with NOE (Table 7.2). In general, CoVrepeat was best for PCr, 
γATP and αATP, i.e. metabolites with the highest signal integrals and smallest fitting 
errors (Table 7.2). A strong correlation existed between mean CRLB and COVrepeat 
(R2=0.91, p<0.0001, Fig. 7.5). 
The agreement between native and NOE-enhanced 31P MRSI, expressed by the 95% 
LoA, was in the range of the repeatability intervals of the individual methods for 
all metabolites except PE (Fig. 7.4A). The variation in NOE enhancements between 
subjects was dominated by the ‘repeat’ component for all metabolites (mean 85%, 
minimum 60% of total variance for PE, Fig. 7.4B). Between-subjects variations 
were negligible (mean 3%, maximum 10% of total variance), while between-voxel 
differences explained a noticeable fraction of the variance only for PE (40%), GPC 
Table 7.2 - Coefficients of Variation in repeated measurement (CoVrepeat) of native and NOE-enhanced data 
per metabolite and for metabolite ratios. 
CoVrepeat
Native NOEenh Native NOEenh
PE 11,8% 7,3% PE/PC 23,1% 19,3%
PC 19,9% 17,8% GPE/GPC 16,1% 18,1%
Pi 16,2% 12,2% PE/PCr 12,8% 8,5%
GPE 11,9% 15,8% Pi/PCr 16,9% 13,0%
GPC 10,9% 8,8% (PE+PC)/PCr 23,2% 17,0%
PCr 4,8% 4,4% PCr/ γATP 8,1% 8,0%
γATP 6,5% 6,7% NAD/ αATP 28,4% 18,5%
αATP 6,6% 6,1%
NAD 27,6% 17,5%
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(34%) and PC (19%). Absolute 1H B1
+ (≥30 Hz) was not a significant predictor for 
NOE enhancement levels (p>0.11) for any of the metabolites except PC (p=0.04). For 
the latter, 1H B1
+ only partially explained the between-voxel variations: controlling 
for this factor still yielded unexplained between-voxel variations of 10% of the total 
variation. 
Discussion
This study was performed to answer the question ‘should we use NOE in 31P MRS(I) 
or not?’. To a great extent, this question can be answered with yes, but we will 
discuss several aspects which should be taken into consideration in deciding upon 
using NOE or not. 
Significantly higher 31P signals were measured using NOE for most metabolites, 
while none of the metabolites showed a (significant) decrease in signal. Moreover, 
the signal enhancement significantly improved fitting accuracy of the metabolite 
resonances with a positive NOE enhancement. These favorable aspects of NOE at 
7 T have been reported before (19,22) and especially the first reason has historically 
led to the use of NOE in in vivo studies. However, when quantifying NOE 
enhancements per metabolite by using native and NOE-enhanced 31P MRSI data, 
considerable variation in absolute enhancement values was observed in this study, 
reproducing findings in many previous studies of different tissues at different field 
strengths (16–19,21,22). This variation may indicate lack of agreement between 
both methods, and in unreplicated studies this can be interpreted as NOE adding 
variability to the data. However, it might also be caused by poor repeatability of (one 
Figure 7.4 - A: 95% Limits of agreement (LoA) between the two methods and repeatability intervals 
(2*RC) of each method. B:  Variance components in NOE enhancement.
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of) the methods. The design of this study allowed us to put this variation into the 
perspective of the repeatability of the individual methods. For a good repeatability 
study, all measurements need to be performed with the same system and method, 
within a short period of time. This is in contrast to reproducibility studies, in which 
the variation in measurements is observed under changing conditions (31). Our 
hypothesis was that variation in NOE enhancement values is caused by the limited 
repeatability of the underlying methods (native and NOE-enhanced 31P MRSI). 
The measurement uncertainties of the 31P metabolite values will propagate in the 
calculation of the NOE enhancement. 
The similarity of the 95% LoA of both methods and the 95% repeatability intervals of 
each method as well as the dominance of the factor repeat in the NOE enhancement 
confirmed our hypothesis. The metabolites PC, Pi, GPE, GPC and NAD showed 
considerable variation in NOE enhancements, but this apparent lack of agreement 
between the methods could be traced back to the repeatabilities of both methods 
for these metabolites. It depends upon the application of the method what relative 
repeatability can be considered sufficient, but for all these metabolites the CoVrepeat 
was above 10% with native 31P MRSI, and improved for all but GPE with NOE. 
Similarly, the CoVrepeat of ratios containing these metabolites improved with NOE. 
GPE showed both a higher absolute and relative repeatability with NOE, although a 
NOE enhancement of 30.1% was observed. We suspect this finding to be incidental, 
resulting from the limited sample size and low SNR of this metabolite. NOE 
enhancements are known to be dependent on dipolar relaxation time (15), which 
might be affected by pH or temperature, but all circumstances were kept the same 
between the repeated measurements, so it is unlikely that the dipolar relaxation 
time has changed within a voxel between the two repeated NOE-enhanced 31P 
MRSI measurements. The relative repeatability of metabolites with endogenously 
higher signal intensities and smaller fitting errors was better (PCr, γATP and αATP) 
compared with the metabolites with lower signal intensities, even though their 
absolute repeatability was slightly worse. These metabolites also showed the smallest 
Figure 7.5 - Relation between fit accuracy of the 
metabolites (expressed in Crámer-Rao Lower Bound, 
CRLB, average across subjects) and the relative 
repeatability (expressed in the coefficient of variation 
in repeated measurements, COVrepeat). Black symbols: 
native. Red symbols: NOE-enhanced.
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variation in their NOE enhancement values. The strong linear correlation between 
fitting accuracy expressed by the CRLB and the relative repeatability indicated that 
CRLB values present a good measure of relative repeatability of 31P MRSI.
PE, and to a smaller extent PC and GPC, showed an  improvement in relative 
repeatability with NOE, but both the Bland-Altman based analysis and the 
decomposition of variance in NOE enhancements indicated the presence of 
additional heterogeneity between voxels next to repeatability variations. We tested 
and excluded local 1H B1
+ to be the reason for additional variation with NOE. A 
different reason for additional variation between voxels with NOE could be spatial 
differences in dipolar interaction between the 1H and 31P spins related to tissue type. 
Because of the large true voxel size in this study, selected voxels contained a mixture 
of gray and white matter, and they were sometimes also contaminated with skull 
tissue or cerebral fluid. The diffuse border of the voxels (30,32) precluded analysis 
of the exact tissue distribution within the spectroscopic voxels by segmentation. To 
study the possible effect of tissue type on NOE enhancements would require a much 
higher spatial resolution and thus considerably longer acquisition times. 
The effect of proton decoupling on repeatability of 31P MRSI, solely or in 
combination with NOE, was not investigated in this study. The beneficial effect of 
proton decoupling decreases with field strength, and it adds considerably to the 
SAR burden. In this 7 T study we opted to saturate the water resonance to generate 
the NOE with a strategy well-known from decoupling; the WALTZ-4 irradiation 
scheme. This irradiation scheme provides a relatively broadband saturation, which 
reduces the sensitivity of water saturation to local B0 inhomogeneities. At clinical 
field strengths one could also use continuous wave irradiation to saturate the water 
resonance. Since the power needed for water saturation with WALTZ-4 contributed 
significantly to the SAR in our study, it would be of interest to determine if a 
lower 1H B1
+ would be sufficient for in vivo experiments compared with phantom 
experiments. 
In the current study, we homogenized B0 and 
1H B1
+ in the posterior part of the brain 
only, whereas for clinical studies homogenization over the whole brain is probably 
more often required. At clinical field strengths the 1H B1
+ and B0 distributions are 
intrinsically more homogeneous than at 7 T, facilitating this prerequisite. Other coil 
configurations or parallel transmit techniques combined with tailored RF pulses may 
also increase the size of the 1H region than can be excited homogeneously at 7 T (33). 
Automatic scanner adjustments of clinical MR scanners obviate the need to calibrate 
the 1H pulse amplitudes for NOE, which was a relative time-consuming procedure in 
this study. The minimum 1H B1
+ for constant NOE using a specific saturation strategy 
should however be determined in a pre-study. In cases where non-uniformities in 
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the 1H RF field are expected, e.g. when using 1H surface coils or at ultra-high field 
strengths, careful examination of the field distribution and amplitude is needed 
before employing NOE. The necessity of 31P flip angle calibration in every single 
subject has to be assessed in a larger cohort. In the 7 subjects within this study, the 
31P B1
+ was very similar. It is very common to use a pre-determined, constant B1
+  
for multinuclear experiments at clinical field strengths, or a pre-determined fixed 
multiplication factor between the X-nucleus and the automated 1H B1
+ calibration, 
because of the lack of automated procedures for multinuclear coils.  
The results of this 31P MRSI study in the brain at 7 T can guide human 31P MRS(I) 
investigations of other tissues including those performed at different field 
strengths. With the current measurement protocol and coil setup, SNR of some low-
concentration metabolites was limited, resulting in relatively poor repeatability. Better 
RF hardware, increasing scan time or decreasing spatial resolution are expected to 
improve SNR and repeatability. As long as positive NOE enhancements are observed 
for the metabolites of interest and SNR is limited, the use of NOE would make sense 
as it increases the amplitude of the metabolites signals and thereby improves their 
fitting accuracy and relative repeatability. This effect is beneficial when metabolite 
ratios are calculated for data analysis, without performing any corrections for 
the individual metabolite NOE enhancements. NOE-enhanced metabolite ratios 
obviously differ from native ratios, but they are more repeatable. When reporting 
NOE-enhanced metabolite ratios, it is of importance to clearly describe the 
way NOE is generated. This allows others to perform similar experiments, thus 
enabling between-site comparisons. When absolute quantification of 31P metabolite 
concentrations is preferred, it has to be realized that data should be corrected for 
the NOE enhancement, which introduces an additional source of uncertainty to the 
quantification. However, as we found only minimal between-subject variation in 
NOE enhancements, a mean NOE enhancement for every metabolite determined 
from a large group of subjects could serve as a reliable correction factor. 
Although it is known that NOE enhancements can vary between tissues (14,16–22), it 
remains uncertain if variations within an organ can exist as well. As discussed above 
we found an indication that this might be the case for NOE enhancements of PE, 
PC and GPC. This finding needs to be confirmed in a larger study. If local variation 
in NOE enhancements exceeds the variation as expected by the repeatability of the 
methods, the differentiation between local physiological differences and variation 
through NOE will be complicated. It is similarly unknown if NOE is different in 
diseased tissue compared with normal tissue or during activation (exercise), or if 
there are changes in NOE with age. In diseased tissue, T1 relaxation times of 
31P may 
change (34), which may have an effect on the absolute NOE enhancements. Whatever 
the factors may be that determine the NOE enhancement, the relatively poor 
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repeatability of in vivo 31P MR spectroscopy data probably precludes determining 
their influence. It would be of interest to study reproducibility of NOE enhanced 31P 
MR data by measuring subjects on different days (20,35). This allows calculation of 
sample sizes needed to reveal significant differences in certain metabolite ratios for 
paired (e.g. response to therapy) and independent (e.g. patient vs. control) studies. 
In conclusion, the signal enhancement generated by NOE improved relative 
repeatability of brain 31P MRSI in healthy volunteers. Variations in NOE enhancements 
per metabolite could almost completely be explained by the degree of repeatability 
of native and NOE-enhanced 31P MRSI. For these reasons, the use of NOE-enhanced 
31P MRSI is encouraged.  
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General Discussion
Increasing evidence shows the benefits of using MRI in prostate cancer management. 
Over the past years, the number of clinical applications of prostate MRI has steadily 
grown thanks to refinement in image acquisition protocols, the introduction 
of functional MR techniques, the increase in magnetic field strength and other 
improvements of the hardware. 
Multiparametric prostate MRI has been studied in a variety of clinical settings; e.g. 
guiding prostate biopsy, selecting men for active surveillance, monitoring tumor 
progression during active surveillance, clinical staging, treatment selection and 
treatment planning (1). Several large studies indicated that multiparametric MRI 
is a reliable tool to rule out clinically significant disease, i.e. potentially aggressive 
tumors (2–5). Multiparametric MRI therefore provides the opportunity to reduce the 
number of unnecessary biopsies and the rate of overdetection and overtreatment. 
An important issue complicating treatment decisions is the ambiguous definition 
of a clinically significant disease (6,7). The progression of certain types of tumors 
residing within the prostate (T2-disease) is still hard to predict. These intermediate 
grade tumors are histopathologically indicated by Gleason score 7 (8,9) and appear 
relatively often (10–12). A common treatment for many of the patients with this 
type of prostate cancer is prostatectomy. This results in low prostate-cancer related 
mortality (13), but it remains an open question for which of these patients a less 
radical treatment approach would have been sufficient as well. A very recent study 
reported that patients with intermediate grade prostate cancer had a higher chance 
of dying from prostate cancer than patients with low-risk disease when managed 
with active surveillance (15-years cause-specific survival 89% and 96% respectively) 
(14), but the monitoring of these patients was performed without MRI. 
Prospective studies with long follow-up are the most accurate way to evaluate the 
performance of new techniques such as multiparametric prostate MRI for patient 
stratification. For an initial evaluation of new techniques it is however common to use 
histopathology results from prostate biopsies or prostatectomy as a surrogate end-
point, and this also allows retrospective studies. This has revealed that quantitative 
and qualitative measures from diffusion weighted MRI, 1H MR spectroscopic 
imaging and dynamic contrast enhanced MRI correlate with tumor aggressiveness 
(11,15–18). However, none of the measures shows absolute discrimination between 
prostate cancer aggressiveness classes. This drives researchers to continuously 
improve the current techniques by engineering better hardware and by optimizing 
RF pulse sequences. Next to this, new MR techniques are developed to study other 
tissue characteristics which are expected to change in cancer. These assumptions are 
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often based on more fundamental research of tissue samples, cell extracts or of tumors 
implanted in animals. Clinical prostate MR is thus a fruitful result of fundamental, 
technical and clinical research. In this work, prostate MR was mainly approached 
from the engineering side. Patient MR results were compared to histopathology 
results when available.  
The lack of good histopathological measures to predict clinical outcome of patients 
with intermediate grade tumors complicates retrospective evaluation of the MR 
techniques for this purpose. Combined information from current multiparametric 
MR techniques should therefore be evaluated prospectively in active surveillance 
studies. When new MR techniques show promising results in discriminating 
between tumor aggressiveness classes, it should be considered to add them in such 
prospective trials. More detailed anatomical or additional functional information 
from the prostate obtained using new or optimized MR techniques could also 
improve prospective cancer assessment in challenging cases, e.g. both inconclusive 
multiparametric MRI and negative prostate biopsies in a patient with a high 
suspicion of prostate cancer based on PSA levels. 
In the studies presented in this thesis several new, advanced prostate MR techniques 
were explored at a magnetic field strength of 7 T. Main focus were 1H and 31P MR 
spectroscopic imaging techniques. Many prostate MR techniques have benefited 
from the step in field strength from 1.5 to 3 T (chapter 2). A fair comparison of MR 
data obtained at different field strengths is difficult because of additional differences 
in coil hardware and protocol settings, but it is clear that the challenges related to 
a higher field strength have led to more advanced RF pulse sequences, allowing 
faster acquisitions and/or producing more robust results. The work performed for 
this thesis encompasses essential adaptations of sequences for the ultra-high field 
strength of 7 T. Their importance for future prostate work will become clear in the 
coming years.   
The spectral-spatial localization technique introduced to perform low-SAR 1H MR 
spectroscopic imaging at 7 T resulted in spectra with a high SNR. It paves the way to 
increase spatial resolution of 1H MR spectroscopic imaging within reasonable scan 
times using smart sampling schemes like spiral-readout (used in chapter 4) or echo 
planar spectroscopic imaging (19). 
The spectral selectivity of the refocusing RF pulses used to localize the signal at 7 T 
invoked in-phase signals of spermine, which considerably changed the appearance 
of the prostate spectra compared with lower field strengths. Because of the (partially) 
disperse spermine signals at 1.5 and 3 T, its resonance at 3.0 ppm is difficult to 
distinguish from choline and creatine. Studies evaluating human prostate specimens 
reported reduced spermine levels in prostate cancer (20,21) and also an in-vivo study 
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using single voxel 2D J-resolved MR spectroscopy showed promising results in 
distinguishing different types of cancer using the (choline+creatine)/ spermine ratio 
(22). Detecting spermine signals independently from choline and creatine could thus 
potentially improve the assessment of prostate cancer. The 3D spectral-spatial 7 T 
1H MR spectroscopic imaging technique may enable in vivo mapping of unaffected 
spermine signals throughout the prostate.
In the few patients examined using spectral-spatial 1H MR spectroscopic imaging, 
no distinct spectral differences were observed between normal-appearing prostate 
tissue and prostate cancer lesions. The broad spermine signal hampered the 
detection of creatine and in many cases also that of choline. Improvements in local 
shim would be necessary to overcome this, but the prostate is a challenging organ 
to achieve smaller linewidths due to the motion of surrounding organs. The intra-
voxel shim may improve by decreasing the voxel size (higher spatial resolutions), 
this requires further investigation. Choline and creatine detection would possibly 
also improve with the use of longer TRs, since this will reduce their T1 saturation. 
Both approaches would only be feasible in combination with the above-mentioned 
fast readout techniques.
An open problem using spectral-spatial MR spectroscopic imaging is occasional 
lipid contamination of the prostate spectra. More accurate selection of the volume 
of interest using longer spectral-spatial RF pulses could potentially solve this issue. 
Another strategy might be to selectively excite the lipid resonance, and spoil its 
signal before selection of the volume of interest, similar to chemical shift selective 
water suppression technique. Although the T1 relaxation time of lipid is considerably 
shorter (~400ms) than that of water, limiting the efficiency of this approach, any 
additional lipid suppression could be advantageous. Care should be taken to avoid 
spoiling of the nearby citrate resonances.
Despite its current limitations, the spectral-spatial 1H MR spectroscopic imaging 
technique has several advantages compared with previously presented techniques 
to perform 1H MR spectroscopic imaging at 7 T (23,24). The energy absorbed by the 
body during this sequence stays well within defined safety limits, because only three 
RF pulses are played out per TR. Secondly, the TE of the sequence can be optimized 
to detect a maximum citrate signal, without compromising the spermine signal. 
Finally, our technique allows for acquisitions without an endorectal coil, whereas 
the endorectal coil was a prerequisite before. A first attempt of spectral-spatial MR 
spectroscopic imaging in a healthy volunteer without endorectal coil was successful, 
though performed at somewhat lower spatial resolution to prevent signal fold in 
from outside the field of view. A higher resolution would have been possible from 
the SNR perspective. 
Chapter 8
8
188 189
The use of an endorectal coil for prostate MR exams is a heavily discussed topic. The 
coil is costly, it requires experienced technicians and additional time for insertion 
and proper positioning, and it causes discomfort for the patient. For prostate cancer 
detection purposes, which may eventually become standard clinical routine before 
taking TRUS-guided biopsies (25,26), the use of an endorectal coil is out of the 
question. Nevertheless, the high local SNR of the endorectal coil can be beneficial in 
answering specific clinical questions, since it allows for higher spatial resolutions. 
In our search for new cancer biomarkers using 31P MR spectroscopic imaging the 
endorectal coil played a crucial role. The intrinsically low 31P metabolite signals can 
be optimally detected with a highly sensitive coil placed as close as possible to the 
tissue of interest. The endorectal coil suited these requirements very well. It allowed 
us to obtain 3D 31P MR spectroscopic imaging datasets of the prostate, showing 
spectra with high SNR close to the coil. 
In contrast to the 1H receive-only endorectal coil, the 31P endorectal coil served 
both transmit and receive purposes. Because the spectroscopic field of view can be 
restricted to the limited field of view of the 31P coil, localization apart from phase 
encoding is not essential with this coil design, allowing pulse-acquire acquisitions. 
The drawback of this transmit-receive coil design is however the need for high-power 
adiabatic pulses to excite the signals in the field of view of the coil homogeneously. 
The high local SAR restricts the minimum TR of the sequence, creating rather long 
total acquisition times for datasets with still limited spatial resolution. In this respect, 
it would be attractive to transmit with an external array coil, creating a homogeneous 
31P transmit field. A coil setup using a transmit birdcage coil and a local receive 
surface coil for 31P, combined with a 1H array coil for standard imaging, has recently 
been presented for 7 T brain applications (27). Apart from the technical challenge 
to develop these kind of complex coil setups, their safety has to be assessed using 
computer models, bench measurements and in vivo tests (like in (28)), making the 
introduction of new coil setups a time-consuming task. 
The possibility to increase spatial resolutions with a new coil setup is of great 
interest, because it is very likely that partial volume effects have obscured spectral 
differences between normal prostate tissue and prostate cancer in our patient study. 
The large and aggressive tumors did show aberrant in vivo spectra, and previous 
in vitro work also showed significant differences between different tumor types 
(29,30). With the 7 T T1 relaxation time values of most 31P metabolites of the prostate 
established in this thesis work, protocols can be readily adapted for optimal detection 
of the metabolites at shorter TR. 
Phospholipid metabolism is known to change in cancer, and MR spectroscopy 
allows us to study some metabolites involved in this metabolism. Four 
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different phospholipid metabolites (phosphoethanolamine, phosphocholine, 
glycerophosphoethanolamine, and glycero-phosphocholine) can be studied with 
31P MR spectroscopy, whereas only the total choline peak represents the choline 
compounds in in vivo 1H spectra. In general, elevated phospholipid metabolite 
levels are expected in prostate cancer, but especially GPC levels might be useful in 
differentiating between different types of prostate cancer aggressiveness (29,30). On 
the other hand, the well-known biomarker of healthy prostate tissue, citrate, can 
only be studied using 1H spectroscopy. Acquiring both 31P and 1H MR spectroscopic 
imaging in one exam might therefore provide extra insight in the characteristics of 
the prostate tissue. An initial report on a combined approach has been presented 
recently, using a transceiver approach with an endorectal coil for both 31P and 1H 
(31). We developed and tested an endorectal coil with transceiver capability on the 
31P frequency and receive-only properties on the 1H frequency, allowing optimal 
performance for a multiparametric 1H MR exam, with 31P MR spectroscopic imaging 
in addition. The coil setup with the external 1H transmit array coil not only serves 
multiparametric 1H MRI, it can also be used to enhance 31P signals using NOE. 
Significant signal increases for the metabolites involved in phospholipid metabolism 
can be achieved in the prostate using NOE and we established that this signal 
increase is not counteracted by additional variety. The benefits of the combined 
1H-31P approach need to be investigated in a larger patient cohort.  
The advantages of using a multiparametric MRI approach for clinical prostate 
management are clear and are adopted in an increasing number of medical centers 
around the world. MR offers extensive possibilities to gain information from the 
prostate tissue, and it remains to be seen if the current combination of MR techniques 
(T2-weighted imaging, diffusion weighted imaging, dynamic contrast-enhanced 
imaging and/or 1H MR spectroscopic imaging) provides the most optimal strategy 
to assess prostate cancer. Next to the 7 T techniques presented in this thesis, several 
other MR techniques are being investigated for potential use in the prostate, e.g. MR 
elastography (32,33) and 23Na MRI (34,35). MR elastography is used to determine 
mechanical properties of tissue, and tumor tissue is expected to be stiffer than normal 
prostate tissue. The sodium concentration is expected to drop in prostate tumors 
because the size of the sodium-rich extracellular space (the prostate glands) reduces 
with cancer. Similar to 31P MR spectroscopic imaging, 23Na MRI will considerably 
benefit from increases in field strength, but this technique has not been tested at 
7 T yet. Other developments focus on retrieving additional information using the 
established sequences, e.g. by measuring or calculating high b-value images to 
improve tumor contrast and conspicuity (36,37) or by applying advanced diffusion 
fitting models that try to extract flow, perfusion and/or microstructural tissue 
characteristics from the diffusion data (38–40). 
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The possible added value of new MR techniques, advanced data modeling and/or 
of a higher field strength needs to be investigated in larger patient trials. To be of 
clinical value, they should fill the weaknesses of the current techniques: improve 
the detection and grading of transition zone cancer (41) and/or provide better 
discrimination between tumor aggressiveness classes. 
Prostate MR exams at 7 T are currently not ready for regular clinical use, because of 
various reasons. The time needed to prepare for multiparametric MRI acquisitions 
is long (10-15 minutes for RF and B0 shimming and pulse angle calibration), and 
there are many manual adjustments to the protocol settings needed. Besides this, 
the multiparametric acquisitions themselves have not reached constant acceptable 
quality yet. It is expected that the total acquisition time can be brought down with 
scanner software and hardware upgrades to integrate currently employed external 
systems. Next to that, less manual adaptations of the sequence protocols will be 
required with dedicated 7 T pulse sequences. Improvements of the hardware and 
further sequence optimizations will probably lead to more robust data quality. 
Since there are still many developments ongoing within the field of 7 T, it is likely 
that prostate MR at 7 T becomes less time-consuming, more robust and more user-
friendly in the coming years. 
Although the potential benefit of prostate exams at 7 T including 31P and 1H 
spectroscopic imaging may not be defined at the moment, our investigations have 
revealed some unknown characteristics of the prostate. Local differences in 31P 
metabolite levels were observed throughout the prostate, and the finding of two 
peaks in the spectral region of inorganic phosphate indicated the presence of separate 
compartments with different pH within the prostate. In-phase detection of spermine 
signal using the spectral-spatial MR spectroscopic imaging sequence showed high 
levels of this metabolite throughout the prostate. These fundamental findings need 
to be taken into account when planning further research in this direction. 
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Summary
The use of MR techniques in the management of prostate cancer has gradually 
gained importance during the last decades. The finding that T2-weighted MRI 
provides excellent contrast between prostatic structures in the late 1980s formed the 
starting point of the multiparametric prostate MR exams used today. These allow us 
to extract both anatomical and functional information from the prostate to detect, 
localize, and assess prostate cancer. This information can guide urologists in finding 
a suitable treatment strategy for every individual patient. 
Multiparametric prostate MR exams typically consist out of anatomical T2-weighted 
imaging, and one to three of the following functional MR techniques: diffusion 
weighted MRI, 1H MR spectroscopic imaging, and dynamic contrast-enhanced MRI. 
These techniques and their resulting images and spectra have largely improved 
over the years. An important factor in these improvements has been the advent of 
3 T clinical scanners in the beginning of the 21th century. Physicists and engineers 
were challenged to overcome several physical, technical and safety limitations 
that inhibited direct exploitation of the increased signal-to-noise ratio and spectral 
resolution at 3 T compared with the lower available magnetic field strengths. 
For prostate MR, the major impedances of the higher field strength are the decreased 
homogeneity of the B0 magnetic field and the increase of RF power deposition. 
Especially diffusion weighted MRI and 1H MR spectroscopic imaging suffer from 
the first issue if no counter measures are taken. By combining single-shot EPI with 
parallel imaging strategies, the accumulation of phase errors during diffusion 
weighted MRI readout is reduced, allowing higher spatial resolutions. Advanced 
shimming needs to be employed before recording 1H MR spectroscopic imaging to 
minimize spectral linewidths. For T2-weighted turbo-spin echo MRI, the increased 
power deposition at higher field strengths requires reductions in the flip angles of 
the refocussing pulses to stay within SAR limits. The changes in T2 relaxation times 
between the field strengths are only minor, but T1 differences between enhancing 
and non-enhancing tissue in dynamic contrast enhanced imaging increase at higher 
field, and this can be exploited to increase its spatial or temporal resolution by using 
intelligent k-space sampling and reconstruction techniques. 
Endorectal receive coils can be used in multiparametric MR exams to increase the 
spatial resolution of T2-weighted imaging and diffusion weighted imaging or for 
increased sensitivity in 1H MR spectroscopic imaging The additional time needed 
for proper insertion of the coil, its cost, and the patient discomfort are however in 
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many clinics reason to perform multiparametric MR exams with external receive 
coils, thereby accepting lower resolution images or longer acquisition times. 
Some MR techniques are still limited in their signal-to-noise ratio at the clinical 
field strengths of 1.5 or 3 T, for example non-proton imaging and spectroscopy. For 
these particular techniques it is of interest to raise the magnetic field strength even 
higher. Several groups have therefore started to explore the feasibility of prostate 
MR at 7 T. The challenges of B0 inhomogeneities and RF power deposition become 
even more severe at 7 T, but next to that inhomogeneities in the 1H RF transmit 
(B1
+) field appear. Complex 1H B1
+ patterns occur throughout the body, resulting in 
varying SNR and signal drop-out at some locations. This complicates all current 
MR techniques used for multiparametric imaging of the prostate. A transmit-receive 
endorectal coil can be used to circumvent the challenges related to external transmit 
fields at 7 T, allowing 1H MR spectroscopic imaging using SAR-intensive semi- or 
full adiabatic sequences. The rapid decrease of B1
+ with increasing distance from 
the endorectal coil however severely compromises anatomical imaging. To allow 
T2-weighted imaging of the prostate with external coils, RF shimming techniques 
are employed. The phase (and amplitude if wished) of RF pulses from every single 
channel of a multichannel array coil are adjusted to ensure sufficient B1
+ magnitude 
in the area of the prostate. To guarantee patient safety, numerical computations of 
the RF field distribution are needed to predict global and especially local SAR with a 
specific coil configuration. Because of the high power deposition associated with the 
T2-weigthed turbo spin-echo sequences and the limited B1
+ available in the prostate, 
prolonged RF pulses are needed to stay within the defined SAR limits and to achieve 
the flip angles needed.  This allows T2-weighted MR imaging of the prostate at 7 T, 
but results in different appearance of the periprostatic tissues compared with lower 
field strengths and the obtainable number of slices is limited by SAR. (Chapter 2)
The opportunities of the higher sensitivity at a higher magnetic field strength result 
in innovative ideas to adapt, improve and accelerate pulse sequences and to improve 
hardware. This enabled the step towards 3 T years ago, and meanwhile improved 
prostate MR at 1.5 T. Additional technical improvements are required to perform 
multiparametric prostate MR at 7 T. The external multi-channel array coil set up 
allowing T2-weighted prostate imaging using RF shimming provided the starting 
point of the 7 T prostate work presented in this thesis.  
The optimal coil configuration for 1H MR spectroscopic imaging at 1.5 and 3 T is the 
external body coil combined with an endorectal receive coil and possibly an external 
array receive coil. This combination generates a homogeneous transmit field, 
allowing the use of conventional (low-power) RF pulses, while it ensures a high 
signal-to-noise ratio in the prostate. To benefit from the advantages of our similar 
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coil configuration at 7 T, a new pulse sequence using spectral-spatial refocusing 
pulses was developed. This sequence did not contain any water or lipid suppression 
pulses, which allowed acquiring a 3D spectroscopic imaging matrix a 7 T with a 
repetition time of 1 second well within the SAR limits. The spectral selectivity of 
the pulses provided excellent suppression of water in the spectra. Some prostate 
spectra showed residual lipid signals, because of limitations in spectral and spatial 
selectivity. The prostate spectra unaffected by lipids showed the common citrate 
signals, but also exhibited high spermine signals concealing creatine and sometimes 
also choline. This feature arises from the use of the spectral-spatial pulses. Only 
the 3.1 ppm group of spermine is refocused by these pulses, which refocuses the 
J-coupling evolution of spermine, leading to in-phase signals independent of echo 
time. The low-SAR 1H MR spectroscopic imaging concept using spectral-spatial RF 
pulses provides the opportunity to increase spatial resolution of in vivo prostate MR 
spectroscopic imaging within reasonable scan times. (Chapter 3) 
Using the coil configuration of the external multi-channel array coil and the 
endorectal receive coil, a multiparametric 7 T prostate MR protocol was tested in 
14 patients. T2-weighted imaging was obtained using a turbo spin-echo sequence 
with prolonged RF pulses. 1H MR spectroscopic imaging was performed using the 
spectral-spatial pulse sequence described in chapter 3, in some cases combined 
with a spiral read-out trajectory which allowed more flexibility in choosing spatial 
resolution, FOV and acquisition time. For diffusion weighted MRI, a 5-shot readout 
segmented echo-planar imaging sequence was used with trace b-values of 0, 100, 400 
and 800 s/mm2. The image quality of T2-weighted images and DWI was rated fair 
to good. Structure delineation in 7 T images did generally not exceed 3 T images, 
despite the higher resolution at 7 T. The quality of the prostate spectra varied among 
the subjects, with lipid contamination the main reason for poor spectra. In only a 
few tumor spectra elevated choline signals could be distinguished from the large 
spermine signal. Although the quality of the MR images and spectra varied between 
patients, this study showed the feasibility of multiparametric prostate MRI at 7 T, 
and several possibilities for improvement were identified. (Chapter 4)
In order to perform 31P MR spectroscopic imaging of the prostate at 7 T, a transmit-
receive endorectal coil tuned to the 31P frequency can be used in combination with 
the external multi-channel array coil for 1H imaging techniques. In order to optimize 
the protocol for pulse-acquire 31P MR spectroscopic imaging T1 relaxation times of 
the 31P metabolites in the prostate were measured. With a repetition time of 1500 ms 
determined by SAR limitations, the optimal flip angle for the adiabatic excitation 
pulse was found to be between 35 and 45° for the 31P spins of different metabolites. 
Moreover, the effect of saturating the water resonance during the 31P acquisition to 
generate an NOE enhancement of the 31P signals was studied and enhancements up 
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to 45% were observed. Using these protocol improvements, a 31P MR spectroscopic 
imaging dataset with optimal signal-to-noise ratio per unit time can be obtained 
within 15 minutes.  (Chapter 5)
Using the optimized protocol for 31P MR spectroscopic imaging, 15 patients with 
prostate cancer were measured at 7 T.  The spectroscopic acquisition was planned 
on T2-weighted images obtained with the external coil array. 31P MR spectra of the 
prostate showed metabolites involved in energy metabolism (PCr, ATPs) and in 
phospholipid metabolism (mainly PE and PC). Remarkably, the spectra also often 
revealed two distinct resonances in the spectral region of Pi, possibly representing 
2 separate pH compartments in the prostate. PCr levels in the prostate were low 
compared with the surrounding smooth muscles. The PC/PE ratio in the seminal 
vesicles was highly elevated compared with the prostate in 5 patients. GPC signals 
were observable in 43% of the voxels in malignant prostate tissue, but in only 
10% of the voxels in normal-appearing tissue away from the seminal vesicles. No 
differences in 31P metabolite ratios were observed between prostate cancer and 
normal-appearing prostate tissue, possibly because of the partial volume effects of 
small tumor foci in large MRSI voxels. The only 2 patients with high aggressive 
prostate tumors presented with high PC and GPC levels in their cancer lesions. 31P 
MR spectroscopic imaging of the prostate at 7 T is therefore a promising technique, 
but higher spatial resolutions are required to study differences between normal and 
cancer tissue in more detail. (Chapter 6)
The usage of the NOE to enhance 31P signals in in vivo measurements is an often 
employed technique at clinical field strengths. In chapter 5, NOE enhancements 
were also generated in the prostate at 7 T. Positive NOE enhancements were 
measured for all metabolites except the ATPs, but considerable variation was 
observed in the enhancement values of the individual metabolites. To understand 
the cause of this variation better, a repeatability study of native and NOE-enhanced 
31P MR spectroscopic brain imaging was performed in 7 healthy volunteers. The 
results showed that variations in NOE enhancements per metabolite could almost 
completely be explained by the degree of repeatability of native and NOE-enhanced 
31P MR spectroscopic imaging. The signal enhancement generated by NOE improved 
the relative repeatability of brain 31P MR spectroscopic imaging, and the use of NOE 
is therefore recommended for low signal-to-noise in vivo 31P MR spectroscopic 
imaging measurements. (Chapter 7) 
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Nederlandse Samenvatting
In de afgelopen decennia is MRI een toenemende rol gaan spelen in het klinisch beleid 
voor de behandeling van prostaat kanker. Een belangrijke reden hiervoor is dat de 
anatomie van de prostaat uitstekend zichtbaar is op zogenaamde T2-gewogen MRI 
beelden. T2-gewogen MRI beeldvorming vormt dan ook de basis van een klinisch 
MR onderzoek van de prostaat. Vaak worden hiernaast ook andere MR technieken 
gebruikt om fysiologische informatie van de prostaat te verkrijgen. Tezamen 
wordt dit een multiparametrisch prostaat onderzoek genoemd. Een radioloog 
kan aan de hand hiervan prostaat kanker detecteren en lokaliseren, alsmede een 
inschatting maken van de ernst van de tumor. De radiologische beoordeling helpt 
de behandelend uroloog te bepalen welke behandeling het meest geschikt is voor 
elke individuele patiënt.
Een multiparametrisch prostaat MRI onderzoek bestaat uit anatomische T2-
gewogen MRI en één tot drie van de volgende functionele MRI technieken: diffusie-
gewogen MRI, waterstof (1H) MR spectroscopische imaging (MRSI) en dynamische 
contrastversterkende MRI. Met diffusie-gewogen MRI wordt de beweeglijkheid 
van water in het lichaam onderzocht, waarbij prostaatkanker zich kenmerkt door 
een restrictie in diffusiewaarden. 1H MRSI brengt de stofwisseling in beeld, hogere 
waarden van het stofwisselingsproduct (metaboliet) choline en lagere waarden van 
het metaboliet citraat zijn hierbij een indicatie voor prostaatkanker. De hoeveelheid 
en permeabiliteit van de bloedvaatjes in de prostaat kunnen kwalitatief beoordeeld 
worden met dynamisch contrastversterkende MRI. Prostaatkanker kleurt sterker 
aan dan gezond prostaatweefsel. 
Deze MRI technieken en de daaruit voortkomende beelden en spectra zijn door de 
jaren heen sterk verbeterd. De ontwikkeling van klinische MR scanners met een 
sterker magneetveld (3 T scanners naast de gebruikelijke 1.5 T apparaten) heeft 
hierin een belangrijke rol gespeeld. Een sterker magneetveld heeft het voordeel dat 
de te detecteren signaalintensiteit toeneemt, waarmee in theorie MRI opnames met 
meer detail (d.w.z. een hogere resolutie) gemaakt kunnen worden. Er gaan echter 
ook verschillende problemen gepaard met het verhogen van de magneetveldsterkte, 
welke het verhinderden direct betere MRI beelden en spectra te verkrijgen met 3 T 
MRI scanners. 
De belangrijkste belemmeringen van een hogere veldsterkte voor prostaat MRI zijn 
de verminderde homogeniteit van het magnetisch veld (B0) en de verhoging van 
het gedeponeerde vermogen in weefsel door radiofrequente (RF) pulsen. Vooral de 
kwaliteit van diffusie-gewogen MRI en 1H MRSI kan lijden onder B0 inhomogeniteiten 
indien er geen tegenmaatregelen getroffen worden. De ontwikkeling van 
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geavanceerde ontvangstspoelen en parallelle beeldvorming strategieën heeft diffusie 
MR opnamen veel robuuster gemaakt en maakte het mogelijk de ruimtelijke resolutie 
van diffusie-gewogen MRI te verhogen. Optimalisatie van het magneetveld ter 
plaatse van de prostaat door middel van het zogenoemde shimmen is noodzakelijk 
voorafgaand aan 1H MRSI opnames om de spectrale lijnbreedtes te minimaliseren. 
Door de flip hoek van de refasering RF pulsen in de T2-gewogen turbo-spin echo 
MRI puls sequentie te verlagen, kan binnen de wettelijk vastgestelde SAR limiet 
gemeten worden, ondanks de verhoging van het gedeponeerde vermogen door RF 
bij de hogere veldsterkte. Verbeteringen in opname technieken en in de scanner 
hardware zijn daarom naast de verhoging in signaalsterkte erg belangrijk geweest 
voor de huidige klinische waarde van 3 T MRI. Hiernaast hebben deze technische 
ontwikkelingen ook de beeldvorming op MRI scanners met lagere veldsterkten 
verbeterd. 
Voor sommige MR technieken is de signaal-ruis-verhouding (SNR) ook op de 
klinische veldsterkte van 3 T nog steeds beperkt. Voorbeelden hiervan zijn MRI van 
andere kernen dan waterstof en MR spectroscopie. Voor deze technieken is het daarom 
interessant de veldsterkte nog verder te verhogen. Verschillende wetenschapscentra 
zijn daarom de haalbaarheid van prostaat MRI op 7 T gaan onderzoeken. Naast 
de verder toenemende B0 inhomogeniteiten en RF vermogensdepositie, vormen ook 
inhomogeniteiten in het 1H RF zendveld (B1
+) een belemmering voor 7 T MRI. De 
complexe 1H B1
+ patronen die ontstaan in het lichaam leiden tot ruimtelijke variaties 
in de SNR en op enkele locaties zelfs tot het compleet wegvallen van het signaal. Dit 
belemmert alle MR technieken in de huidige multiparametrische MRI onderzoeken 
van de prostaat.
De complicaties die gepaard gaan met het zenden van buitenaf kunnen deels 
vermeden worden door een endorectale spoel die zowel RF velden kan zenden als 
ontvangen. Hiermee is 1H MRSI met SAR intensieve semi- of volledig adiabatische 
puls sequenties mogelijk op 7 T. Met de afstand vanaf de endorectale spoel neemt 
echter ook de B1
+ snel af, waar de anatomische beeldvorming van de prostaat ernstig 
onder lijdt. Door gebruik te maken van zogenaamde RF shimming technieken blijkt 
het ook op 7 T mogelijk te zijn met externe spoelen T2-gewogen beelden van de 
prostaat zonder B1
+ artefacten te maken. Tijdens het RF shimmen wordt de fase 
(en eventueel de amplitude) van de RF pulsen van elk individueel zendkanaal 
van een multi-kanaals array spoel aangepast zodat de B1
+ magnitude in een klein 
gebied, in dit geval de prostaat, hoog genoeg is. Voor de patiënt veiligheid zijn 
numerieke berekeningen van de RF-veldverdelingen nodig om globale en lokale 
SAR te voorspellen met een specifieke spoel of combinatie van spoelen. Vanwege 
het hoge gedeponeerde vermogen dat gepaard gaat met T2-gewogen turbo spin-
echo sequenties en de beperkt beschikbare B1
+ in de prostaat op 7 T, zijn verlengde 
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RF pulsen nodig om binnen de gedefinieerde SAR limieten te blijven alsmede om de 
benodigde flip hoeken te bereiken. Deze maatregelen maken T2-gewogen MRI van 
de prostaat mogelijk op 7 T, zij het met enkele neveneffecten: het periprostatische 
weefsel wordt donkerder afgebeeld dan op lagere veldsterkten en het aantal haalbare 
plakken is sterker gelimiteerd door SAR. (Hoofdstuk 2)
We hebben gezien dat het verhogen van het magneetveld hand in hand gaat 
met innovatieve ideeën voor RF puls sequenties, signaal-uitleestechnieken en 
verbeteringen in hardware om belemmeringen gepaard gaande met een verhoging 
in het magneetveld te verhelpen of te verminderen en zo te profiteren van de hogere 
signaalsterkte. Deze innovaties maakten jaren geleden de stap naar 3 T systemen 
mogelijk, en in de tussentijd heeft ook prostaat MR op 1.5 T hiervan geprofiteerd. 
Aanvullende ontwikkelingen zijn nodig om multiparametrische prostaat MR op 7 T 
mogelijk te maken. 
In het werk gepresenteerd in dit proefschrift zijn verschillende MRSI technieken 
voor 7 T ontwikkeld en getest in patiënten, alsmede een multiparametrisch protocol 
voor prostaat MR op 7 T inclusief diffusie-gewogen MRI. Alle nieuwe methoden 
maken gebruik van de externe multi-kanaal array spoel waarmee, door middel van 
RF shimming, T2-gewogen prostaat MRI beelden gemaakt kunnen worden.
Door op 7 T de multi-kanaals array spoel te combineren met een endorectale 
ontvangstspoel ontstaat een opstelling vergelijkbaar met de optimale meetopstelling 
voor 1H MRSI op 1.5 en 3 T (ingebouwde volume zendspoel samen met externe 
phased-array spoelen en een endorectale spoel voor signaalontvangst). Beide 
spoelopstellingen garanderen een homogeen zendveld (lokaal in de prostaat op 7 T), 
zodat conventionele (laag-vermogen) RF pulsen gebruikt kunnen worden, terwijl 
ook een hoge SNR in de prostaat gegarandeerd is. Een nieuwe MRSI puls sequentie 
die gebruik maakt van conventionele refaserings RF pulsen met zowel spectraal als 
ruimtelijke selectieve eigenschappen werd ontwikkeld om te profiteren van deze 
nieuwe spoelconfiguratie op 7 T. Deze sequentie bevat geen onderdrukkingspulsen 
voor water of vet, waardoor het totaal afgegeven RF vermogen beperkt blijft. Dit 
maakt acquisitie van 3D 1H MRSI met een repetitie tijd van 1 seconde op 7 T mogelijk, 
ruim binnen de SAR limiet. Metingen in proefpersonen lieten zien dat de spectrale 
selectiviteit van de pulsen voor excellente wateronderdrukking in de prostaat spectra 
zorgt. Enkele spectra bevatten residuele vetsignalen, vanwege beperkingen in de 
spectrale en ruimtelijke selectiviteit van de RF pulsen. De prostaat spectra zonder 
vetcontaminatie vertoonden de gebruikelijke citraat signalen en opmerkelijke 
hoge spermine signalen. Hierdoor was geen creatine signaal meer zichtbaar en in 
sommige spectra maskeerde spermine ook het choline signaal. Het hoge spermine 
signaal komt voort uit het de spectrale selectiviteit van de refaserings-pulsen. Alleen 
de 3.1 ppm groep van spermine wordt gerefaseerd door deze pulsen, waardoor de 
Chapter 10
10
206 207
J-koppeling evolutie van spermine gerefaseerd wordt en een in-fase signaal ontstaat, 
onafhankelijk van de echo tijd. Het 7 T 1H MRSI concept met spectraal-ruimtelijke 
RF pulsen verschaft de mogelijkheid de ruimtelijke resolutie van in vivo prostaat 
MRSI te verhogen binnen acceptabele scan tijden. (Hoofdstuk 3)
Met de nieuwe methode voor 1H MRSI en de bijbehorende spoelopstelling is 
multiparametrische prostaat MRI op 7 T technisch gezien binnen handbereik. De 
haalbaarheid en kwaliteit hiervan is onderzocht in 14 patiënten met prostaatkanker. 
Anatomische T2-gewogen prostaat opnamen werden verkregen met een turbo 
spin-echo sequentie met verlengde RF pulsen. Voor 1H MRSI werd de sequentie 
met spectraal-ruimtelijke RF pulsen gebruikt, in enkele gevallen gecombineerd 
met een geavanceerde uitleesmethode van de data, waarmee meer flexibiliteit 
ontstaat in het kiezen van de ruimtelijke resolutie, het gezichtsveld (FOV) en de 
acquisitie tijd. Diffusie-gewogen MRI vormde de tweede functionele techniek 
in het multiparametrische prostaat MRI onderzoek. Hiervoor werd een 5-shot 
gesegmenteerde EPI sequentie gebruikt met b-waarden van 0, 100, 400 and 800 s/
mm2. 
De beeldkwaliteit van de T2-gewogen en diffusie-gewogen beelden werd als redelijk 
tot goed beoordeeld. Ondanks de hogere ruimtelijke resolutie van de anatomische 
beelden op 7 T, was de weergave van de weefselstructuur niet duidelijk beter dan 
op 3 T beelden. De kwaliteit van de prostaat spectra wisselde tussen de patiënten. In 
een paar tumor spectra konden verhoogde choline signalen onderscheiden worden 
van het hoge spermine signaal. De spectrale kwaliteit leed voornamelijk onder 
vetcontaminatie. Hoewel de kwaliteit van de MR beeldvorming en spectra varieerde 
tussen patiënten, toonde deze studie de haalbaarheid van multiparametrische 
prostaat MRI op 7 T aan en werden meerdere mogelijkheden ter verbetering 
geïdentificeerd. (Hoofdstuk 4)
De hogere signaalintensiteit op 7 T biedt ook goede mogelijkheden voor MRSI 
van minder gevoelige kernen dan waterstof. Met fosfor (31P) MRSI kunnen andere 
stofwisselingsproducten gemeten worden dan met 1H MRSI, waardoor we mogelijk 
meer over prostaatkanker, bijvoorbeeld over de agressiviteit van de tumor, te weten 
kunnen komen. 
Voor 31P MRSI van de prostaat op 7 T is een endorectale spoel nodig die zowel 
RF velden op de 31P frequentie kan zenden als ontvangen. Deze endorectale spoel 
kan gebruikt worden in combinatie met de externe multi-kanaal array spoel (op 
1H frequentie) voor de beeldvorming van de prostaat. Om het protocol voor de 
zogenaamde ‘pulse-acquire’ 31P MRSI te optimaliseren werden T1 relaxatie tijden 
van de 31P metabolieten in de prostaat gemeten. Met de minimale repetitie tijd 
van 1500 ms opgelegd door SAR beperkingen bleek de optimale flip hoek voor 
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de adiabatische excitatie puls tussen de 35 en 45° te liggen voor de verschillende 
metabolieten. Ook werd het effect van watersaturatie tijdens de 31P MRSI meting 
bestudeerd. Dit zorgde voor het zogeheten nucleaire Overhauser effect (NOE), dat 
de 31P signalen tot 145% versterkte. Met deze protocol verbeteringen kan een 7 T 
31P MRSI dataset van de prostaat met optimale SNR per tijdseenheid opgenomen 
worden binnen 15 minuten. (Hoofdstuk 5)
Het geoptimaliseerde protocol voor 31P MRSI werd ingezet om 15 patiënten met 
prostaatkanker te meten op 7 T. De spectroscopische opname werd gepland op basis 
van de T2-gewogen anatomische prostaat beelden die opgenomen waren met de 
externe array spoel. 31P MR spectra van de prostaat bevatten metabolieten die betrokken 
zijn in de energiestofwisseling (fosfocreatine [PCr], adenosinetrifosfaat [ATP]) en 
in de opbouw en afbraak van celmembranen (voornamelijk fosfoethanolamine 
[PE] en fosfocholine [PC]). Opvallend genoeg hadden de spectra vaak twee aparte 
pieken in de spectrale regio van anorganisch fosfaat (Pi), wat mogelijk duidt op twee 
aparte pH compartimenten in de prostaat. Het PCr niveau in de prostaat was laag 
vergeleken met het gladde spierweefsel om de prostaat heen. De PC/PE verhouding 
in de zaadblaasjes was sterk verhoogd in vergelijking met de prostaat zelf in 5 
patiënten. Glycerofosfocholine (GPC) signalen waren aanwezig in 43% van de 
voxels in prostaatkanker, waar het in normaal ogend prostaat weefsel slechts in 10% 
van de voxels voorkwam. In 31P metaboliet ratios werden geen verschillen gevonden 
tussen prostaatkanker en normaal ogend prostaat weefsel, waarschijnlijk door de 
deelvolume effecten van kleine tumoren in grote MRSI voxels. De tumorlaesies van 
de enige 2 patiënten met hoog agressieve prostaatkanker vertoonden hoge PC en 
GPC niveaus. 31P MRSI van de prostaat op 7 T is daarom een veelbelovende techniek, 
maar een hogere ruimtelijke resolutie is noodzakelijk om verschillen tussen normaal 
en tumor weefsel in meer detail te bestuderen. (Hoofdstuk 6)
De NOE techniek om 31P metaboliet signalen te versterken is vaak toegepast op 
klinische magneetveldsterkten (1.5 en 3 T). In hoofdstuk 5 werden NOE signaal 
versterkingen ook opgewekt in de prostaat op 7 T. Positieve NOE versterkingen 
werden waargenomen voor alle metabolieten behalve de ATP’s, maar er was ook 
aanzienlijke variatie in de versterkingsfactoren van de individuele metabolieten 
aanwezig. De oorzaak van deze variatie is onderzocht met een herhaalbaarheidsstudie 
van standaard (d.w.z. niet-versterkte) en NOE-versterkte 31P MRSI van het 
brein in 7 gezonde vrijwilligers. De resultaten laten zien dat de variaties in NOE 
versterkingsfactoren per metaboliet bijna volledig verklaard konden worden door 
de mate van herhaalbaarheid van standaard en NOE-versterkte 31P MRSI. De NOE 
signaal versterkingen verbeterden de relatieve herhaalbaarheid van 31P MRSI van 
het brein en het gebruik van NOE is daarom aan te raden voor humane 31P MRSI 
metingen met lage SNR. (Hoofdstuk 7)
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Abbreviations and Symbols
1H  hydrogen / proton
31P  phosphor
ADC  apparent diffusion coefficient
AFP  adiabatic full passage
ATP  adenosine triphosphate
B0  magnetic field
B1  radiofrequency field
B1
+  transmit radiofrequency field
BIR  B1-insensitive rotation
BPH  benign prostatic hyperplasia 
Cho  choline
Cit  citrate
Cr  creatine
COR  coronal
CoV  coefficient of variation
CRLB  Cramér-Rao lower bound
CSA  chemical shift anisotropy
d  mean bias between native and NOE-enhanced measurements
δ  chemical shift 
DCE  dynamic contrast-enhanced 
DWI  diffusion-weighted imaging 
η  NOE enhancement 
EPI  echo-planar imaging
FA  flip angle
FID  free induction decay
FOV  field of view
γ  gyromagnetic ratio
GPC  glycerophosphocholine
GPE  glycerophosphoethanolamine
GX, GY, GZ  gradient on x, y and z axis, respectively
HR-MAS  high resolution magic angle spinning
LASER  localization based on adiabatic selective refocusing
LoA  limits of agreement
M0  net total magnetization at thermal equilibrium
mpMRI  multiparametric magnetic resonance imaging
MR  magnetic resonance
MRI  magnetic resonance imaging
MRSI  magnetic resonance spectroscopic imaging
μ  mean metabolite integral over all voxels and measurements
NAD  nicotinamide adenine dinucleotide
nativerepeat  mean integral of non-enhanced repeated measurements per voxel
NMR  nuclear magnetic resonance
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NOE  nuclear Overhauser effect
NOEenhrepeat  mean integral of NOE-enhanced repeated measurements per voxel
OVS  outer volume saturation
PC  phosphocholine
PCa  prostate cancer
PCr  phosphocreatine
PE  phosphoethanolamine
Pi  inorganic phosphate
PIRADS  prostate imaging reporting and data system
ppm  parts per million
PRESS  point-resolved spectroscopy
PSA  prostate specific antigen
PZ  peripheral zone
RC  repeatability coefficient
RF  radiofrequency
Rx  receive
SAG  sagittal
SAR  specific absorption rate
SD  standard deviation
σd  standard deviation of differences between methods
σrepeat  standard deviation of repeated measurements
sLASER  semi localization based on adiabatic selective refocusing
SNR  signal-to-noise ratio
SPSP / SP2  spectral-spatial
SP3  spectral-spatial-spiral
Spm  spermine
T  Tesla (unit of magnetic field strength)
T1  longitudinal relaxation time
T2  transverse relaxation time
T2*  transverse relaxation time including influence from macroscopic inhomogeneities
T2W  T2-weighted 
τ  delay time 
tCho  total choline
TE  echo time
TSE  turbo spin-echo
TR  repetition time
TRA  transversal
TRUS  transrectal ultrasound
Tx  transmit
TxRx  transmit-receive
TZ  transition zone
VERSE  variable rate selective excitation
VOI  volume of interest
WALTZ  wideband alternating-phase low-power technique for zero residual splitting
ω0  Larmor frequency
Abbreviations and Symbols
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